Conditions: Neurofibroma, Plexiform Neurofibromatosis Type I
Keywords: Surrogate Markers 3-Dimensional Magnetic Resonance Imaging (MRI) Natural History of Neurofibromatosis Type 1 (NF1) Tumor Tissue Bank Neurofibromatosis NF1 Neurofibromatosis Type 1 Plexiform Neurofibroma Neurofibroma
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 62
Healthy volunteers: no

Brief summary:
This study will examine whether the experimental drug R115777 (Tipifarnib) can shrink or slow the growth of plexiform neurofibromas in children and young adults with neurofibromatosis type 1 (NF1) and determine what side effects are related to treatment. Plexiform tumors arise from nerves; the only effective treatment is surgical removal. Often, however, not all the tumors can be removed, because of their number or location.

Patients with NF1 have a reduced amount of the protein neurofibromin. Neurofibromin is thought to help control the activity of another protein, called ras, which regulates cell growth. Too little neurofibromin, therefore, may allow for uncontrolled cell growth and tumor formation. R115777 interferes with the function of the ras and other proteins. In test tube and animal studies, R115777 has blocked the growth of cancer cells. This study will examine whether the drug is effective against plexiform tumors.

Patients with NF1 and progressive plexiform neurofibromas between 3 and 25 years of age may be eligible for this study. Patients whose tumors can be successfully removed surgically may not participate in this study. Candidates are screened with a medical history and physical and eye examinations, blood and urine tests, and magnetic resonance imaging (MRI). Photographs are taken of tumors visible on the body surface.

Study participants are randomly assigned to receive either R115777 or placebo (an inactive substance). They take R115777 or placebo tablets every 12 hours for 21 days, followed by a 7-day rest period. This constitutes one 28-day treatment cycle. Treatment continues for as long as the tumors remain stable or shrink and side effects are tolerable. The treatment is switched (for example, from placebo to R115777) or stopped if the tumors grow or if side effects become unacceptable. Patients (or their parents) keep a record of side effects.

For the first 3 treatment cycles, patients have a physical examination and blood tests every other week. Blood tests are also done before starting treatment, and at one time point after at least 14 days of treatment to measure the effect of R115777 on proteins in blood cells. A blood sample is obtained before starting treatment and before cycles 4, 7 and 10 and then after every 6 cycles to measure the level of a substance called nerve growth factor. The analysis of nerve growth factor is used to determine if it can predict which patients might be at risk of developing side effects from R115777.

Detailed description:
R115777 (Tipifarnib) is a farnesyltransferase inhibitor that blocks the post-translational isoprenylation of ras and other farnesylated proteins. The ras proteins are integral in cell signaling pathways, and farnesylation is essential for the function of both mutant and non-mutant ras proteins. Patients with neurofibromatosis type 1 (NF1) have an increased risk of developing tumors of the central and peripheral nervous system, and there are no standard treatment options, other than surgery, available for these tumors. Neurofibromin, which is the product of the NF1 gene, contains a domain with significant homology to ras GTPase-activating proteins (GAP). Although NF1 patients lack germline ras mutations, the decreased levels of neurofibromin have been shown to be associated with a constitutively activated ras-GTP status. Thus, upstream inhibition of ras farnesylation may inhibit growth of tumors in NF1 patients. A randomized, cross-over, double-blinded, placebo-controlled pediatric phase II trial of oral R115777 will be performed in children and young adults with NF1, who have progressive, plexiform neurofibroma(s) to determine the effect of this novel anticancer drug on the rate of growth of neurofibromas. The endpoint of the trial is time to progression. R115777 will be administered orally at a dose of 200 mg/m(2) twice daily for cycles of 21 days followed by a 7 day rest period based on the results of our prior pediatric phase I trial.

Arms:
arm 1: Patients receive oral R115777 (Tipifarnib) first followed by placebo. 200 mg/m\^2/dose BSA every 12 hours by mouth (po)on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. arm 2: Patients receive oral placebo first followed by R115777 (Tipifarnib). 200 mg/m\^2/dose BSA every 12 hours by mouth (po)every 12 hours on days 1-21. Courses repeat as in arm I.

Interventions: intervention 1: tipifarnib intervention 2: placebo
Intervention descriptions: intervention 1: Given orally, 200 mg/m\^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days intervention 2: Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.

Protocol document:
Prot_SAP_ICF_000.pdf: 


CTEP Protocol No: 
T-99-0090 
CC Protocol No: 01-C-0222 
Amendment: J 
Revised: 
4/21/09 
IRB Approval Date: 
 
 
 
 1
A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled 
Trial of the Farnesyltransferase Inhibitor R115777 in Pediatric Patients with 
Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas 
Coordinating Center:
Pediatric Oncology Branch, NCI 
Principal Investigator:
Brigitte Widemann, M.D.* (POB, NCI) 
NIH Associate Investigators:
Frank M. Balis, M.D. (POB, NCI)  
Beth Fox, M.D. (POB, NCI) 
Kathy Warren, M.D. (NOB, NCI) 
Andy Gillespie, R.N. (ND, CC) 
Eva Dombi, MD (POB, NCI)** 
Nalini Jayaprakash, (POB, NCI) 
Diane Cole, (POB, NCI) 
Seth Steinberg, Ph.D. (BDMB, DCS, NCI) 
Nicholas Patronas, M.D. (DR, CC)** 
Maria Tsokos, M.D., (Laboratory of Pathology, NCI)** 
Pamela Wolters, Ph.D. (HAMB, NCI) 
Staci Martin, Ph.D. (HAMB, NCI) 
Jeffrey Solomon, (NIH and Sensor Systems, Inc.) 
Non-NIH Associate Investigators:
Wanda Salzer, M.D. **  
Keesler Air Force Base, Biloxi, Mississippi)  
81st MDOS/SGOC 301 Fisher Street, Room 1A132 Keesler 
AFB, MS 39534-2519  
Phone: 228-377-6524  
E-mail: wanda.salzer@keesler.af.mi 
Bruce R. Korf, M.D., Ph.D. **  
Chair, Department of Genetics 
Univeristy of Alabama at Birmingham 
1530 3rd Ave. S. 
Birmingham, AL 35294 
Phone: (205)-934-9411, Fax: (205)-934-9488 
E-mail: bkorf@uab.edu 
David H. Gutmann, M.D., Ph.D. ** 
Department of Neurology 
Washington University School of Medicine 
St. Louis Children’s Hospital 
Box 8111, 660 S. Euclid Avenue 
St. Louis, MO 63110 
Phone: (314)-632-7149, Fax: (314)-362-9462 
E-mail: gutmannd@neuro.wustl.edu 


4/21/2009 
T-99-0090, 01-C-0222 
 
 2
Arie Perry, M.D. ** 
Division of Neuropathology 
Washington University School of Medicine 
Campus Box 8111, 660 S. Euclid Avenue 
St. Louis, MO 63110 
Phone: (314) 362-9130, Fax: (314) 362-4096 
E-mail: aperry@pathology.wustl.edu 
M. Watson, M.D., Ph.D. ** 
Division of Laboratory Medicine/Box 8118 
Alvin J. Siteman Cancer Center/Box 8100 
Washington University School of Medicine 
660 S. Euclid Avenue, St. Louis, MO 63110 
Phone: (314)-454-7919, Fax: (314)-454-5525 
E-mail: watsonm@labmed.wustl.edu 
Margaret Wallace, Ph.D. 
Associate Professor, Pediatric Genetics 
University of Florida 
Box 100296, 1600 SW Archer Road 
Gainesville, FL 32610-0296 
Phone: (352) 392-3055; Fax: (352) 392-3051 
E-mail: peggyw@cmg.health.ufl.edu 
David Muir, Ph.D. 
Associate Professor  
Pediatric Neurology & Neuroscience 
Box 100296, JHMHC 
University of Florida, College of Medicine 
Gainsville, FL 32610 
Phone: (352)-392-0312; Fax: (352) 392-9520 
E-mail: muir@ufbi.ufl.edu 
Participating Institution:
Johns Hopkins Oncology Center (M1011) 
Responsible Investigator:
IRB contact:
Pharmacy contact:
Robert J. Arceci, M.D., Ph.D. 
Bunting-Blaustein Cancer Research Building 
1650 Orleans Street, 2M51 
Baltimore, MD 21231 
Phone: 410-502-7518, Fax: 410-955-8897 
E-mail: arcecro@jhmi.edu 
Monica Carlton 
550 N. Broadway, Room 1121 
Baltimore, MD 21287 
Phone 410-955-0350, Fax: 410-614-1328 
Pauline Newman 
600 N. Wolfe Street 
Baltimore, MD 21205 
CMSC 209 Pediatric Pharmacy 
Phone: 410-955-5926, Fax: 410-955-0283 
E-mail: pnewman@JHH.Pharmacy 


4/21/2009 
T-99-0090, 01-C-0222 
 
 3
Participating Institution:
Children’s Hospital of Philadelphia, PA (M1257) 
Responsible Investigator:
IRB contact:
Pharmacy contact:
Jean Belasco, M.D. 
34th and Civic Center Blvd, Philadelphia, PA 19104 
Phone: (215) 590-2848, Fax: (215) 590-4183 
E-mail: belasco@email.chop.edu 
 
Carol Sazama 
The Children’s Hospital of Philadelphia 
1st floor Abramson Building 
3517 Civic Center Boulevard 
Philadelphia, PA 19104-4399 
Phone: 215-590-2830 
E-mail: sazama@email.chop.edu 
Betsy Bickert, Pharm D. 
4th floor pharmacy, 4th floor main building 
34th & Civic Center Boulevard 
Philadelphia, PA 19104 
Phone: 215-590-3833 
E-mail: bickert@email.chop.edu 
Participating Institution:
Responsible Investigator:
IRB contact:
Pharmacy contact:
SUNY Upstate Medical University, NY (M1303) 
Ronald Dubowy, M.D. 
Department of Pediatrics – 5C 
750 E Adams Street, Syracuse, NY 13210 
Phone: (315) 464-5294; Fax: (315) 464-7238 
E-mail: dubowyr@upstate.edu  
Karen Bilynsky, RN, CCRA 
SUNY Upstate Medical University, NY 
Department of Pediatrics 5C 750 E Adams Street, 
Syracuse, NY 13210 
Phone: 315-464-7601, Fax: 315-464-7515 
E-mail: bilynskk@upstate.edu 
Andrea Allen 
SUNY Upstate Medical University, NY 
Department of Pharmacy  5C 750 E Adams Street, 
Syracuse, NY 13210 
Phone: 315-464-4210, Fax: 315-464-4314 
E-mail: allena@upstate.edu 
Participating Institution:
Responsible Investigator:
IRB contact:
Texas Children's Hospital, Houston, TX (M1060) 
Susan, M. Blaney, M.D. 
Division of Hematology/Oncology, 6621 Fannin Street, 
Texas Children's Hospital, CC 1410.00,  
Houston, TX 77030 
Phone: 832-822-1482; Fax: 832-825-4299 
E-mail: sblaney@bcm.tmc.edu 
Stacey Berg M.D., Kay Motil, M.D. 
Baylor College of Medicine 
One Baylor Plaza S108 


4/21/2009 
T-99-0090, 01-C-0222 
 
 4
Pharmacy contact:
Houston, TX 77030 
Phone: 713-798-6970 
E-mail: sberg@txccc.org, kmotil@bcm.tmc.edu 
Renee A. Robinson RPh 
Texas Children’s Hospital 
Pharmacy department MC 2-2510  
6621 Fannin Street 
Houston, TX 77030 
Phone: 713-770-3899 
E-mail rarobins@txccc.org 
 
 
Participating Institution:
Responsible Investigators:
IRB contact:
Pharmacy contact:
The Children’s Hospital, Dana-Farber Cancer Institute,  
Boston, MA (M1034)  
Mark W. Kieran, MD, PhD 
Director, Pediatric Medical Neuro-Oncology 
Dana-Farber Cancer Institute 
44 Binney Street, Boston, MA, 02115 
Phone: (617) 632-4907; Fax: (617) 632-4248 
E-mail: mark_kieran@dfci.harvard.edu 
Jessica Jacobs, Protocol Administrator 
Protocol Administration Office 
Dana-Farber Cancer Institute 
44 Binney Street 
Boston, MA 02115 
Phone: 617-632-5737, Fax: 617-632-2686 
E-mail: Jessica_Jacobs@dfci.harvard.edu 
Peter Blanding 
Clinical Pharmacist-Pediatric  Clinic 
Department of Pharmacy L-2 
Dana-Farber Cancer Institute 
44 Binney Street 
Boston, MA 02115 
Phone 617-632-3785, Fax: 617-632-4410 
E-mail: peter_blanding@dfci.harvard.edu 
Participating Institution:
Responsible Investigator:
IRB contact:
St. Louis Children’s Hospital, St. Louis, MO (M1123) 
Allison King, M.D. 
Washington University School of Medicine 
St. Louis Children’s Hospital 
660 S. Euclid Avenue 
Campus Box 8116 
St. Louis, MO 63110 
Phone: (314)-286-1170, Fax: (314)-454-2780 
E-mail: king_a@kids.wustl.edu 
Kirsten Cady 
Washington University School of Medicine 
660 S. Euclid Avenue 


4/21/2009 
T-99-0090, 01-C-0222 
 
 5
Pharmacy contact:
Campus Box 8056 
St. Louis, MO 63110 
Phone: 314-362-7773, Fax: 314-747-0232 
E-mail: kcady@im.wustl.edu 
Melissa Heigham, RPh 
Investigational Pharmacist 
St. Louis Children’s Hospital 
One Children’s Place 8W25 
St. Louis, MO 63110 
Phone: 314-454-2361, fax: 314-454-2441 
E-mail: mheigham@bjc 
Participating Institution:
Responsible Investigator:
IRB contact:
Pharmacy contact:
Children’s Hospital Los Angeles, CA (M1118)  
Jonathan L. Finley, M.D., Ch.B. 
Childrens Hospital Los Angeles 
4650 Sunset Blvd, Mail Stop 54 
Los Angeles, CA 90027 
Phone 323-906-8147,  
Fax: (323)-660-7128 
E-mail: jfinlay@chla.usc.edu 
Rhonda Crutcher 
4650 Sunset Blvd, Mailstop 54 
Los Angeles, CA 90027 
Phone: 323-660-2450 ext. 5701, Fax: 323-671-1585 
E-mail: rcrutcher@chla.usc.edu 
John Pech, MS 
4650 Sunset Blvd, Mailstop 44 
Los Angeles, CA 90027 
Phone: 323-660-2450 ext. 5989, Fax: 323-664-0326 
E-mail: jpech@chla.usc.edu 
Participating Institution:
Responsible Investigator:
IRB Contact:
Pharmacy Contact:
Cincinnati Children’s Hospital (FWA 00002988) 
John Perentesis, M.D. 
Division, Hematology/Oncology ML 7015 
Cincinnati Children’s Hospital Medical Center 
3333 Burnet Ave. 
Cincinnati, Ohio 45229 
Phone: 513-636-8241, Fax: 513-636-3459 
E-mail: john.perentesis@cchmc.org 
Irwin Light, M.D. 
Cincinnati Children’s Hospital Medical Center 
229 Erkenbrecher Ave. ML 5020 
Cincinnati, Ohio 45229 
Phone: 513-636-8039, Fax: 513-636-3959 
E-mail: Irwin.light@cchmc.org 
Denise Lagory, RPh 
Investigational Pharmacy 
Cincinnati Children’s Hospital Medical Center 
3333 Burnet Ave ML 1011 


4/21/2009 
T-99-0090, 01-C-0222 
 
 6
Cincinnati, Ohio 45229 
Phone: 513-636-3016, Fax: 513-636-2740 
E-mail: denise.lagory@cchmc.org 
 
Participating Institution:
Responsible Investigator:
IRB contact:
Pharmacy contact:
Children’s Memorial Hospital, Chicago, IL (M1484) 
Stewart Goldman, M.D. 
Children’s Memorial Hospital 
2300 Children’s Plaza, Box # 30 
Chicago, IL 60614 
Phone: (773)-880-3270, Fax: (773)-880-3053 
E-mail: sgoldman@nwu.edu 
Gary Dennison, IRB Manager 
Joel Frader, M.D., IRB Chair 
Children’s Memorial Institute for Education and 
Research, Office of Research Administration 
Institutional Review Board 
2300 Children’s Plaza, Box # 205 
Chicago, IL 60614 
Phone: 773-880-8116 
Susan Berg, R.Ph. (Hem/Onc Pharmacy) 
Marianne Chan, PharmD., Director Pharmacy Services 
Children’s Memorial Hospital  
2300 Children’s Plaza, Box 74 
Chicago, IL 60614 
Phone: 773-880-4471 
Participating Institution:
Responsible Investigator:
IRB Contact:
Pharmacy Contact:
Hospital for Sick Children in Toronto (T3859) 
Douglas J. Hyder, M.D. 
Hospital for the Sick Children 
555 University Ave. 
Toronto, ON   M5G  1X8 
Phone: 416-813-7758 
Fax: 416-813-8024 
E-mail: douglas.hyder@sickkids.ca 
Melvin Freedman, M.D. 
Chair, Research Ethics Board 
Hospital for Sick Children 
555 University Ave. 
Toronto, ON   M5G  1X8 
Phone: 416-813-6152 
Fax: 416-813-5327 
E-mail: melvin.freedman@sickkids.ca 
Darcy Nicksy 
Research Support Pharmacist 
555 University Ave. 
Toronto, ON M5G 1X8 
Phone: 416-813-7605 


4/21/2009 
T-99-0090, 01-C-0222 
 
 7
Fax: 416-813-7886 
E-mail: darcy.nicksy@sickkids.ca 
Participating Institution:
Responsible Investigator:
IRB Contact:
Pharmacy Contact:
University of Alabama at Birmingham (M1149) 
Alyssa Reddy, MD 
1600 7th Ave. South 
ACC 512 
Birmingham, AL  35233 
Phone:  (205) 939-9285, Fax: (205) 975-6377 
E-mail: areddy@peds.uab.edu 
Sheila Moore 
Director, UAB Institutional Review Board 
Administration Building, Room 470 
701 20th Street, South 
Birmingham, AL  35294 
Phone: (205) 934-3789 
E-mail: smoore@provost.uab.edu 
Kathleen (Keen) Blair 
Investigational Study Pharmacist 
1600 7th Ave., South 
Birmingham, AL  35233 
Phone: (205) 939-5918, Fax: (205) 939-9934 
E-mail: keen.blair@chsys.org 
Participating Institution:
Responsible Investigator:
 
IRB Contact:
 
Pharmacy Contact:
Klinikum Nord, Hamburg, Germany (FWA 00003228) 
Victor-F. Mautner M.D. 
Klinikum Nord 
Langenhorner Chaussee 560 
D-22419 Hamburg, Germany 
Phone: 040-5271-2872, Fax: 040-5271-462 
E-mail: VRGes@aol.com 
Helga Hinzmann 
Ethik-Kommission der Ärztekammer Hamburg 
Heinrich-Hertz-Str. 125 
D-22083 Hamburg, Germany 
Phone: 040-22802-517, Fax: 040-22802-597 
E-mail: Helga.heinzmann@aerztekammer-hamburg.de 
Gerhard Mützelburg 
Apotheke Niedersachsenhaus 
Heimfelder Str. 43 
D-21075 Hamburg, Germany 
Phone: 040-7905325,  Fax: 040-7906678 
Trial Sponsor:
Cancer Therapy Evaluation Program (CTEP), NCI 
Study Drug: 
R115777 (IND. #58359) 
Supplied by:
CTEP 
 
 
* Pharmacology & Experimental Therapeutics Section 


4/21/2009 
T-99-0090, 01-C-0222 
 
 8
Pediatric Oncology Branch, NCI 
10 Center Drive, MSC 1920 
Building 10, Room 13C103 
Bethesda, MD 20892-1920 
Phone: (301) 496-7387/Fax: (301) 480-8871 
E-mail: Bw42y@nih.gov 
**Not responsible for direct patient care related to this trial 
 
 
PROPRIETARY and CONFIDENTIAL 
 
This protocol contains confidential information that should only be disclosed to those persons responsible for execution and 
organization of the trial and on condition that all such persons agree not to further disseminate it. 


4/21/2009 
T-99-0090, 01-C-0222 
 
 9
PRECIS 
R115777 is a farnesyltransferase inhibitor that blocks the post-translational 
isoprenylation of ras and other farnesylated proteins. The ras proteins are integral in cell 
signaling pathways, and farnesylation is essential for the function of both mutant and 
non-mutant ras proteins.  Patients with neurofibromatosis type 1 (NF1) have an 
increased risk of developing tumors of the central and peripheral nervous system, and 
there are no standard treatment options, other than surgery, available for these tumors.  
Neurofibromin, which is the product of the NF1 gene, contains a domain with 
significant homology to ras GTPase-activating proteins (GAP).  Although NF1 patients 
lack germline ras mutations, the decreased levels of neurofibromin have been shown to 
be associated with a constituitively activated ras-GTP status.  Thus, upstream inhibition 
of ras farnesylation may inhibit growth of tumors in NF1 patients.  A randomized, 
cross-over, double-blinded, placebo-controlled pediatric phase II trial of oral R115777 
will be performed in children and young adults with NF1, who have progressive, 
plexiform neurofibroma(s) to determine the effect of this novel anticancer drug on the 
rate of growth of neurofibromas.  The endpoint of the trial is time to progression.  
R115777 will be administered orally at a dose of 200 mg/m2 twice daily for cycles of 21 
days followed by a 7 day rest period based on the results of our prior pediatric phase I 
trial. 


4/21/2009 
T-99-0090, 01-C-0222 
 
 10
TABLE OF CONTENTS 
PRECIS ........................................................................................................................................................................9 
1.0 
INTRODUCTION ...........................................................................................................................................12 
1.1 
OBJECTIVES ...................................................................................................................................................12 
1.2 
BACKGROUND AND RATIONALE ....................................................................................................................13 
1.2.1 
Introduction...........................................................................................................................................13 
1.2.2 
Inhibition of Post-Translational Farnesylation.....................................................................................13 
1.2.3 
Preclinical Antitumor Activity of R115777 ...........................................................................................14 
1.2.4 
Toxicology of R115777..........................................................................................................................15 
1.2.5 
Phase I Clinical Trials of R115777 in Adults........................................................................................16 
1.2.6 
Phase I Clinical Trials of R115777 in Children....................................................................................17 
1.2.7 
Clinical Pharmacokinetics of R115777 in adults and children.............................................................19 
1.2.8 
Proposed Pediatric Phase II Trial of R115777.....................................................................................20 
2.0 
ENROLLMENT PROCEDURES ..................................................................................................................24 
2.1 
ELIGIBILITY CRITERIA ...................................................................................................................................24 
2.1.1 
Inclusion Criteria ..................................................................................................................................24 
2.1.2 
Exclusion Criteria .................................................................................................................................27 
2.2 
PRE-TREATMENT EVALUATION (SEE APPENDIX 7)........................................................................................27 
3.0 
IMPLEMENTATION OF STUDY ................................................................................................................29 
3.1 
STUDY DESIGN ..............................................................................................................................................29 
3.1.1 
Randomized Design...............................................................................................................................29 
3.1.2 
Patient Registration and Randomization...............................................................................................29 
3.1.3 
Dosing Schedule and Prescribing .........................................................................................................30 
3.1.4 
Monitoring Time to Progression and Response ....................................................................................31 
3.1.5 
Definition of Tumor Progression...........................................................................................................31 
3.1.6 
Tissue Procurement...............................................................................................................................31 
3.1.7 
Establishment of tumor cell lines and tissue bank.................................................................................32 
3.1.8 
FPTase Activity in PBMC .....................................................................................................................32 
3.1.9 
Nerve Growth Factor (NGF).................................................................................................................32 
3.1.10 
Monitoring  Toxicity............................................................................................................................32 
3.2 
DRUG ADMINISTRATION................................................................................................................................32 
3.3 
MODIFICATIONS FOR TOXICITY .....................................................................................................................33 
3.4 
ON STUDY EVALUATION (SEE APPENDIX 7) ..................................................................................................34 
3.5 
CONCURRENT THERAPY.................................................................................................................................36 
3.6 
OFF STUDY CRITERIA ....................................................................................................................................36 
3.7 
POST-STUDY EVALUATION............................................................................................................................37 
4.0 
SUPPORTIVE CARE .....................................................................................................................................37 
5.0 
DATA COLLECTION AND EVALUATION...............................................................................................38 
5.1 
DATA COLLECTION........................................................................................................................................38 
5.1.1 
Case Report Forms................................................................................................................................38 
5.2 
RESPONSE CRITERIA......................................................................................................................................39 
5.3 
TOXICITY CRITERIA.......................................................................................................................................40 
5.4 
STATISTICAL CONSIDERATIONS .....................................................................................................................40 
5.4.1 
Subject Accrual .....................................................................................................................................40 
5.4.2 
Statistics and Feasibility .......................................................................................................................40 
5.5 
MULTI-INSTITUTIONAL GUIDELINES..............................................................................................................42 
5.5.1 
IRB Approvals .......................................................................................................................................42 
5.5.2 
Amendments and Consents....................................................................................................................42 
5.5.3 
Patient Registration...............................................................................................................................42 


4/21/2009 
T-99-0090, 01-C-0222 
 
 11
5.5.4 
Data Collection and Toxicity Reporting................................................................................................42 
5.5.5 
Data and Center Audits.........................................................................................................................43 
6.0 
HUMAN SUBJECTS PROTECTIONS.........................................................................................................43 
6.1 
RATIONALE FOR SUBJECT SELECTION............................................................................................................43 
6.2 
PARTICIPATION OF CHILDREN........................................................................................................................43 
6.3 
EVALUATION OF BENEFITS AND RISKS/DICOMFORTS......................................................................................43 
6.4 
RISK/BENEFIT ANALYSIS.................................................................................................................................44 
6.5 
CONSENT AND ASSENT PROCESS AND DOCUMENTATION ................................................................................44 
6.6 
HANDLING OF RESEARCH SAMPLES...............................................................................................................45 
7.0 
DATA REPORTING.......................................................................................................................................45 
7.1 
PATIENT REGISTRATION AND RANDOMIZATION ............................................................................................46 
7.2 
CASE REPORT FORMS ....................................................................................................................................46 
7.3 
SAFETY REPORTING.......................................................................................................................................46 
7.3.1 
Adverse Events ......................................................................................................................................46 
7.3.2 
Adverse Event Reporting.......................................................................................................................47 
7.4 
ASSURANCES .................................................................................................................................................50 
7.5 
IRB APPROVALS............................................................................................................................................50 
7.6 
PATIENT DATA REPORTING AND AUDITS.......................................................................................................50 
8.0 
PHARMACEUTICAL INFORMATION......................................................................................................50 
8.1 
R115777 AND PLACEBO ................................................................................................................................50 
8.2 
DRUG ORDERS, TRANSFERS, RETURNS, ACCOUNTABILITY / EMERGENCY UNBLINDING ................................59 
9.0 
CLINICAL TRIALS AGREEMENT (CTA).................................................................................................60 
10.0 
REFERENCES...............................................................................................................................................62 
11.0 
APPENDICES................................................................................................................................................64 
APPENDIX 1:  PROTOCOL FOR REQUIRED PRE STUDY AND ON STUDY MRI STUDIES .............................................64 
APPENDIX 2: PATHOLOGY ANALYSIS OF PLEXIFORM NEUROFIBROMAS ...................................................................72 
APPENDIX 3: INSTRUCTIONS FOR TISSUE ACQUISITION OF DISCRETE AND PLEXIFORM NEUROFIBROMAS.................77 
APPENDIX 4: INSTRUCTIONS FOR SHIPMENT OF TUMOR BIOPSIES.............................................................................79 
APPENDIX 5: PROCEDURE PBMC SEPARATION FOR FARNESYLTRANSFERASE ACTIVITY........................................81 
APPENDIX 6:  DETERMINATION OF NERVE GROWTH FACTOR..................................................................................83 
APPENDIX 7: REQUIRED STUDY EVALUATIONS.......................................................................................................85 
APPENDIX 8 A:  ELIGIBILITY CHECKLIST FOR PROTOCOL........................................................................................87 
APPENDIX 8 B: BLINDED PATIENT ON-STUDY FORM ..............................................................................................89 
APPENDIX 9A: PROGRESSION CHECKLIST FOR PROTOCOL......................................................................................91 
APPENDIX 9 B: BLINDED PATIENT CROSSOVER / OFF-STUDY FORM.......................................................................92 
APPENDIX 10: ROADMAP FOR PATIENT REGISTRATION AND CROSSOVER ..............................................................94 
APPENDIX 11A: PATIENT DIARY FOR R115777/PLACEBO.......................................................................................96 
APPENDIX 11 B: PILL COUNT CASE REPORT FORM .................................................................................................98 
 


4/21/2009 
T-99-0090, 01-C-0222 
 
 12
1.0 
INTRODUCTION 
1.1 
OBJECTIVES 
PRIMARY STUDY OBJECTIVES: 
1.1.1 To assess the effect of R115777, administered on a chronic oral schedule 
(21 days on followed by 7 days rest), on the time to disease progression in 
children and young adults with neurofibromatosis type 1 (NF1) and 
progressive plexiform neurofibromas. 
1.1.2 To define the objective response rate of progressive plexiform 
neurofibromas to R115777. 
1.1.3 To describe and define the toxicities of R115777, administered on a chronic 
oral schedule (21 days on followed by 7 days rest), in pediatric patients 
and young adults. 
SECONDARY STUDY OBJECTIVES: 
1.1.4 To measure the level of farnesylprotein transferase (FPTase) activity in 
tumor specimens and peripheral blood mononuclear cells obtained from 
patients treated on this trial, and to assess the value of FPTase activity as a 
surrogate marker for the antiproliferative effect of R115777.  
1.1.5 To assess the value of three-dimensional MRI (3D-MRI) and uni-
dimensional MRI (1D-MRI) data analysis in the evaluation of plexiform 
neurofibromas, and to compare both to conventional two-dimensional 
MRI (2D-MRI) data analysis. 
1.1.6 To analyze tumor specimens from patients with NF1 treated with R115777 
for the level of expression of N-ras, K-ras, and H-ras, and to correlate the 
level of expression and the ras mutation status with the efficacy of 
R115777.  
1.1.7 To analyze tumor specimens from patients treated on this trial, for NF1 
gene mutations in the GAP related domain, and to correlate these findings 
with the antiproliferative effect of R115777. 
1.1.8 To establish tumor cell lines from tumor specimens (plexiform 
neurofibromas and discrete neurofibromas) obtained from patients treated 
on this trial.  
1.1.9 To contribute tumor specimens obtained on this trial to an already 
existing tissue bank.  Tumor samples from plexiform neurofibromas will 
undergo a central pathology review including a detailed morphologic, 
ultrastructural and immunohistochemical analysis.  Tumor cell lines and 
tumor samples will be made available to the scientific community, after 
obtaining IRB approval in order to collect more information on the 


4/21/2009 
T-99-0090, 01-C-0222 
 
 13
pathology, genetics, and cell biology of plexiform and discrete 
neurofibromas. 
1.1.10 To determine circulating levels of nerve growth factor from blood samples 
at various time points during treatment with R115777/placebo, and to 
correlate levels of NGF with the development of clinical neurotoxicity 
from R115777. 
1.1.11 To assess the quality of life of patients treated with R115777 or placebo 
using the newly developed National Institutes of Health (NIH) Impact of 
Pediatric Illness (IPI) Scale, which assesses the impact of disease and 
treatment on children’s behavior, and to evaluate the ability of this new 
assessment tool to measure changes in a child’s quality of life. 
1.2 
BACKGROUND AND RATIONALE 
1.2.1 INTRODUCTION 
Neurofibromatosis 1 (NF1) is a common autosomal dominant, progressive genetic 
disorder with an incidence of 1:3000 (>80,000 persons affected in The United States). 
NF1 is characterized by diverse, progressive cutaneous, neurological, skeletal and 
neoplastic manifestations with no standard drug treatment options available. Patients 
with NF1 have an increased risk of developing tumors of the central and peripheral 
nervous system including plexiform neurofibromas (27%)[10] optic gliomas gliomas 
(15-20%), pheochromocytomas (1%),[1] malignant peripheral nerve sheath tumors (5%), 
and neurofibrosarcomas (6%).[5, 17]  Plexiform neurofibromas are nerve sheath tumors 
that grow along the length of nerves and involve multiple branches of a nerve.  They 
are a major source of morbidity, causing disfigurement, impairment of nerve function, 
and in some cases development of malignant peripheral nerve sheath tumors. 
Neurofibromin, the NF1 gene product, contains a domain with significant 
homology to ras GTPase-activating proteins (GAP).[1, 8, 14]  The ras proteins are 
integral in cell signaling pathways, and activation of ras leads to cell proliferation.  
GAPs catalyze the hydrolysis of ras-GTP (the active form of ras) to ras-GDP and lead to 
ras inactivation.  Patients with NF1 have decreased levels of neurofibromin, which is 
associated with an activated ras-GTP status.  Agents directed at inhibiting ras, therefore, 
are a rational choice for trials of potential therapeutic agents in patients with NF1 and 
progressive plexiform neurofibromas. 
1.2.2 INHIBITION OF POST-TRANSLATIONAL FARNESYLATION 
Farnesylation is a post-translational modification in which a farnesyl isoprene 
group is added to a number of cellular proteins by the enzyme, farnesyl-protein 
transferase (FPTase).  The ras family of G proteins is one of the classes of proteins that 
are modified by FPTase.  H-, K-, and N-ras are 21 kDa guanine nucleotide-binding 
proteins that control a multitude of cell signaling events.[2, 22]  Mutant ras genes have 
the ability to transform cells into a malignant phenotype, and ras mutations have been 
observed in approximately 30% of all human cancers.[21]  Patients with NF1 do not 


4/21/2009 
T-99-0090, 01-C-0222 
 
 14
have germline ras mutations.  However, tumor cell lines established from malignant 
schwannomas of NF1 patients have been shown to have a constituitively activated ras-
GTP status.  Neurofibromin, which is the product of the NF1 gene, contains a domain 
that shows significant homology to ras GTPase-activating proteins (GAP).[8]  In these 
cell lines, there are normal levels of GAP, but decreased levels of neurofibromin, 
supporting the role of the NF1 gene as a tumor suppressor gene.  Advances in the 
understanding of ras oncoprotein function suggest novel points for anti-tumor 
intervention.  Ras is synthesized as a cytosolic precursor that ultimately localizes to the 
cytoplasmic face of the plasma membrane after a series of post-translational 
modifications.  The first obligatory step in this series of post-translational modifications 
is the addition of a farnesyl moiety.  This modification is essential for ras function.[13]  
FPTase appears to be an appropriate biochemical target for the development of 
inhibitors of post-translational processing of ras resulting in prevention of ras-mediated 
cellular transformation[4, 7, 16, 19]. 
1.2.3 PRECLINICAL ANTITUMOR ACTIVITY OF R115777 
R115777 is a potent and selective non-peptidomimetic inhibitor of FPTase both in 
vitro and in vivo.  In several preclinical studies, R115777 was shown to inhibit the 
growth of H-ras, K-ras and N-ras transformed tumors.[6] 
In intact tumor cells in culture, R115777 produced antiproliferative effects at 
nanomolar concentrations.  The proliferation of NIH 3T3 stably transfected with the 
activated T24 H-ras oncogene (T24 cells) was inhibited by R115777 with an IC50 of 1.7 
nM.  Inhibition of p21 ras farnesylation was observed in T24 cells in the same 
concentration range which inhibited cell proliferation.  In LoVo cells and HCT116 cells, 
two human colon cancer cell lines transformed by an activated K-rasB oncogene, 
R115777 inhibited cell proliferation with IC50's of 16 and 22 nM, respectively.  In intact 
CAPAN-2 human pancreatic cancer cells, which bear a K-rasB mutation, R115777 
inhibited cell proliferation with an IC50 of 16 nM.  
Although FPTase inhibitors were developed to treat tumors with ras mutations, it 
has been shown in established cell lines that FPTase inhibitors also inhibit tumors 
without ras mutations, including breast, colon, prostate, epidermoid, Ewing’s sarcoma 
and rhabdomyosarcoma. Peptidomimetic FPTase inhibitors inhibit the growth of the 
Ewing’s sarcoma cell line RD-ES, which does not contain a ras mutation.[24] 
Patients with neurofibromatosis type 1 (NF1) do not have germline ras mutations.  
However, tumor cell lines established from malignant schwannomas of NF1 patients 
have been shown to have a constituitively activated ras GTP status. The growth of the 
malignant schwannoma cell line, ST88-14, derived from a patient with NF1 was 
inhibited by a bisubstrate analog FPTase inhibitor in a concentration-dependent 
manner.[27]  
In nude mice bearing subcutaneous T24 cell tumors, R115777 administered orally 
(BID) at doses of 6.25, 12.5 and 25 mg/kg inhibited the growth of tumors by 56%, 84% 
and 86%, respectively after 15 days of treatment.  In nude mice bearing the K-rasB 


4/21/2009 
T-99-0090, 01-C-0222 
 
 15
transformed LoVo human colon tumors, R115777 administered orally (BID) at doses of 
25, 50 and 100 mg/kg inhibited tumor growth by 11%, 68% and 81%, respectively after 
32 days of treatment.  In nude mice bearing subcutaneous CAPAN-2 tumors, R115777 
administered orally (BID) significantly inhibited tumor growth at doses of 50 and 100 
mg/kg.  A 56% reduction of final tumor weight was observed at the 50 mg/kg dose 
level and a 76% reduction of final tumor volume was observed at the 100 mg/kg dose 
level. 
1.2.4 TOXICOLOGY OF R115777 
The toxicity profile of R115777 has been well characterized in animals.  In a one-
month repeat-dose pilot toxicity study in rats, five males and five females per dosage 
group were dosed orally by gavage with R115777 at doses 0, 5, 20 and 80 mg/kg/day.  
Rats dosed at 5 mg/kg showed no adverse effects.  At 20 mg/kg, a minimal decrease in 
body weight gain and slight atrophic and degenerative histological changes in the nasal 
epithelium were the only effects observed.  Dosing at 80 mg/kg resulted in sedation, 
ptosis, salivation and in a decrease in body weight.  Hematological examination 
revealed slight decreases in the number of white blood cells (decrease in lymphocytes 
and eosinophils). 
A one-month pilot study was conducted in Beagle dogs.  Doses of 0, 2.5, 10 and 40 
mg/kg were given orally to two males and two females per dosage group.  Dosing at 
2.5 mg/kg resulted in a slightly decreased weight of the testes, histologically confirmed 
by slight atrophy.  At 10 mg/kg, changes consisted of a decrease in platelets in one dog 
and a decreased weight of the testes.  Dosing at 40 mg/kg resulted in the death of all 
four dogs within 15 days.  Vomiting, diarrhea and decreased food consumption and 
body weight were noted.  Hematological changes were characterized by marked 
leucopenia, thrombocytopenia, an increase in activated partial thromboplastin time, and 
a slight decrease in hematocrit and hemoglobin.  Biochemistry revealed decreases in 
sodium, potassium, chloride, inorganic phosphate and gamma glutamyltransferase 
while increases in total protein, cholesterol, phospholipids, blood urea nitrogen, total 
bilirubin and alkaline phosphatase were observed.  Histological examination in most 
dogs given 10 mg/kg and in all dogs given 40 mg/kg revealed atrophy of the 
hematopoietic tissue with signs of mitotic arrest (e.g., bone marrow, thymus, lymph 
nodes, mucosa-associated lymphoid tissue and spleen).  As a consequence of the severe 
thrombocytopenia, systemic hemorrhage was seen in the intestine, mesentery, 
hematopoietic system, lung, brain, adrenals, skeletal muscle, vagina and subcutaneous 
tissue.  In a toxicity study with recovery in Beagle dogs, oral doses of 10 mg/kg and 40 
mg/kg were administered daily until hematological changes occurred.  Two dogs per 
group were tested.  Leukopenia and thrombocytopenia were noted after four and seven 
days in both dogs, after which dosing was stopped.  Within 14 days after dosing was 
stopped, complete hematological recovery was observed.  Histological examination of 
the testes indicated moderate atrophy.  Slight lymphoid depletion in the mesenteric 
lymph node and the gut associated lymphoid tissue were also seen in the male.  
Examination of three bone marrow biopsies, taken at different times during the study, 


4/21/2009 
T-99-0090, 01-C-0222 
 
 16
revealed distinct regeneration of the hematopoietic tissue.  The degree of atrophy 
ranged from severe atrophy with marked loss of early precursors at the end of dosing to 
slight atrophy and increase in blast cells at the end of recovery. 
Dose dependent lens opacities have been observed after 1 month of dosing of 60 
mg/kg in male Wistar rats (2 out of 30 rats), in 10 mg/kg dosed females (1 out of 20 
rats), in 40 mg/kg dosed females (13 out of 19 rats) and in 60 mg/kg dosed females (26 
out of 28 rats). Changes consisted of localized or diffuse (sub)capsular opacification at 
the posterior pole of the lens. The degree of opacification and the area involved was 
never so extended as to make visualization of the fundus difficult.  This effect was not 
observed in dogs receiving chronic administration of R115777 
1.2.5 
PHASE I CLINICAL TRIALS OF R115777 IN ADULTS 
Solid tumor trials: In the first adult phase I trial (R115777-USA-1), oral R115777 
was administered initially as a solution, then as capsules every 12 hours for 5 days, and 
repeated every 2 weeks.[28]  Doses were escalated from 25 mg q12h to 1300 mg q12h.  
An MTD was not reached in this trial.  One of six patients on the 1300 mg dose level 
developed dose-limiting grade 3 peripheral neuropathy, described as severe burning in 
the lower extremities, oral cavity and vaginal area. The pain resolved within 24 hours of 
stopping R115777.  This patient had a history of prior mild peripheral neuropathy 
attributed to paclitaxel therapy.  Non-dose-limiting toxicities (non-DLT) observed at the 
800 and 1300 mg dose levels were fatigue and an increase in serum creatinine.  Nausea 
and vomiting were observed more frequently with the oral solution than with the 
capsules, but were observed with the capsule formulation at the 800 and 1300 mg dose 
levels. Myelosuppression was mild.  
A phase I trial of oral R115777 on a q12h for 21 day schedule followed by a 7 day 
rest period was performed at the Fox Chase Cancer Center (R115777-USA-3).  At doses 
>300 mg q12h, dose-limiting myelosuppression was observed. In addition, some 
patients experienced fatigue and weakness. 
Two additional adult phase I trials were performed in Europe (R115777-BEL-7, 
R115777-BEL-2) to evaluate the safety, pharmacokinetics and define and MTD of 
R115777, when administered for 4 weeks and continuously for 3 months or more, 
respectively. Reversible grade III diarrhea was reported in a single patient from the 
Netherlands treated at a dose 300 mg bid.  Grade II hypokalemia and grade II renal 
insufficiency was observed in one patient.  After stopping study medication 
hypokalemia and renal insufficiency decreased to grade I.  
On the continuous dosing phase I trial R1157777 was administered at doses from 
50 mg to 500 mg BID.[23]  Dose limiting toxicities (DLT) toxicities were grade 4 
neutropenia (1 pt each at 400 and 500 mg), grade 3 thrombocytopenia (1 patient at 500 
mg), and sensory and motor peripheral neuropathy grade 3 (at 500 mg). The 
neuropathy was not completely reversible in all patients. One patient developed grade 
3 skin hypersensitivity at 150 mg BID. The MTD was 300 mg BID. One partial remission 
was seen in a patient with non-small cell lung cancer.  


4/21/2009 
T-99-0090, 01-C-0222 
 
 17
A phase II study of R115777 in patients with advanced breast cancer was recently 
completed.[12]  R115777 was administered continuously at a dose of 400 mg BID to six 
patients, and because of dose-limiting neutropenia on this schedule, at a reduced dose 
of 300 mg BID to the subsequent 21 patients. Sixteen patients had received prior 
chemotherapy. Toxicities in the 21 patients included grade 3 to 4 neutropenia (29%), 
grade 3 thrombocytopenia (11%), grade 2 to 3 paresthesias/numbness (26%) after a 
median of 10 weeks on therapy, grade 2 to 3 diarrhea (11%), skin rash (11%), and 
fatigue (28%). Confirmed partial responses (PR) were seen in 3 patients (12%). The 
abstract did not describe the time frame for recovery from R115777 associated toxicities 
or if patients fully recovered from neurotoxicity. 
A phase I trial of the combination of oral R115777 with gemcitabine,[20] in which 
gemcitabine was administered at a fixed dose of 1000 mg/ m2 i.v. on days 1, 8, and 15 
every 4 weeks, and R115777 was administered continuously at doses ranging from 100 
to 300 mg q12h was also performed. The MTD of R1157777 on this trial is 200 mg q12h, 
and neutropenia was the DLT.  
A sensory peripheral neuropathy manifesting with pain, tingling, numbness and 
dysesthesias was observed in more than 50% of 19 adult patients who were treated in 
Europe on a trial of continuous administration of R115777 at a dose of 350 mg twice 
daily. The neuropathy was only observed in patients who received doses of R115777 
>200 mg q12h, and who had received the drug for >12 weeks duration. Peripheral 
neuropathy had not previously been observed on the intermittent schedule, but there 
were not as many patients on the intermittent schedule who had prolonged therapy.  
The neuropathy was reversible in all patients after discontinuation of R115777.  
Leukemia trial: A phase I trial of R115777 in adult patients with refractory 
leukemias was conducted at the University of Maryland.17  Patients received oral 
R115777 q12h for up to 21 days at doses ranging from 100 to 1200 mg for 21 days 
followed by a 1-2 week rest period. Thirty patients with refractory leukemias (22 AML, 
5ALL, 3 CML in blast crisis) were enrolled. Reversible myelosuppression was observed 
at doses ≥ 600 mg q12h. Reversible polydipsia and paresthesias were observed at the 
900 mg dose level. Dose-limiting neurotoxicity manifesting with confusion, ataxia and 
vision changes was observed in 3/3 patients entered at the 1200 mg dose level within 48 
hours of starting R115777. These toxicities resolved completely within 72 hours of 
stopping R115777.  Responses (2 CR, 7 PR) were observed at all dose levels. Inhibition 
of FPTase was > 80% at dose levels ≥ 300 mg q12h. Inhibition of farnesylation of lamin 
A and heat shock protein HDJ2 was observed in 4/4 and 6/6 patients at the 600 mg 
dose level, respectively. The MTD was 900 mg q12h, which is 3-fold higher than the 
MTD in adults with solid tumors. 
1.2.6 
PHASE I CLINICAL TRIALS OF R115777 IN CHILDREN 
Solid Tumor Phase I:  The Pediatric Oncology Branch, Texas Children's Cancer 
Center, and the Children Hospital of Cincinnati are currently completing a collaborative 
pediatric phase I trial of R115777 in patients with refractory solid tumors or patients 


4/21/2009 
T-99-0090, 01-C-0222 
 
 18
with neurofibromatosis type 1 (NF1) and progressive neurofibromas (R115777-USA-6).  
The MTD was initially determined on a q12h for 21 days schedule followed by a 7-day 
rest.  The MTD determined on the 21 day schedule was then administered on a 
continuous dosing schedule (28 day cycles with no rest period).  No dose escalation on 
the continuous dosing schedule was planned.  Thirty-six patients (23 with refractory 
solid tumors, 13 with NF1) were entered on the 21 day dosing schedule, and six patients 
(2 with refractory solid tumors, 4 with NF1) on the continuous dosing schedule. Four 
dose levels were studied: 150 mg/m2/dose (n=4), 200 mg/m2/dose (21-day schedule, 
n=13; continuous dosing, n=6), 275 mg/m2/dose (n=12), and 375 mg/m2/dose (n=7). 
Non dose-limiting toxicities included myelosuppression, rash, nausea, diarrhea, 
abdominal pain, and fatigue. Observed dose limiting toxicities are shown in the table 
below: 
Dosel Level 
(mg/m2/dose) 
Pts 
(n) 
Pts DLT
(n) 
Dose-limiting toxicities 
(grade) 
21 day schedule followed by 7 days rest 
150 
4 
 
 
200 
13 
2 
1 Seizure (3), 1 Platelets (4) 
275 
12 
3 
2 Platelets (3)+ANC (4), 1 diarrhea (3) 
375 
7 
4 
2 Rash (3), 1 ANC (4) + 
hypofibrinogenemia (3), 1 Nausea, 
Vomiting, Diarrhea (3) 
Continuous dosing schedule with no rest 
200 
6 
1 
Rash (3) 
The seizure was observed on day 21 of treatment in one patient with 
adrenocortical carcinoma and no prior history of seizures. MRI of the head showed 
diffuse white matter changes, which improved on a follow-up scan. All dose-limiting 
toxicities resolved after discontinuation of R115777. The MTD determined for patients 
with NF1 and refractory solid tumors combined was 200 mg/ m2/dose q12h on both 
schedules 
Four patients with NF1 continue to receive R115777 on the 21 day schedule after a 
median of 19 (range 18-23) cycles, and 3 patients with NF1 continue to receive R115777 
on the continuous dosing schedule after a median of 11 cycles (range 4-13). Peripheral 
neuropathy has not been observed in this trial. However, because of the development of 
peripheral neuropathy in adults, who were treated on the continuous dosing schedule, 
the 21 day schedule followed by a 7 day rest period will be used in future trials with 
R115777. 


4/21/2009 
T-99-0090, 01-C-0222 
 
 19
Leukemia Phase I:  A phase I trial of R115777 for children with refractory 
leukemias is ongoing. Twenty children with refractory ALL (n=11), AML (n=8), or 
JMML (n=1) were treated.  Overall, R115777 has been well tolerated.  At the starting 
dose (300 mg/m2 q12h po x 21 d, repeated q28 d), 3 of 6 evaluable patients had grade 3 
adverse events (AE), which included rash (n=1), hyperbilirubinemia (n=1), 
hyperbilirubinemia and AST (n=1).  The dose was de-escalated to 200 mg/m2, and 2 of 
6 evaluable patients developed grade 3 AE, which included mucositis (n=1), 
hyperbilirubinemia (n=1).  Two of the three patients who developed grade 3 
hyperbilirubinemia, had a history of hyperbilirubinemia during the days preceding 
treatment with R115777, but normal or grade 1 bilirubin immediately prior to R115777.  
After discontinuation of R115777, bilirubin remained elevated in one patient, continued 
to increase in one patient, and decreased to grade 1 toxicity in one patient.  The 
relationship of the study drug to this AE, and of the dose of study drug to this AE are 
thus unclear.  
The protocol was amended to only allow entry of patients with normal liver function 
tests at trial entry (normal bilirubin, AST, and ALT).  Currently, the 300 mg/m2 dose 
level is expanded to enroll up to 12 evaluable patients.   
1.2.7 
CLINICAL PHARMACOKINETICS OF R115777 IN ADULTS AND CHILDREN 
Pharmacokinetic analysis of plasma samples from 19 patients treated on an adult 
phase I trial with R115777 revealed:  
• R115777 is rapidly absorbed after oral administration (time to peak was 
approximately 2-4 hours).  The bioavailability of the capsules increased when 
given after a meal. 
• The concentrations of R115777 decline biphasically with an initial, dominant half-
life of about 2-3 hours and with a median terminal T1/2 of about 6 hours; 
• Over the dosage range studied to date the pharmacokinetics of R115777 appear 
to be linear; 
• The average accumulation ratio of R115777 was calculated at 1.1, and therefore 
minimal accumulation is expected on the q12 hr dosing regimen. 
• In healthy human adults plasma protein binding of R115777 was very high, with 
a free fraction of 0.66-0.77%. 
• In human hepatocytes glucuronidation of R115777 at the imidazole nitrogen was 
the major metabolic pathway. 
 
Pharmacokinetic analysis of oral R115777 has also been performed on plasma 
samples from 30 children (median age 13 years, age range 5 to 17 years) treated on our 
pediatric phase I trial.  In general the pharmacokinetics of R1157777 are similar in adults 
and children. Preliminary observations regarding the plasma pharmacokinetics of 
R115777 in pediatric patients are:  


4/21/2009 
T-99-0090, 01-C-0222 
 
 20
• R115777 is rapidly absorbed after oral administration: The average time to peak 
concentration was 2.7 hours (range 1.0 –8.0 hours); 
• The Average terminal half-life was 6.8 hours (range 2.8-16.7 hours) The 
determination of T1/2 was limited by the 36-hr sampling and highly dependent 
on the ability to quantify low concentrations of R115777 in the terminal phase; 
• Over the dosage range studied to date the pharmacokinetics of R115777 appear 
to be linear: The average AUC increased from 4318 ng•h/ml (± 1763) at the 150 
mg/ m2 dose level to 13536 ng•h/ml (± 7831) at the 375 mg/ m2 dose level. The 
Cmax increased from 1034 ng/ml (± 566) at the 150 mg/ m2 dose level to 2433 
ng/ml (± 730) at the 375 mg/ m2 dose level.  
• Minimal accumulation is expected on the q12 hr dosing regimen. 
 
1.2.8 
PROPOSED PEDIATRIC PHASE II TRIAL OF R115777 
Patients with NF1 are at increased risk of developing a variety of benign and 
malignant tumors of the central and peripheral nervous system.  Plexiform 
neurofibromas occur with the highest frequency, and are associated with considerable 
morbidity.  Management of plexiform neurofibromas is generally surgical.  However, 
up to 44% of tumors progress after the first surgery, most commonly in patients 
younger than ten years of age with head and neck tumors that could not be completely 
resected.[18] There is no other standard treatment modality for patients with 
progressive plexiform neurofibromas. 
Neurofibromas do not follow a classical oncology model, in which tumor growth 
occurs unchecked unless therapy is provided.  Rather, neurofibroma growth can be 
unpredictable, including periods of rapid growth and others of quiescence.  Some 
neurofibromas remain static indefinitely after a period of active growth.  This erratic 
behavior can make it difficult to document the effectiveness of a potential treatment.  
A “Natural History Protocol” (Principal Investigator Dr. Bruce Korf) is currently 
open to patients with NF1 with the main goal to provide data on the growth rate of 
neurofibromas. Patients entered on this study do not receive treatment for their disease, 
but are followed closely clinically and by serial MRI’s. Volumetric MRI analysis is 
evaluated for it’s value in determining the growth rate of plexiform neurofibromas. 
Results from this study will prove very valuable for the design of treatment protocols, 
but are not available to this time point. 
This trial will be a randomized, cross-over, double-blinded, placebo-controlled 
pediatric phase II trial of oral R115777 in children and young adults with NF1 who have 
progressive plexiform neurofibroma(s). Each patient will serve as his/her own control 
for the primary endpoint of time to progression. After documentation of progressive 
disease on the first treatment, patients will be crossed over to receive R115777 (if 
placebo was first given) or placebo (if R115777 was first given). The first treatment that 
a patient is randomized to receive (either placebo or R115777) is defined as “phase A”, 


4/21/2009 
T-99-0090, 01-C-0222 
 
 21
and the second treatment (either placebo or R115777), is defined as “phase B”. This trial 
design is ethical, because alternative designs without placebo control could bias 
observation, and there is no standard treatment to which R115777 may be compared. In 
addition, each patient will receive study medication provided there is disease 
progression, and therefore may derive benefit from the trial.  
R115777 or placebo will be administered twice daily for 21 days followed by a 7 
day rest period between cycles. The dose of R115777 for this trial will be 200 
mg/m2/dose every 12 hours, the MTD on the intermittent dosing schedule on the 
pediatric phase I trial.  
Imaging and measurement of plexiform neurofibromas:  Tumor response criteria 
that are used for cancers are based on one-dimensional (1-D) and two-dimensional (2-
D) tumor measurements (Therasse et al., 2000; Estey et al, 1986). These methods have 
limited value in the assessment of treatment outcome for plexiform neurofibromas, 
which are frequently large, have a complex (non-spherical) shape, and have a slow, 
erratic growth pattern. In order to reproducibly quantify the size of these complex 
lesions and detect small changes in the size over time, we used MR imaging 
characteristics of plexiform neurofibromas to develop an automated method of lesion 
detection and volume measurement. Short T1-Inversion Recovery (STIR) MR images, 
on which plexiform neurofibromas are bright lesions compared with normal 
surrounding tissue, were used to develop a program for automated image analysis 
within 
MEDx 
(v3.41) 
software 
(Sensor Systems, Inc. Sterling, VA). 
Reproducibility and inter-observer 
variability 
of 
this 
automated 
method were determined by 2 
observers who quantified volumes 
for plexiform neurofibromas of the 
orbit 
(n=2), 
face/neck 
(n=3), 
abdomen (n=1), and pelvis (n=3) on 
three different days. For each MR 
image (Figure 1A), the tumor is 
roughly 
outlined 
manually 
including a rim of low signal 
intensity normal tissue (Figure 1B). 
The program then performs a histogram analysis of signal intensity pixel by pixel and a 
threshold that distinguishes high signal intensity tumor from normal tissue is defined 
(Figure 1C). Tumor contours are then determined using a gradient image, connected 
component analysis and automatic edge following operation (Figure 1D). There is an 
option for re-analysis of MR images using an average or selected threshold. Tumor 
volume is calculated by summing the results from all images based on the resulting 2-D 
contours and slice thickness; and a report is generated. 
 
Figure 1: Axial MRI of pelvic plexiform 
neurofibroma. Steps of automated volumetric 
analysis A-D. 
A
B
D
C


4/21/2009 
T-99-0090, 01-C-0222 
 
 22
For comparison, plexiform neurofibroma volume was also determined by manually 
tracing the tumor borders on each MR image. The results of application of the 
automated method are shown in the table below. 
 
Observer 1 
Observer 2 
Mean tumor volume ml, median (range)
291 (80.9-1581) 
290 (75.7-1603)
Inter-day CV %, median (range)
3.6 (0.7-6.0) 
1.6 (0.6-5.6) 
Median (range) % difference in volume between 
observers
6.4 (1.4 – 11.9) 
Correlation automated vs. manual method, R
0.999 
0.999 
This automated volumetric MRI analysis is applicable to most plexiform neurofibromas, 
has excellent intra- and inter-observer reproducibility and agrees with volumes 
determined by manual tumor tracing. This method is used in the currently ongoing 
phase II trial of the farnesyltransferase inhibitor R115777 and in the phase I trial of 
pirfenidone for children with NF1 and plexiform neurofibromas to assess changes in 
tumor size, and in both clinical trials tumor progression is defined as an increase in 
tumor volume by ≥20%.  
This volume increase corresponds to much smaller changes in 1-D, or 2-D 
measurements as outlined in the table below.  
Phase II R117555 
Response Criteria 
RECIST 
Diameter, 2r 
WHO 
Product, (2r)2 
Volume, 4/3Πr3 
Disease progression (Increase) 
20 
44 
73 
12 
25 
40 
 
6 
13 
20 
Shaded areas show current criteria used to define disease progression by RECIST, 
WHO, and the ongoing R115777 NF1 phase II trial 
3D-MRI analysis will be evaluated against conventional 2D-MRI and 1D-MRI 
analysis for its reproducibility in the assessment of disease status of plexiform 
neurofibromas.  Tumor response will therefore also be assessed using 1D-MRI data 
analysis.  Each patient will undergo MRI imaging of all known disease prior to entry on 
each phase of the study. At the time of study entry the extent of the progressive 
plexiform neurofibroma(s) will be determined, and followed for response using 1D-, 
2D-, and 3D-MRI (appendix 1).   
In order to enhance the knowledge about the molecular basis of NF1, and to 
develop surrogate markers for tumor response, this study will attempt to obtain 
biopsies from easily accessible discrete neurofibromas or superficial plexiform 
neurofibromas from all eligible patients prior to entry to treatment, and if feasible at a 
later time point during treatment on each arm of the study. Discrete neurofibromas 
undergo a natural history, beginning as small growing lesions, and maturing into static 
lesions. It is possible that the biology of these lesions differ, and hence might yield 
different results in studies of ras expression, ras mutations and FPTase activity. 


4/21/2009 
T-99-0090, 01-C-0222 
 
 23
However, they may still prove valuable as surrogates.  Furthermore, it is anticipated 
that some patients may require surgery during their treatment on this trial, either for 
complications of NF1 or for other unrelated medical reasons, and attempts will be made 
to obtain tumor biopsies at this time. Tumor biopsies are invasive procedures, and 
patients may refuse to undergo biopsies and still be eligible for the study.   
Tumor samples obtained on this study will be contributed to an already existing 
tumor tissue bank, and samples obtained from plexiform neurofibromas will undergo a 
central pathology review including a detailed morphologic, ultrastructural and 
immunohistochemical analysis (Appendix 2, 3, 4).  All tumor samples will be used to 
establish tumor cell lines (Appendix 3, 4).  Tumor samples obtained prior to study 
entry, and once at steady state on treatment during each study phase (“A”, “B”), will be 
used for molecular biological studies (FPTase activity), expression of N-ras, K-ras, and 
H-ras, ras mutations, and NF1 gene mutations in the GAP related domain.   
Peripheral blood mononuclear cells and tumor specimens obtained at various time 
points during the trial will also be used to measure the level of farnesyl-protein 
transferase (FPTase) activity in order to determine the value of FPTase activity as a 
surrogate marker of tumor response (Appendix 5).   
The contribution of tumor specimens to a central tissue repository will provide 
valuable resources for ongoing as well as future studies aimed at investigating the 
molecular pathogenesis of NF1 tumors, and may allow for the development of 
predictive markers (clinical or molecular) to identify individuals at risk for cancer 
development.  The identification of at risk individuals will have significant impact on 
our management and evaluation of individuals with this common inherited 
predisposition to cancer syndrome. 
Recently the development of chemotherapy induced peripheral neuropathy has 
been correlated with circulating levels of nerve growth factor [3]. Patients who received 
neurotoxic agents experienced a decrease in circulating levels of NGF, which correlated 
with the development and severity of peripheral neuropathy. Peripheral neuropathy 
has been observed in adult patients after ≥12 weeks of chronic dosing. This trial will 
therefore attempt to measure NGF at various time points during treatment with 
R115777 and placebo, and to correlate levels with the development of neuropathy 
(Appendix 6). 
The quality of life of patients treated with R115777 or placebo on this study will be 
assessed using the National Institutes of Health (NIH) Impact of Pediatric Illness (IPI) 
Scale. This questionnaire was developed to assess the effects of chronic illness and 
treatment on the everyday behavior of children. It assesses adaptive behavior, 
emotional functioning, physical status and central nervous system symptoms. This 
questionnaire has not been completely validated, and means and standard deviations 
for different subgroups of patients on the scale and subscales are not available yet. 
Without normative data on this scale for patients with NF1, and having a relatively 
small sample size in the protocol, it may be difficult to analyze the data as an outcome 


4/21/2009 
T-99-0090, 01-C-0222 
 
 24
measure for this particular study. Attempts will be made to compare the quality of life 
of patients while they receive treatment with placebo or R115777. The IPI scale should 
be administered to all patients ≥6 years and ≤ 18 years of age and their primary 
caregiver prior to the start of therapy. This questionnaire will not be administered to 
patients > 18 years. This assessment consists of an age-appropriate questionnaire and 
generally takes less than 30 minutes to complete.  Patients between the ages of 6 and 10 
years of age should be administered the IPI-Young Child form; patients between 11 and 
18 years of age should be administered the IPI-Older Child/Adolescent form; the 
patient’s primary caregiver should receive the IPI-Parent Form. 
2.0 ENROLLMENT PROCEDURES 
2.1 
ELIGIBILITY CRITERIA 
2.1.1 INCLUSION CRITERIA 
2.1.1.1  Age:  ≥3 years and ≤25 years of age 
2.1.1.2  Diagnosis:  Patients with NF1 and progressive plexiform neurofibromas 
that have the potential to cause significant morbidity, such as (but not limited to) head 
and neck lesions that could compromise the airway or great vessels, brachial or lumbar 
plexus lesions that could cause nerve compression and loss of function, lesions that 
could result in major deformity (e.g., orbital lesions), lesions of the extremity that cause 
limb hypertrophy or loss of function, and painful lesions.  Histologic confirmation of 
tumor is not necessary in the presence of consistent clinical and radiographic findings, 
but should be considered if malignant degeneration of a plexiform neurofibroma is 
clinically suspected.  In addition to plexiform neurofibroma(s), all study subjects must 
have at least one other diagnostic criteria for NF1 listed below (NIH Consensus 
Conference[9]): 
1. Six or more café-au-lait spots (≥0.5 cm in prepubertal subjects or ≥1.5 cm 
in postpubertal subjects) 
2. Freckling in the axilla or groin 
3. Optic glioma 
4. Two or more Lisch nodules 
5. A distinctive bony lesion (dysplasia of the sphenoid bone or dysplasia or 
thinning of long bone cortex) 
6. A first degree relative with NF1 
In this study a plexiform neurofibroma is defined as a neurofibroma that has 
grown along the length of a nerve and may involve multiple fascicles and branches. A 
spinal plexiform neurofibroma involves two or more levels with connection between 
the levels or extending laterally along the nerve. 
2.1.1.3  Measurable disease:  Patients must have measurable plexiform 
neurofibroma(s). For the purpose of this study a measurable lesion will be defined as a 


4/21/2009 
T-99-0090, 01-C-0222 
 
 25
lesion of at least 3 cm measured in one dimension. There must be evidence of recurrent 
or progressive disease as documented by an increase in size or the presence of new 
plexiform neurofibromas on MRI. Progression at the time of study entry is defined as:  
• A measurable increase of the plexiform neurofibroma (≥ 20% increase in the volume, 
or a ≥ 13% increase in the product of the two longest perpendicular diameters, or a ≥ 
6% increase in the longest diameter) over the last two consecutive scans (MRI or 
CT), or over the time period of approximately one year prior to evaluation for this 
study. 
• Patients who underwent surgery for a progressive plexiform neurofibroma will be 
eligible to enter the study after the surgery, provided the plexiform neurofibroma 
was incompletely resected and is measurable.  
2.1.1.4  Prior therapy: Patients with NF1 are eligible at the time of recurrence or 
progression of inoperable plexiform neurofibroma. 
A surgical consultation should be obtained prior to enrollment on the study to 
evaluate if tumor resection is a feasible option. Patients will only be eligible if complete 
tumor resection is not feasible, or if a patient with a surgical option refuses surgery. 
Since there is no standard effective chemotherapy for patients with NF1 and 
progressive plexiform neurofibromas, patients may be treated on this trial without 
having received prior therapy. 
Patients must have recovered from the toxic effects of all prior therapy before 
entering this study.  The Cancer Therapy Evaluation Program Common Toxicity 
Criteria (CTC) Version 2.0 will be used for toxicity assessment. A copy of the CTC 
version 2.0 can be downloaded from the CTEP home page at http://ctep.cancer.gov. 
Recovery is defined as a toxicity grade <2, unless otherwise specified in the Inclusion 
and Exclusion Criteria.   
Patients must have had their last dose of radiation therapy at least six weeks 
prior to study entry, and their last dose of chemotherapy at least four weeks prior to 
study entry.  Patients who received G-CSF after the prior cycle of chemotherapy must 
be off G-CSF for at least one week prior to entering this study. 
2.1.1.5  Performance Status:  Patients should have a life expectancy of at least 12 
months and an ECOG performance score of 0, 1, or 2 (see below).  Patients who are 
wheelchair bound because of paralysis should be considered “ambulatory” when they 
are up in their wheel chair. 


4/21/2009 
T-99-0090, 01-C-0222 
 
 26
ECOG Performance Status 
Score Clinical Status 
0 
Asymptomatic 
1 
Symptomatic, fully ambulatory 
2 
Symptomatic, in bed < 50% of the day 
3 
Symptomatic, in bed > 50% of the day but not bedridden 
4 
Bedridden 
2.1.1.6  Hematologic Function:  Patients must have an absolute granulocyte count  
≥1,500/µL , a hemoglobin ≥ 9.0 gm/dl, and a platelet count ≥150,000/µL at study entry, 
and a normal fibrinogen. 
2.1.1.7  Hepatic Function:  Patients must have a bilirubin within normal limits 
and SGPT ≤ 2x upper limit of normal. Patients with Gilbert syndrome are excluded 
from the requirement of a normal bilirubin. (Gilbert syndrome is found in 3-10% of the 
general 
population, 
and 
is 
characterized 
by 
mild, 
chronic 
unconjugated 
hyperbilirubinemia in the absence of liver disease or overt hemolysis). 
2.1.1.8  Renal Function:  Patients must have an age-adjusted normal serum 
creatinine (see table below) OR a creatinine clearance ≥ (70 mL/min/1.73 m2) . 
Age 
(Years) 
Maximum Serum Creatinine 
(mg/dl) 
≤ 5 
0.8 
5 < age ≤ 10 
1.0 
10 < age ≤ 15 
1.2 
> 15 
1.5 
2.1.1.9 Informed Consent: All patients or their legal guardians (if the patients is 
<18 years old) must sign an IRB approved document of informed consent (screening 
protocol) prior to performing studies obtained exclusively to determine patient 
eligibility. After confirmation of patient eligibility all patients or their legal guardians 
must sign the protocol specific informed consent to document their understanding of 
the investigational nature and the risks of this study before any protocol related studies 
are performed (other than the studies which were performed to determine patient 
eligibility). When appropriate pediatric patients will be included in all discussion. Per 
institutional guidelines, age appropriate assent forms for children from 7 through 12 
years, and for children may be developed and, when appropriate, will be signed by the 
pediatric patients in order to obtain written assent.  
2.1.1.10  Durable Power of Attorney (DPA):  All patients ≥18 years of age will be 
offered the opportunity to assign DPA so that another person can make decisions about 
their medical care if they become incapacitated or cognitively impaired. 


4/21/2009 
T-99-0090, 01-C-0222 
 
 27
2.1.1.11  Ability to undergo MRI examinations. 
2.1.2 EXCLUSION CRITERIA 
2.1.2.1  Pregnant or breast feeding females are excluded, because the toxic effects 
and pharmacology of R115777 in the fetus and newborn are unknown. 
2.1.2.2  Clinically significant unrelated systemic illness (serious infections or 
significant cardiac, pulmonary, hepatic or other organ dysfunction) which in the 
judgment of the Principal or Associate Investigator would compromise the patient’s 
ability to tolerate R115777 or are likely to interfere with the study procedures or results. 
2.1.2.3  Prior treatment with >1 prior myelosuppressive chemotherapy regimen. 
2.1.2.4  An investigational agent within the past 30 days. 
2.1.2.5  Evidence of an optic glioma, malignant glioma, malignant peripheral 
nerve sheath tumor or other cancer requiring treatment with chemotherapy or radiation 
therapy. 
2.1.2.6  Ongoing radiation therapy, chemotherapy, hormonal therapy directed at 
the tumor, or immunotherapy.  
2.1.2.7  Inability to return for follow-up visits or obtain follow-up studies 
required to assess toxicity and response to therapy. 
2.1.2.8  Prior treatment with R115777. 
2.2 
PRE-TREATMENT EVALUATION (SEE APPENDIX 7) 
Pre-treatment blood tests should be performed within 2 weeks prior to enrollment 
on the trial unless otherwise stated. The evaluation required prior to starting treatment 
phase “A” and “B” is listed in table form in Appendix 7. 
2.2.1  History and Physical Examination: Complete history (including prior and 
concurrent therapy), physical examination including documentation of measurable 
disease, performance status, and signs and symptoms.  A complete neurologic 
examination should be performed and focus on signs of sensory peripheral neuropathy.  
Height, weight and body surface area must be recorded.  History and physical 
examination will be documented in case report forms as outlined Section 5.1.1. The BSA 
should be calculated from the average of 3 repeated measurements of weight and 
height on the same day using the formula below or a formula used at a participating 
institution: 
BSA = Weight  (kg)0.425 • Height  (cm)0.725
139.315
 
 
2.2.2  PHOTOGRAPHY:  When possible, plexiform neurofibromas that are visible on 
the body surface should be photographed prior to treatment with R115777 and placebo. 
A size marker should be taped to the skin in the field of view when appropriate, and 


4/21/2009 
T-99-0090, 01-C-0222 
 
 28
the plexiform neurofibroma should be photographed so that it fills the frame.  Frontal 
and side images will be taken, as appropriate.  Copies of photographs should be sent to 
the study coordinator, identified by the subject ID number, date, and treatment phase 
(“A” or “B”) and treatment cycle number. 
2.2.3  HEMATOLOGY:  Complete blood counts, differential, platelet count, PT, PTT 
and fibrinogen. 
2.2.4  CHEMISTRIES: Electrolytes (including calcium, phosphorus and magnesium), 
creatinine, SGPT, and bilirubin. 
2.2.5  URINALYSIS 
2.2.6  URINE PREGNANCY TEST: For all females of child-bearing potential. 
2.2.7  RADIOGRAPHIC EVALUATION (APPENDIX 1): MRI scan of the progressing 
plexiform neurofibroma(s) within 2 weeks prior to enrollment on study.  In addition, if 
possible, MRI scan of all known additional, measurable plexiform neurofibroma(s) 
within 2 weeks of enrollment on study. The progressing plexiform neurofibroma(s) will 
be identified as index lesion(s), and will be studied by 3-D MRI. Should there be more 
than 3 progressing plexiform neurofibromas, the three most clinically relevant 
plexiform neurofibromas will be followed by 3-D MRI analysis. The imaging protocol 
outlined in Appendix 1 will be used each time MRI examinations are performed to 
assess the effect to R115777. 
2.2.8  OPHTHALMOLOGIC EVALUATION: Ophthalmologic examination prior to or 
within the first three days of starting treatment with R115777 or placebo, including 
visual fields if the patient is able to cooperate with the exam and examination of the lens 
for opacifications. 
2.2.9 
TISSUE 
PROCUREMENT: 
In 
patients 
with 
easily 
accessible 
discrete 
neurofibromas or superficial plexiform neurofibromas, who consent to the procedure, 
biopsies will be performed prior to the first dose of treatment at study entry.  In 
addition, attempts will be made to obtain tumor specimens from any patients requiring 
surgery for complications of their tumors or for unrelated medical problems.  Peripheral 
blood mononuclear cells for FPTase assay (Section 2.2.10, Appendix 5) should be 
obtained at the same time as biopsy whenever possible.  As this is an invasive 
procedure, patients may refuse biopsy and still be eligible for the study. 
Kits will be supplied for handling and shipping of tumor specimens.  To obtain a 
kit, please call Ms. Andy Gillespie at (301) 402-1848 seven days prior to the planned 
surgery (Appendix 3, Appendix 4).  Two kits will be sent by FedEx to arrive several 
days prior to the surgical procedure.  Included in the kits will be all media and tubes 
needed for shipment. Procedures for tissue handling and shipment are provided in 
Appendices 3 and 4, respectively. 
2.2.10  FARNESYL-PROTEIN TRANSFERASE (FPTase) ACTIVITY IN PERIPHERAL BLOOD 
MONONUCLEAR CELLS (PBMC): Peripheral blood mononuclear cells (PBMC) will be 


4/21/2009 
T-99-0090, 01-C-0222 
 
 29
collected pretreatment. The activity of FPTase will be measured in these samples as a 
surrogate for tumor FPTase inhibition.  If the patient has consented to a tumor biopsy, 
PBMCs should be obtained at the same time as the biopsy (Section 2.2.9).  PBMC should 
be separated from 20 ml of heparinized blood (10 ml in children ≤10 kg) as described in 
Appendix 5.  
2.2.11  NERVE GROWTH FACTOR (NGF):  A blood sample will be collected 
pretreatment. NGF levels will be correlated with the development of clinical 
neurotoxicity (Appendix 6). 
2.2.12  QUALITY OF LIFE (QOL) ASSESSMENT:  The National Institutes of Health 
(NIH) Impact of Pediatric Illness (IPI) Scale, which assesses the impact of disease and 
treatment on children’s behavior, should be administered to all patients ≥ 6 ≤ 18 years of 
age and their primary caregiver prior to the start of therapy.  This assessment consists of 
an age-appropriate questionnaire and generally takes less than 30 minutes to complete.  
Patients between the ages of 6 and 10 years of age should be administered the IPI-
Young Child form; patients between 11 and 18 years of age should be administered the 
IPI-Older Child/Adolescent form; the patient’s primary caregiver should receive the 
IPI-Parent Form. This questionnaire will not be administered to patients > 18 years. 
3.0 IMPLEMENTATION OF STUDY 
 3.1 STUDY DESIGN 
3.1.1 RANDOMIZED DESIGN 
This is a randomized, cross-over, double-blinded, placebo-controlled pediatric 
phase II trial of oral R115777 in children and young adults with NF1 who have 
progressive plexiform neurofibroma(s). Patients will be randomized to either receive 
R115777 or placebo first. After documentation of progressive disease on the first 
treatment, patients will be crossed over to receive R115777 (if placebo was first given) or 
placebo (if R115777 was first given). The first treatment that a patient is randomized to 
receive (either placebo or R115777) is defined as “phase A”, and the second treatment 
(either placebo or R115777), is defined as “phase B”. There should be a 2 week washout 
period, during which no drug is administered, when crossing over from the first (phase 
A) to the second (phase B) treatment. The treatment cycle number will reset to “1” when 
the patient crosses over from “phase A” to “phase B”. For study purposes “arm 1” is 
defined as treatment with R115777 first followed by placebo, and “arm 2” is defined as 
treatment with placebo first followed by R115777.  
3.1.2 PATIENT REGISTRATION AND RANDOMIZATION 
Patients must be registered by contacting Ms. Andy Gillespie at the Pediatric 
Oncology Branch (POB) (phone number, 301-402-1848, e-mail: gillesan@mail.nih.gov). 
When registering a patient, information about all entry criteria (e.g., laboratory results) 
must be available to allow for verification of eligibility. Dr. Brigitte Widemann (phone 
number: 301-496-7387, e-mail: bw42y@nih.gov) or Dr. Frank Balis (phone number 301-


4/21/2009 
T-99-0090, 01-C-0222 
 
 30
496-0085, e-mail balisf@mail.nih.gov) must also be contacted to discuss the patient prior 
to entry on study. The completed Eligibility Checklist (Appendix 8A) and the Blinded 
Patient On Study Form (Appendix 8B) must be faxed to the (POB) c/o Ms. Andy 
Gillespie (Fax: 301-480-8871). All patients will be registered with Orkand (phone: 301-
402-1732, fax: 301-480-0757) by the POB research nurse.  Orkand will notify the POB 
research nurse and the Pharmaceutical Management Branch (PMB), CTEP, NCI of the 
patient’s ID number using the completed Blinded Patient On Study Form (Appendix 
8B). The POB research nurse will notify the registering site of the patient’s ID number 
and, based on notification by Orkand, the PMB will ship drug for that specific patient 
ID number to the registering site (see section 8.0).  After patient registration the POB 
research nurse will also ship a module with the necessary materials to administer the 
quality of life assessment, and the required tests outlined in Appendix 5, 6, and 7 to the 
participating institution. The POB research nurse must also be notified when the patient 
progresses after “phase A” (i.e., crossover notification to the PMB) and when the patient 
progresses after “phase B” (i.e., off-study notification to Orkand and PMB) by faxing the 
completed Progression Checklist (Appendix 9A) and the Blinded Patient Crossover/Off 
Study Form (Appendix 9B) to the Pediatric Oncology Branch (c/o Andy Gillespie) at 
(301) 480-8871.  The POB research nurse will notify the PMB when a patient progresses 
on treatment “phase A”, and Orkand and the PMB when a patient progresses on 
treatment “phase B” using the completed Blinded Patient Crossover/Off Study Form 
(Appendix 9B). A “roadmap” for the patient registration process is shown in Appendix 
10. 
3.1.3 DOSING SCHEDULE AND PRESCRIBING  
R115777 or placebo will be administered orally q12h for 21 days followed by a 7 
day rest period between cycles (28-day treatment cycle).  The patient’s prescriptions 
must include the patient ID number (e.g., 01C0222-01), the patient initials (e.g. ABC = 
first three letters of patient’s last name), the phase (i.e., “Phase A” or “Phase B”), the 
body surface area (in m2), and the dose (i.e.___ mg po q12h). “Phase A” will be defined 
as the treatment after initial randomization until documentation of progressive disease.  
“Phase B” will be defined as the treatment after the patient is crossed over to receive 
R115777 (if placebo was first given) or placebo (if R115777 was first given).  The dosage 
of R115777 will be 200 mg/m2/dose (see dosing table in section 3.2).  Patients will 
continue on therapy until they meet one of the off-study criteria (Section 3.6).  There 
should be a 2 week washout period, during which no drug is administered, when 
crossing over from “Phase A” to “Phase B”. Patients or their guardians will keep a diary 
to document the intake of each dose of R115777 and potential side effects (Appendix 
11A). Each institutional pharmacy will ensure quality control procedures for R115777 
and placebo allocation, and will use the Pill Count Case Report Form (Appendix 11B) 
for dispensing the boxes, and for counting the dispensed and returned tablets. The 
tearoff labels from boxes will also be attached on this form. The patient diary and the 
Pill Count Case Report Form should be reviewed with the patient’s family after 
completion of every three treatment cycles, and drug should be accounted for at this 


4/21/2009 
T-99-0090, 01-C-0222 
 
 31
time (Appendix 11A/B). These diaries and copies of the Pill Count Case Report Form 
will be forwarded to Ms. Andy Gillespie (Pediatric Oncology Branch, NCI, FAX: 301-
480-8871, Phone: 301-402-1848) after completion of every 3 treatment cycles. 
3.1.4 MONITORING TIME TO PROGRESSION AND RESPONSE  
This phase II trial is designed to determine the time to tumor progression and 
response rate with R115777 in patients with NF1 and progressive plexiform 
neurofibromas.  The primary endpoint will be time to progression.  Each patient will 
undergo MRI imaging of all known disease prior to entry on study. At the time of study 
entry one to three progressing plexiform neurofibroma(s) will be identified as index 
lesion(s), and followed for progression and response using 1D-, 2D-, and 3D-MRI.  
Results obtained with 1D-MRI and 3D-MRI analysis will be compared to conventional 
2D-MRI analysis for their ease and reproducibility.  The imaging protocol outlined in 
Appendix 1 will be used each time MRI scans are performed to assess response to 
R115777. MRI scans are performed prior to cycles 1, 4, 7, 10, and then after every 6 
cycles on each study phase.  If a patient is removed from a study phase because of 
clinical evidence of disease progression, the MRI scans should be repeated if they had 
not been performed within the past 4 weeks. 
3.1.5 DEFINITION OF TUMOR PROGRESSION 
• A ≥ 20% increase in the volume (by 3D-MRI) of at least one of the index plexiform 
neurofibromas compared to the pretreatment volume measured prior to the start of 
the current treatment phase. 
• Appearance of new discrete dermal neurofibroma(s) does not qualify for disease 
progression. 
• Worsening of existing symptoms or the appearance of new symptoms that persist 
for more than 7 days and that are felt to be definitely related to plexiform 
neurofibroma should be evaluated by repeating the MRI.  Patients should not be 
classified as having progressive disease solely on the basis of new or increased 
symptoms without discussing the case with the protocol Principal Investigator. 
• Patients with other evidence of disease progression than outlined above should also 
be discussed with the Principal Investigator. 
3.1.6 TISSUE PROCUREMENT 
This study will attempt to obtain biopsies from easily accessible discrete 
neurofibromas or superficial plexiform neurofibromas from all eligible patients prior to 
the start of treatment, and if feasible at a later time point during treatment (at steady 
state, between day 15-21 on cycle 1) on each treatment phase.  In addition, attempts will 
be made to obtain tumor specimens from any patients requiring surgery for 
complications of their tumors or for unrelated medical problems (Appendices 3 and 4).  
Peripheral blood mononuclear cells for FPTase activity (Section 3.1.8, Appendix 5) 
should be collected at the same time as the biopsy. 


4/21/2009 
T-99-0090, 01-C-0222 
 
 32
The following studies will be performed with tumor specimens (Appendices 2, 3, 
4): (1) FPTase activity, (2) expression of N-ras, H-ras, and K-ras, and (3) ras mutations, 
and (4) NF1 mutations in the GAP related domain, (5) establishment of tumor cell lines, 
and (6) detailed immunohistochemical analysis (plexiform neurofibromas only).  
Findings will be correlated with response to treatment with R115777.  It is hypothesized 
that ras mutations will be rare, germline NF1 mutations will be found in all tumors, and 
additional NF1 mutations will be found in many cases.  
 3.1.7 ESTABLISHMENT OF TUMOR CELL LINES AND TISSUE BANK 
Attempts will be made to establish tumor cell lines from tumor specimens from 
patients treated on this trial. The tissue bank and pathology review will be open to use 
by the scientific community, provided IRB approval for research questions not 
addressed by this protocol is obtained, in order to collect more information on the 
pathology, genetics, and cell biology of plexiform neurofibromas. 
3.1.8 FPTASE ACTIVITY IN PBMC 
FPTase activity will be assessed in PBMCs pretreatment and once between days 15 
and 21 of treatment (steady state) on cycle #1 of each treatment phase (“A” and “B”) as 
a surrogate marker for the effect of R115777 (Appendix 5).  PBMCs should be obtained 
at the same time as tumor biopsies in patients who consent to a biopsy. 
3.1.9 NERVE GROWTH FACTOR (NGF) 
A blood sample will be collected pretreatment, and then prior to cycles 4, 7, 10, 
and then after every six cycles on treatment phase (“A” and “B”). NGF levels will be 
correlated with the development of clinical neurotoxicity (Appendix 6). 
3.1.10 MONITORING  TOXICITY 
The hematologic and non-hematologic toxicities of R115777 will be monitored and 
recorded throughout treatment with R115777 or placebo. (Appendix 1 and Sections 3.4 
and 3.7).  The Cancer Therapy Evaluation Program Common Toxicity Criteria (CTC) 
Version 2.0 will be used for toxicity assessment. A copy of the CTC version 2.0 can be 
downloaded from the CTEP home page at http://ctep.cancer.gov (Section 5.3). 
3.2 
DRUG ADMINISTRATION   
R115777 or placebo in 50 mg tablets will be manufactured by Janssen 
Pharmaceuticals and supplied by CTEP, NCI under IND #58359.  Tablets will be 
administered orally immediately after a meal every 12 hours for 21 days followed by a 7 
day rest period (28 day cycles).  The dose of R115777or placebo will be 200 mg/m2 
every 12 hours, and is based on the maximum tolerated dose on the intermittent dosing 
schedule from the pediatric phase I trial. See Section 2.2.1 for calculation of BSA.  Each 
patient’s dose will be rounded to the nearest 50 mg according to the following dosing 
table:  


4/21/2009 
T-99-0090, 01-C-0222 
 
 33
 
BSA (m2) 
R115777 / Placebo  
(mg po q12h) 
R115777 / Placebo 
(# of 50 mg tablets po q12h) 
0.00 - 0.37 
50 
1 
0.38 - 0.62 
100 
2 
0.63 - 0.87 
150 
3 
0.88 - 1.12 
200 
4 
1.13 - 1.37 
250 
5 
1.38 + 
300 
6 
Tablets may be crushed for easier consumption in young children. 
R115777/placebo should be re-taken if vomiting occurs within 30 minutes of 
taking the dose. 
Patients who have to undergo an elective major surgical procedure (not to include 
the biopsy of discrete neurofibromas requested on this protocol) should stop taking 
study drug one week before the surgery, and are allowed to resume study drug 2 weeks 
after surgery, provided they have recovered from the procedure. 
3.3 
MODIFICATIONS FOR TOXICITY 
Patients who experience grade 2 toxicity (CTC v. 2) related to R115777 or placebo 
should have R115777/placebo withheld until the toxicity resolves (grade ≤1) and then 
restarted at the same dose level.  If the grade 2 toxicity recurs, the R115777/placebo 
dose should be withheld again until the toxicity resolves (grade ≤1) and then reduced 
by 50 mg per dose. For patients with a BSA ≤0.37 the dose will be reduced to 50 mg 
once daily.  If the grade 2 toxicity recurs the patient should be taken off protocol.  If a 
grade 2 toxicity persists for >10 days off therapy, the patient should be discussed with 
the PI. 
Patients who experience grade 3 or 4 toxicity related to R115777 or placebo should 
have their dose withheld.  If the toxicity returns to grade ≤1 within 10 days, patients 
may resume R115777/placebo at a dose reduced by 50 mg per dose. For patients with a 
BSA ≤0.37 the dose will be reduced to 50 mg once daily.  If the toxicity persists at grade 
≥2 for >10 days without administration of R115777/placebo or the grade 3 or 4 toxicity 
recurs at the lower dose level, the patient should be removed from the study (see 
Section 3.6.2). 
If the toxicity warrants, the physician can determine whether the patient is 
receiving R115777 or placebo (unblind the study) by calling Dr. Brigitte Widemann 
(301) 496-7387 or Dr. Frank Balis (301) 496-0085.  These physicians can also be reached 
through (301) 496-7704 or the NIH page operator (301) 496-1211 (see section 8.2.5).  
Pediatric Oncology Branch staff will require the protocol number (i.e., ‘T99-0090’), the 
patient’s ID number (e.g., ‘00-C0222-01’), the phase (i.e., ‘A’ or ‘B’), and the patient’s 


4/21/2009 
T-99-0090, 01-C-0222 
 
 34
initials (first three letters of last name, eg., ‘ABC’) to unblind the patient.  The unblinded 
patient must be removed from the study.  
3.4 
ON STUDY EVALUATION (SEE APPENDIX 7) 
3.4.1  HISTORY & PHYSICAL EXAMINATION: Every 2 weeks during the first 3 cycles  
on each treatment phase (“A”, “B”).  Physical exam should include assessment of 
performance status (documentation if changed from baseline), measurement of visible 
or palpable neurofibroma, height, weight and body surface area prior to every 
treatment cycle.  A complete neurologic examination should be performed and focus on 
signs of sensory peripheral neuropathy.  After cycle 3 perform prior to each cycle. 
History and physical examination will be documented in case report forms as outlined 
Section 5.1.1. 
3.4.2  PHOTOGRAPHY: When possible, plexiform neurofibromas that are visible on 
the body surface should be photographed prior to treatment cycle 1, 4, 7, 10, and then 
after every 6 cycles on each treatment phase (“A”, “B”).  A size marker should be taped 
to the skin in the field of view when appropriate, and the plexiform neurofibroma will 
be photographed so that it fills the frame.  Frontal and side images will be taken, as 
appropriate.  Copies of photographs identified by the patient ID number, date, 
treatment phase (“A” or “B”), and treatment cycle should be sent to: 
Andy Gillespie, R.N. 
Pediatric Oncology Branch, NCI 
10 Center Drive, MSC 1928 
Bldg. 10/Rm. 13N240 
Bethesda, MD 20892-1928 
3.4.3  LABORATORY ASSESSMENT (see Appendix 7). Laboratory studies will be 
documented in case report forms as outlined Section 5.1.1. 
Hematology: During the first 3 cycles of treatment on each treatment phase (“A”, 
“B”), obtain complete blood count, differential and platelet count every other week 
(more frequent monitoring may be performed if the ANC <1,000/mm3 or platelet count 
<50,000/mm3).  During subsequent cycles complete blood count, differential, and 
platelet count will be obtained prior to each cycle.  PT, PTT and fibrinogen will be 
obtained prior to each treatment cycle on each treatment phase. 
Chemistries: During the first 3 cycles of treatment on each treatment phase (“A”, 
“B”), obtain electrolytes, creatinine, calcium, magnesium, phosphorus, SGPT, and 
bilirubin every other week.  During subsequent cycles these tests should be performed 
prior to each treatment cycle. 
Urinalysis:  Prior to treatment cycle 1, 4, 7, 10, and then q 6 cycles on each 
treatment phase (“A”, “B”). 
3.4.4  RADIOGRAPHIC EVALUATION: Evaluate the index lesions by MRI prior to cycle  
1 on treatment phase “A”, and prior to cycle 4, 7, 10, and then after every 6 cycles on 
each treatment phase (“A”, “B”).  The protocol outlined in Appendix 1 will be used each 


4/21/2009 
T-99-0090, 01-C-0222 
 
 35
time MRI examinations are performed to assess progression or response to R115777 or 
placebo. In patients with clinical suspicion of disease progression MRI analysis should 
be performed earlier using the protocol outlined in Appendix 1. At the time of disease 
progression on treatment phase “A”, if possible, a MRI scan of all known measurable 
plexiform neurofibromas in addition to the index lesions should be performed, in order 
to have a new baseline prior to treatment phase “B” (Appendix 1). 
3.4.5  OPHTHALMOLOGIC EVALUATION: Prior to or within the first three days of 
starting treatment phase “A”, and prior to or within the first 3 weeks of starting 
treatment phase “B”. Exam should include visual fields if the patient is able to 
cooperate with the exam and examination of the lens for opacifications. 
3.4.6  TISSUE PROCUREMENT: In patients with easily accessible discrete 
neurofibromas or superficial plexiform neurofibromas, who consent to the procedure, 
biopsies will be performed prior to the first dose of treatment on phase “A”, and if 
feasible at one steady state time point on each treatment phase (“A”, “B”) (between day 
15-21 on cycle #1) of treatment.  In addition, attempts will be made to obtain tumor 
specimens from any patients requiring surgery for complications of their tumors or for 
unrelated medical problems.  Peripheral blood mononuclear cells for FPTase assay 
(Section 3.4.7, appendix 5) should be obtained at the same time as biopsy whenever 
possible.  As this is an invasive procedure, patients may refuse biopsy and still be 
eligible for the study. 
Two kits will be supplied for handling and shipping of tumor specimens.  To 
obtain the kits, please call Ms Andy Gillespie (301)-402-1848.  Kits will be sent by FedEx 
to arrive several days prior to the surgical procedure.  Included in the kits will be all 
media and tubes needed for shipment. Procedures for tissue handling and shipment are 
provided in Appendices 3 and 4, respectively. 
3.4.7 FPTase ACTIVITY IN PBMC: PBMC should be collected pretreatment, and once 
between days 15 and 21 of treatment (steady state) on cycle #1 of each treatment phase 
(“A” and “B”). If the patient has consented to a tumor biopsy, PBMCs should be 
obtained at the same time as the biopsy (Section 3.4.6).  PBMC should be separated from 
20 ml of blood (10 ml in children ≤10 kg) as described in Appendix 5. 
3.4.8  NERVE GROWTH FACTOR: A blood sample will be collected pretreatment, and 
prior to cycles 4, 7, 10, and then after every six cycles on each treatment phase (“A”, 
“B”). Nerve growth factor levels will be correlated with the development of clinical 
neurotoxicity (Appendix 6). 
3.4.9  QUALITY OF LIFE (QOL) ASSESSMENT: The National Institutes of Health (NIH) 
Impact of Pediatric Illness (IPI) Scale, which assesses the impact of disease and 
treatment on children’s behavior, should be administered to all patients ≥6 years to 18 
years of age and their primary caregiver prior to the start of therapy, and then prior to 
cycles 4, 7, 10, and then after every 6 cycles on each treatment phase.  This questionnaire 
has not been completely validated, and means and standard deviations for different 
subgroups of patients on the scale and subscales are not available yet.  This assessment 


4/21/2009 
T-99-0090, 01-C-0222 
 
 36
consists of an age-appropriate questionnaire and generally takes less than 30 minutes to 
complete.  Patients between the ages of 6 and 10 years of age should be administered 
the IPI-Young Child form; patients between 11 and 18 years of age should be 
administered the IPI-Older Child/Adolescent form; the patient’s primary caregiver 
should receive the IPI-Parent Form. This questionnaire will not be administered to 
patients > 18 years. Patient and parent response forms should be photocopied after 
completion and copies sent to Ms. Andy Gillespie, Pediatric Oncology Branch, NCI, 
FAX: (301)-480-8871, Building 10, Room 13N240, 10 Center Drive, Bethesda, MD 20892-
1928 within 2 weeks of completion of the cycle of therapy.  Any questions regarding the 
administration of the IPI Scale should be addressed to Pam Wolters, Ph.D. at phone: 
301-496-0561, e-mail: pw34m@nih.gov. 
 
3.5 
CONCURRENT THERAPY 
Other cancer chemotherapy, radiation therapy, immunotherapy, or investigational 
agents can not be administered to patients receiving R115777 or placebo. 
Alternative Therapy: Oral vitamin or nutritional supplements may be used if 
approved by the patient’s primary physician, and should be recorded in the patient’s 
history and diary. 
Pharmacokinetic data suggest that H2 antagonists and proton pump inhibitors do 
not alter the exposure to R115777 to a clinically significant extent. Patients may use 
proton pump inhibitors or H2 antagonists during the treatment portion of this study. 
However, patients should be instructed to use antacids (Mg- or Al-containing 
formulations) AT LEAST 2 hours before or after intake of the oral study drug.  
3.6 
OFF STUDY CRITERIA 
3.6.1  ADMINISTRATIVE:  A patient may be taken off the study for the following non-
medical or administrative reasons: 
• Patient refusal of further treatments (reasons must be noted on the patient’s CRF). 
• It is deemed in the best interest of the patient.  In this instance the Principal 
Investigator should be notified and the reasons for withdrawal should be noted in 
the CRF.  
• Serious protocol violation as determined by the PI or representative from CTEP. 
3.6.2  TOXICITY:  Recurrent grade 3 or 4 toxicity after dose reduction or persistent 
toxicity grade ≥2 for >10 days without administration of drug that is considered 
primarily related to study drug (Section 3.3).  Persistent (>10 days) grade 2 toxicity 
should be discussed with the PI prior to removing the patient from the study.  The 
protocol Principal Investigator and CTEP should be notified immediately in the event of 
severe or life-threatening toxicity (Dr. Brigitte Widemann, 301-496-7387, 301-496-1211 


4/21/2009 
T-99-0090, 01-C-0222 
 
 37
page operator, and CTEP, Investigational Drug Branch (301) 230-2330 (recorder after 
hours). 
If toxicity necessitates unblinding the study drug for a patient, the patient should 
be removed from the study. 
3.6.3  TUMOR PROGRESSION:  Any patient with clinical or radiographic evidence of 
progressive disease (see Section 3.1.5) on treatment “phase A”, as documented by 3D-
MRI, following any treatment cycle will be switched to treatment “phase B” (from 
R115777 to placebo or vice versa). After disease progression on both treatment phases, 
patients will be removed from study (see Sections 3.1.5 and 5.2).  The POB research 
nurse must be notified when the patient progresses after “phase A” (crossover 
notification to PMB) and when the patient progresses after “phase B” (i.e., off-study 
notification to Orkand and PMB) by faxing the completed Tumor Progression Checklist 
and the Crossover / Off-Study Form (Appendix 9A/B) to the Pediatric Oncology 
Branch (c/o Andy Gillespie) at (301) 480-8871.  
3.6.4  The development of a concurrent serious medical condition that might 
preclude or contraindicate the further administration of R115777. 
3.7 
POST-STUDY EVALUATION 
The following tests and procedures should be performed, if possible, at the time a 
patient comes off study regardless of the reason for coming off study, unless the test or 
procedure has been performed in the past 6 weeks (2 weeks for physical examination 
and laboratory assessment). 
3.7.1  HISTORY & PHYSICAL EXAMINATION (including a neurologic exam, 
performance status, and measurement of visible or palpable tumor lesions). 
3.7.2  PHOTOGRAPHS of visible lesions (See Section 3.4.2) 
3.7.3  LABORATORY ASSESSMENT 
Complete blood count, differential and platelet count, PT, and PTT. 
Electrolytes, creatinine, calcium, magnesium, phosphorus, SGPT, bilirubin. 
Urinalysis. 
3.7.4  MRI Scan of the index lesions and any other progressing lesions using the 
protocol outlined in Appendix 1. 
4.0 SUPPORTIVE CARE 
GENERAL: Appropriate antibiotics, blood product support, antiemetics and general 
supportive care will be used as indicated. 
HEMATOPOIETIC GROWTH FACTORS: Hematopoietic growth factors (e.g., EPO, G-CSF, 
GM-CSF) should not be administered except to those patients with either grade 4 
neutropenia and blood culture positive septicemia, or grade 4 neutropenia of ≥7 days 
duration. 


4/21/2009 
T-99-0090, 01-C-0222 
 
 38
5.0 DATA COLLECTION AND EVALUATION 
5.1 DATA COLLECTION 
The POB, NCI will coordinate data collection and supply the data to the trial 
sponsor (CTEP) via the CDUS online system.  Data will also be entered into the NCI 
Center for Cancer Research (CCR) C3D database. Documentation and date of IRB 
approval must be provided to CTEP and the POB, NCI prior to initial patient entry 
from each institution. The completed Eligibility Checklist and On-Study Form 
(Appendix 8 A/B) must be faxed to Ms. Andy Gillespie at (301) 480-8871 prior to 
patient entry onto the trial. The completed Tumor Progression Checklist and Crossover 
/ Off-Study Form (Appendix 9A/B) must be faxed to Ms. Andy Gillespie at the time a 
patient has documented tumor progression on treatment phase “A” and on treatment 
phase “B”. 
5.1.1 CASE REPORT FORMS   
Case Report Forms have been developed by the POB. CRFs should be completed 
after each patient evaluation and submitted within 2 weeks of completion of each 
evaluation to: 
Pediatric Oncology Branch, NCI 
c/o Ms. Andy Gillespie 
FAX: (301) 480-8871 
Bldg. 10/Rm. 13N240 
10 Center Drive, MSC 1928 
Bethesda, MD 20892-1928 
The following forms should be submitted to the POB: 
ELIGIBILITY CHECKLIST AND BLINDED PATIENT ON STUDY FORM (APPENDIX 8 A/B): To 
be completed at study entry and forwarded to Ms. Andy Gillespie (301) 480-8871 
(Phone, 301-402-1848) 
PROGRESSION CHECKLIST AND BLINDED PATIENT CROSSOVER / OFF-STUDY FORM  
(Appendix 9A/B): To be completed and forwarded to Ms. Andy Gillespie (301) 480-
8871 (Phone, 301-402-1848) when a patient progresses on treatment phase “A” and “B”. 
PATIENT DIARIES AND PILL COUNT CASE REPORT FORM (APPENDIX 11A/B): Patients or 
their guardians will keep a diary to document the intake of each dose of R115777 or 
placebo and potential side effects (Appendix 11A). Each pharmacy will use the Pill 
Count Case Report Form (Appendix 11B). The completed diaries and Pill Count Case 
Report Forms will be forwarded to Ms. Andy Gillespie after every three treatment 
cycles at (301) 480-8871 (Phone, 301-402-1848).  
MRI STUDIES (Appendix 1): A copy of the MRI protocol used to obtain the baseline 
MRI study should be Faxed to Ms. Andy Gillespie within 1 week of obtaining the MRI 
study.  MRI studies should be submitted electronically or on CD or optical disk to the 


4/21/2009 
T-99-0090, 01-C-0222 
 
 39
NCI POB within 1 week of obtaining the study.  The institutional radiology report for 
each study should be faxed to Ms. Andy Gillespie within 1 week. 
QOL ASSESSMENT (NIH IPI SCALE) FORMS:  Patient and parent response forms 
should be photocopied after completion and copies sent to Ms. Andy Gillespie, 
Pediatric Oncology Branch, NCI, FAX: (301)-480-8871, Building 10, Room 13N240, 10 
Center Drive, Bethesda, MD 20892-1928 within 2 weeks of completion of the cycle of 
therapy.  Any questions regarding the administration of the IPI Scale should be 
addressed to Pam Wolters, Ph.D. at phone: 301-496-0561, e-mail: pw34m@nih.gov. 
LABORATORY STUDIES:  Results of laboratory studies requested per protocol should 
be faxed to Ms. Andy Gillespie within 1 week of performing the study. 
Protocol violations should be directly reported to Dr. Brigitte Widemann (phone: 
301-496-7387, fax: 301-480-8871, e-mail: bw42y@nih.gov). 
Patients will be identified in all data collection forms and on photographs only by 
their initials and study number in an effort to maintain patient confidentiality. All 
patient documents, including informed consent and case report forms, will be kept in 
designated offices, in locked file cabinets with access only to personnel involved in the 
clinical trial. The NCI Center for Cancer Research (CCR) C3D electronic database is 
password protected and allow access only to persons directly involved in the clinical 
trial. All documents will be stored for at least 2 years after the drug has received 
marketing approval, or after the decision has been made not to market the drug.  
5.2 RESPONSE CRITERIA 
Response is assessed at the time that follow-up 3D-MRI scans are performed (prior 
to cycles 4, 7, 10, then q6 cycles). For the purpose of determining the level of response 
(complete, partial, minor, etc.) measurements from the follow-up scans are compared to 
the tumor size in the pretreatment MRI scan using 3D data analysis. Response 
determined using 3D-MRI volumetric analysis will be compared with 2D- and 1D-MRI 
measurements.   
COMPLETE RESPONSE (CR): A complete resolution of all measurable or palpable soft 
tissue tumors for ≥ 4 weeks and no appearance of new lesions. 
PARTIAL RESPONSE  (PR): A ≥50% reduction in the sum of the volume of all index 
lesions for ≥4 weeks.  
MINOR RESPONSE (MR): A ≥25% but <50% reduction in the sum of the volume of all 
index lesions for ≥4 weeks.  
STABLE DISEASE (SD): A <20% increase, and < 25% decrease in the sum of the 
volume of all index lesions for ≥4 weeks.  
PROGRESSIVE DISEASE (PD):  


4/21/2009 
T-99-0090, 01-C-0222 
 
 40
• A ≥ 20% increase in the volume (by 3D-MRI) of at least one of the index plexiform 
neurofibromas compared to the pretreatment volume measured prior to the start of 
the current treatment phase. 
• The appearance of new discrete subcutaneous neurofibromas does not qualify for 
disease progression.  
• Worsening of existing symptoms or the appearance of new symptoms that persist 
for more than 7 days and that are felt to be definitely related to the plexiform 
neurofibroma should be evaluated by repeating the MRI.  Patients should not be 
classified as having progressive disease solely on the basis of new or increased 
symptoms without discussing the case with the protocol Principal Investigator. 
• Patients with other evidence of disease progression than outlined above should also 
be discussed with the Principal Investigator. 
5.3 TOXICITY CRITERIA 
Toxicity will be graded according to the CTEP Expanded Common Toxicity 
Criteria, version 2. The Cancer Therapy Evaluation Program Common Toxicity Criteria 
(CTC) Version 2.0 will be used for toxicity assessment. A copy of the CTC version 2.0 
can be downloaded from the CTEP home page (http://ctep.cancer.gov).  
5.4 STATISTICAL CONSIDERATIONS 
5.4.1 SUBJECT ACCRUAL 
Subjects of both genders, from all racial and ethnic groups are eligible for this trial 
if they meet the criteria outlined in Section 2.1. To date, there is no information that 
suggests differences in drug metabolism or disease response among racial or ethnic 
groups or between the genders, indicating that results of the trial will be applicable to 
all groups. Most plexiform neurofibroma grow out of proportion to somatic growth for 
a period of time during childhood, but reach a plateau by the end of puberty.  Efforts 
will be made to extend the accrual to a representative population, but in a phase II 
study with limited accrual, a balance must be struck between patient safety 
considerations and limitations on the number of individuals exposed to potentially 
toxic or ineffective treatments on the one hand and the need to explore gender, racial, 
and ethnic aspects of clinical research on the other. If differences in outcome that 
correlate to gender, age, racial, or ethnic identity are noted, accrual may be expanded or 
additional studies may be performed to investigate those differences more fully.  
5.4.2 STATISTICS AND FEASIBILITY 
The primary objective of the study is to determine whether R115777 (“drug”) is 
able to increase the time to progression of patients who have NF1 with progressive 
plexiform neurofibromas.  The study will be conducted as a crossover, two-arm 
randomized, double-blind, placebo controlled trial.  After being randomized to drug or 
placebo, patients will be followed until progression.  Once patients have progressed 
(documented by MRI), they will be crossed over to receive the placebo if they originally 


4/21/2009 
T-99-0090, 01-C-0222 
 
 41
received drug, and drug if they originally received placebo.  Because the time until 
crossover is dependent on time until progression, this differs from a classic crossover 
study, in which patients are followed on both treatment arms for a predetermined fixed 
period of time, evaluated, given a wash-out period, and then followed identically on the 
other agent.  As such, results from the first placebo vs. drug period will be used to 
determine sample size, and will constitute the primary endpoint of time to disease 
progression.  The natural history of the growth rate and range of plexiform 
neurofibromas is not well known.  In addition to the analysis of time to disease 
progression on the first treatment phase, a paired comparison of the first and second 
treatment phase (each patient will serve as his/her own control) will be performed 
using appropriate non parametric methods.  This analysis will also help provide 
additional information on the differences in the natural history of NF1, and also address 
the effect of other variables, for example age differences, which may impact on the 
growth rate of plexiform neurofibromas.  
Because the estimate of time to progression for patients eligible for this trial is 
approximately 6 months, it would be desirable to increase this time to 12 months.  A 
one-tailed hypothesis will be used since it would only be considered interesting to see 
the improvement of drug compared to placebo.  With 80% power and a one-tailed 
alpha=0.05, in order  to detect a difference in median time to progression (during the 
first part of the trial) between the two arms of 6 vs. 12 months, 30 patients per arm are 
required (60 total) assuming 36 months of accrual and 12 months of additional follow-
up following entry of the last patient. Kaplan-Meier analysis using log-rank statistics 
will be used to perform the required evaluation. We plan to replace patients who were 
diagnosed with a malignant peripheral nerve sheath tumor (MPNST) after enrolling on 
study, as these patients will not be evaluable for the primary outcome measure, which 
is time to progression of progressive plexiform neurofibromas.  For this reason we will 
increase the accrual ceiling to 63 patients   
Randomization of patients between the two study arms will be performed 
centrally by Orkand (See Section 3.1.1, 3.1.2).  With more than one institution 
participating, it is expected that 20 patients per year can be entered onto the trial, with 
an expected accrual period of 3 years. 
This trial will be monitored by the NCI/DCS Data Safety and Monitoring Board.  
Due to the projected accrual rate, it is expected that 3 interim evaluations and a final 
evaluation will take place at each of 4 consecutive annual meetings of the DSMB. Using 
the O’Brien-Fleming approach, if the p-values at the following evaluations are less than 
or equal to those tabled below, then the trial would be declared to have a statistically 
significant result; no further accrual would be required once such a determination has 
been made. 
Evaluation # 
Threshold p-Value 
(one-tailed) 
1 
0.00005 


4/21/2009 
T-99-0090, 01-C-0222 
 
 42
2 
0.0039 
3 
0.0184 
4 (FINAL) 
0.0412 
In addition, if, at any annual evaluation, a conditional power analysis indicates that 
there is a minimal chance of declaring a significant advantage to drug with the addition 
of the remaining planned patients based on results to date and the hypothesized results,  
then the DSMB may choose to close the study to further accrual. 
Time to progression between the two study arms will be compared separately for 
the two periods of the cross-over study; initial treatment and second (crossover) 
treatment.  Both comparisons will be reported in order to describe the effect of drug on 
this endpoint.  In addition, because each patient will have received both placebo and 
drug, comparisons of time to progression can be undertaken between both treatment 
conditions, employing methodology for paired subject data in order to further interpret 
the findings. 
The quality of life of patients treated with R115777 and placebo on this study will 
be assessed using the National Institutes of Health (NIH) Impact of Pediatric Illness 
(IPI) Scale (Section 1.2.8), and scores of patients will be compared using the paired t-test. 
5.5 
MULTI-INSTITUTIONAL GUIDELINES 
5.5.1 IRB APPROVALS 
The PI from each participating institution will provide the Study Coordinator 
with a copy of the initial IRB protocol approval and the yearly IRB continuing 
reviews, and the Study Coordinator will submit these to the NCI IRB.  
Registration will be halted at a participating institution if a current continuing 
approval is not on file at the NCI IRB. 
5.5.2 AMENDMENTS AND CONSENTS 
The PI from each participating institution will provide the Study 
Coordinator with a copy of IRB approval of all amendments to the 
protocol or consent, and the Study Coordinator will submit these 
institutional reviews to the NCI IRB. 
5.5.3 PATIENT REGISTRATION 
All patients entered at the POB, NCI will be registered with the DCS 
Central Office (ORKAND). The completed eligibility checklist and On-
Study Form (Appendix 8 A/B) must be FAXed to the POB prior to 
enrollment on the trial. 
5.5.4 DATA COLLECTION AND TOXICITY REPORTING 
The trial is being sponsored by CTEP and monitored through the CDUS 
system.  Case report forms developed by the Pediatric Oncology Branch 
will be used for submitting clinical data to the coordinating center and this 
data will be entered into the NCI CCR C3D database.  Data must be 


4/21/2009 
T-99-0090, 01-C-0222 
 
 43
submitted to the Coordinating Center within 2 weeks of completing each 
treatment cycle while the patient is on treatment.  All adverse events from 
participating institutions will be submitted to the NCI IRB by the Study 
Coordinator. 
5.5.5 DATA AND CENTER AUDITS 
The trial will be audited by the trial sponsor CTEP for compliance and 
safety.  In addition, the NCI CCR will audit this trial via contract for 
compliance and safety.  Volumetric MRI analysis will be used to 
determine the primary study endpoint, which is disease progression. The 
volumetric analysis for all measurements will be performed centrally at 
the NCI, POB with Dr. N. Patronas serving as the responsible 
neuroradiologist for this trial.   
6.0 HUMAN SUBJECTS PROTECTIONS 
6.1 RATIONALE FOR SUBJECT SELECTION 
Neurofibromatosis type 1 is a genetic disorder and the incidence of the disease in 
the various racial and ethnic groups may vary. This may impact on our ability to recruit 
sufficient numbers of patients within each group to this trial.  Subject accrual in regards 
to gender, and racial and ethnic groups is described in Section 5.4.1.  None of these 
groups are being excluded from participation in the trial.  Females who are pregnant or 
breast feeding will not be eligible for entry onto the trial because of the potential and 
unknown risks that R115777 could pose to the fetus or newborn.  This trial is designed 
to determine the activity of R115777 in childhood with NF1 and plexiform 
neurofibromas and, therefore, children will be entered onto this research trial.  Patients 
who are ≥18 years will be offered the opportunity to assign DPA prior to study entry.   
6.2 
PARTICIPATION OF CHILDREN  
This trial is designed to study the effect of R115777 on time to disease progression 
in children and young adults with progressive plexiform neurofibromas.  Therefore 
children who meet eligibility criteria for this trial will be entered in the study.  Children 
will be evaluated and cared for by physicians trained in pediatrics and pediatric 
oncology, and will be followed in the Pediatric Oncology Branch clinic. 
6.3 EVALUATION OF BENEFITS AND RISKS/DICOMFORTS  
This trial will be a randomized, cross-over, double-blinded, placebo-controlled 
pediatric phase II trial of oral R115777 in children and young adults with NF1 who have 
progressive plexiform neurofibroma(s).  Each patient will serve as his/her own control 
for the primary endpoint of time to progression.  Because of the unpredictable nature of 
tumor growth in NF1, alternative designs without placebo control could bias 
observation, and there is no standard treatment to which R115777 may be compared.  In 
addition, each patient will receive study medication provided there is disease 
progression, and therefore may derive benefit from the trial.  R115777 is a 
farnesyltransferase inhibitor.  It was designed to inhibit the farnesylation of ras and 


4/21/2009 
T-99-0090, 01-C-0222 
 
 44
therefore inhibit the activity of mutated ras proteins.  However, it may also be useful for 
other mutations upstream from the farnesylation of ras, such as is found in patients 
with NF1.  Since neurofibromin, the product of the NF1 gene, is decreased in tumors 
from patients with NF1, and since this is associated with a constituitively activated ras 
protein, R115777 is a rational therapeutic approach for patients with plexiform 
neurofibromas.  The potential benefit from participation in this trial is the stabilization 
or reduction in the size of the tumor(s), relief of symptoms caused by the tumor(s), and 
prolongation of life. The primary risk to the subjects from participation in this trial is 
from R115777 toxicity (primarily myelosuppression).  Toxicities from R115777 are 
outlined in Section 1.2.5, 1.2.6, and 8.1.9 and have been reversible when they occur.  The 
attempt will be made to obtain tumor biopsies from easily accessible tumor nodules at 
several time points during the study to answer study related research questions.  Tumor 
samples will be contributed to a central tissue repository, and will be made available to 
researchers who obtain IRB approval to study additional research questions.  Samples 
will be identified by a code number that can be traced to the patient only by contacting 
the trial coordinating center.  However, as the tumor sample is linked to the patient’s 
name, a small risk persists that unauthorized persons could gain access to information. 
Some testing may eventually reveal information that, could result in discrimination 
with health or life insurance or employment.  We believe that these risks are minimal 
since it is already known that patients enrolled on the study have neurofibromatosis. 
All research results will be kept confidential. Patients who do not give permission for 
tumor biopsies will still be eligible for the treatment part of this study. Patients also 
have the right to withdraw the tumor specimen from the tissue repository at any time.  
6.4 RISK/BENEFIT ANALYSIS 
The  primary objective of this phase II trial is to define the time to progression of 
plexiform neurofibromas treated with R115777 or placebo, and thus patients entered on 
the trial will be treated with therapeutic intent and response to the therapy will be 
closely monitored. Therefore, this protocol involves greater than minimal risk to 
children, but presents the potential for direct benefit to individual subjects.  Although 
patients will be treated with placebo, the risk of placebo is minimal and no other 
standard therapy is available.  In addition, all patients will receive R115777, provided 
there is disease progression on the first treatment phase. 
6.5 CONSENT AND ASSENT PROCESS AND DOCUMENTATION 
The investigational nature and objectives of this trial, the procedures and 
treatments involved and their attendant risks and discomforts and benefits, and 
potential alternative therapies will be carefully explained to the patient or the patient’s 
parents or guardian if he/she is a child, and a signed informed consent document will 
be obtained. The investigators have received a waiver from the IRB to allow only one 
parent to sign the informed consent to enter a child on the protocol.  Because many 
patients must travel to the clinical site from long distances at substantial expense, 
requiring both parents to be present for the consent process could be a financial 


4/21/2009 
T-99-0090, 01-C-0222 
 
 45
hardship for many families.  Consent will be obtained by the PI or an associate 
investigator on the trial.  Where deemed appropriate by the clinician and the child’s 
parents or guardian, the child will also be included in all discussions about the trial. 
Age appropriate assent forms for children from 7 through 12 years, and for children 
from 13 through 17 years have been developed and will be signed by the pediatric 
patients in order to obtain written assent. This is a multi-institutional trial, and the NCI 
as coordinating center will require evidence of local IRB approval of the protocol prior 
to allowing for accrual of patients at that institution. This trial will be conducted in 
compliance with the protocol, Good Clinical Practice (GCP) and the applicable 
regulatory requirements.  
6.6 HANDLING OF RESEARCH SAMPLES 
This study is conducted at and coordinated by the Pediatric Oncology Branch, NCI.  
Sample labeling, collection and initial processing will be conducted as outlined in the 
study Section 3.4 6, 3.4.7, and 3.4.8, as well as in Appendices 2 to 6. Tumor samples sent 
to the central tissue procurement facility at Washington University will be handled as 
described in Section 3.4.6 and in Appendix 2. Should tumor sample be left after 
completion of research studies described in the protocol, prospective approval from the 
IRB with oversight of the tissue bank will be obtained prior to performing additional 
studies. This is also described in the informed consent. Blood samples sent to the NCI 
for analysis of farnesyltransferase activity (Section 3.4.7, Appendix 5), or for nerve 
growth factor analysis (Section 3.4.8, Appendix 6) will be stored in designated 
monitored freezers at -70°C or -20°C as indicated in the protocol in the Pharmacology & 
Experimental Therapeutics Section (PETS) Laboratory, POB, NCI on 1 West. Samples 
will identified by protocol specific patient ID number, and will be tracked using the 
PETS 
pharmacokinetics 
filemaker 
database.  
Samples 
will 
be 
analyzed 
for 
farnesyltransferase activity and nerve growth factor at the NCI, POB and be considered 
the responsibility of Brigitte Widemann, MD.  Once analyzed for studies outlined in this 
protocol any remaining samples will be stored by the POB, NCI until the study is 
complete, and the manuscript describing the study has been accepted for 
publication. At this point remaining samples will be destroyed. The study will remain 
open and status reported to the NCI IRB until all samples have been analyzed, reported 
or destroyed. Unintentional loss or destruction of any samples will be reported to the 
NCI IRB as part of annual continuing reviews.  Any use of samples not outlined in 
Sections 3.4.7 and 3.4.8 or in Appendices 5 and 6 will require prospective NCI IRB 
review and approval. 
7.0 DATA REPORTING 
Unless otherwise stated, all forms should be submitted to:  
Andy Gillespie , R.N. 
Pediatric Oncology Branch, National Cancer Institute 
Building 10/Room 13N240, 10 Center Drive 
Bethesda, MD 20892 


4/21/2009 
T-99-0090, 01-C-0222 
 
 46
Phone (301) 402-1848 
FAX (301) 480-8871 
7.1 PATIENT REGISTRATION AND RANDOMIZATION 
See Section 3.1.2 and Appendix 10.  The eligibility checklist is in Appendix 8 A/B. 
7.2 
CASE REPORT FORMS 
The POB will provide Case Report Forms for recording relevant clinical data for 
each patient entered on the trial (Section 5.1).  The Progression Checklist (Appendix 
9A/B) must be submitted before patients can be crossed over from phase A to phase B 
(see Appendix 10).  Patient diaries and Pill Count Case Report Forms (Appendix 
11A/B) should be provided to patients and their families and submitted after 
completion with the label from the patient’s prescription attached after completion of 
every 3 treatment cycles. 
7.3 
SAFETY REPORTING 
7.3.1 ADVERSE EVENTS 
Adverse events are any unfavorable and unintended sign (including an abnormal 
laboratory finding) symptom or disease temporally associated with the use of a medical 
treatment or procedure regardless of whether it is considered related to the medical 
treatment or procedure (attribution of unrelated, unlikely, possible, probable or 
definite). 
Life-threatening adverse events are any adverse event that places the patient or 
subject, in view of the investigator at an immediate risk of death from the reaction. 
Serious adverse events are any adverse event occurring at any dose that result in 
any of the following outcomes: Death, a life-threatening adverse event, inpatient 
hospitalization or prolongation of existing hospitalization, a persistent or significant 
disability/incapacity, a congenital anomaly/birth defect, and other medically 
significant events. 
Unexpected adverse events are any adverse events, which are not listed in the 
Agent Specific Adverse Event List (ASAEL) which is a subset of the Comprehensive 
Adverse Events and Potential Risks List (CAEPR).  
Expected adverse events are those events listed in the Agent Specific Adverse 
Event List (ASAEL) which is a subset of the Comprehensive Adverse Events and 
Potential Risks List (CAEPR) (Section). 
All observed or volunteered adverse events, regardless of treatment group or 
suspected causal relationship to study drug, will be recorded on the Adverse Event 
page(s) of the case report form. Events involving adverse drug reactions, illnesses with 
onset during the study, or exacerbation of pre-existing illnesses should be recorded. 
Objective test findings (e.g., electrocardiogram changes, abnormal laboratory test 
results) that result in a change in study drug dosage should also be recorded.  


4/21/2009 
T-99-0090, 01-C-0222 
 
 47
Adverse events should be graded according to the CTEP Common Toxicity 
Criteria version 2, which can be downloaded from http://ctep.cancer.gov. Next it will 
be determined if the adverse event is related to the medical treatment (attribution). If so, 
it will be determined whether the adverse event is expected or unexpected. Using the 
guidelines outlined in Section 7.3.2 adverse events will then be reported to the NCI 
using a routine report (CDUS), and if required, the Adverse Event Expedited Reporting 
System (AdEERS), an electronic system for expedited submission of adverse event 
reports, in addition to the CDUS. 
The adverse event page will contain information if the reported event was 
expected or unexpected, and if the reported toxicity is included in the informed consent. 
A justification will be provided on the adverse event page if the observed toxicity in not 
included in the informed consent. For all adverse events, the investigator must pursue 
and obtain information adequate both to determine the outcome of the adverse event 
and to assess whether it meets the criteria for classification as a serious adverse event 
requiring immediate notification to the sponsor. Follow-up of the adverse event, even 
after the date of therapy discontinuation, is required if the adverse event or its sequelae 
persist. Follow-up is required until the event or its sequelae resolve or stabilize at a level 
acceptable to the investigator and sponsor.  
7.3.2 ADVERSE EVENT REPORTING 
The NCI/DCTD requirements for reporting Adverse Events (AE) will be followed. 
All serious adverse events, and the adverse events outlined in the table below 
regardless of attribution require expedited reporting. 
Expedited AE reporting for this study must use AdEERS (Adverse Event 
Expedited 
Reporting 
System), 
accessed 
via 
the 
CTEP 
home 
page 
(http://ctep.cancer.gov).  The reporting procedures to be followed are presented in the 
“CTEP, NCI Guidelines: Adverse Event Reporting Requirements” which can be 
downloaded from the CTEP home page (http://ctep.cancer.gov).   
 
In the rare occurrence when Internet connectivity is lost, an AE report may be 
submitted using CTEP's Adverse Event Expedited Report-Single Agent or Multiple 
Agent paper template (available at http://ctep.cancer.gov) and faxed to 301-230-0159.  
A 24-hour notification is to be made to CTEP by telephone at 301-897-7497, only when 
Internet connectivity is disrupted.  Once Internet connectivity is restored, an AE report 
submitted on a paper template or a 24-hour notification phoned in must be entered 
electronically into AdEERS by the original submitter at the site. 
 


4/21/2009 
T-99-0090, 01-C-0222 
 
 48
Phase 2 and 3 Trials utilizing an Agent under a CTEP IND: AdEERS Reporting 
Requirements for Adverse Events That Occur Within 30 Days1 of the Last Dose of the 
Investigational Agent 
 
 
Grade 1 
 
Grade 2 
 
Grade 2 
 
Grade 3 
 
Grade 3 
Grades 
4 & 5
2 
Grades 
4 & 5
2 
Unexpected 
Expected 
 
Unexpected 
and 
Expected 
 
Unex-
pected 
 
 
Expected 
with  
Hospitali-
zation 
without 
Hospitali- 
zation 
with  
Hospitali-
zation 
without 
Hospitali-
zation 
Unex- 
pected  
Expected 
Unrelated 
Unlikely 
Not 
Required 
Not 
Required 
Not 
Required 
10 
Calendar 
Days 
Not 
Required 
10 
Calendar
Days 
Not 
Required 
10 
Calendar 
Days 
10 
Calendar 
Days 
Possible 
Probable 
Definite 
Not 
Required 
10 
Calendar 
Days 
Not 
Required 
10 
Calendar 
Days 
10 
Calendar 
Days 
10 
Calendar
Days 
Not 
Required 
24-Hour; 
5 Calendar 
Days 
10 
Calendar 
Days 
1 Adverse events with attribution of possible, probable, or definite that occur greater than 30 days after the last 
dose of treatment with an agent under a CTEP IND require reporting as follows: 
AdEERS 24-hour notification followed by complete report within 5 calendar days for: 
• 
Grade 4 and Grade 5 unexpected events  
 
AdEERS 10 calendar day report: 
• 
Grade 3 unexpected events with hospitalization or prolongation of hospitalization 
• 
Grade 5 expected events 
2 Although an AdEERS 24-hour notification is not required for death clearly related to progressive disease, a full report is 
required as outlined in the table. 
December 15, 2004
 
Note:  All deaths on study must be reported using expedited reporting regardless of 
causality.  Attribution to treatment or other cause should be provided. 
 
 
• 
Expedited AE reporting timelines defined: 
¾ “24 hours; 5 calendar days” – The investigator must initially report the AE via 
AdEERS within 24 hours of learning of the event followed by a complete 
AdEERS report within 5 calendar days of the initial 24-hour report. 
¾ “10 calendar days” - A complete AdEERS report on the AE must be submitted 
within 10 calendar days of the investigator learning of the event.  
 
• 
Any medical event equivalent to CTCAE grade 3, 4, or 5 that precipitates 
hospitalization (or prolongation of existing hospitalization) must be reported 
regardless of attribution and designation as expected or unexpected with the 
exception of any events identified as protocol-specific expedited adverse event 
reporting exclusions. 
 
• 
Any event that results in persistent or significant disabilities/incapacities, 
congenital anomalies, or birth defects must be reported via AdEERS if the event 
occurs following treatment with an agent under a CTEP IND. 
 


4/21/2009 
T-99-0090, 01-C-0222 
 
 49
• 
Use the NCI protocol number and the protocol-specific patient ID provided 
during trial registration on all reports. 
 
• 
The Comprehensive Adverse Events and Potential Risks List (CAEPR), the 
Agent Specific Adverse Event List (ASAEL), and a list of toxicities with yet 
undetermined relationship to R115777 can be found in the protocol in Section 
8.1.11. 
 
A list of all known toxicities can be found in the protocol document (Section 8) or 
consent form.  
Reactions judged definitely not treatment related should not be reported. 
However, a report should be submitted if there is reasonable suspicion of drug effect.  
Hospitalizations for procedures judged definitely not treatment related do not require 
expedited reporting. 
All reportable adverse events (as defined above), regardless of treatment group 
or suspected relationship to study drug, must be reported to:  
Brigitte Widemann, M.D. 
Pediatric Oncology Branch 
10 Center Drive, 10-CRC, Room 1-5750 
Bethesda, MD  20892 
Phone: (301) 496-7387 
FAX: (301) 402-0575 
E-mail: bw42Y@nih.gov 
All serious adverse events (as defined in Section 7.3) for NCI patients must be 
reported to the Institutional Principal Investigator, Dr. Brigitte Widemann, M.D., 
within 7 days (see contact information above).  
The NCI Protocol PI will report to the NCI-IRB: 
• All serious adverse events (SAEs) that are not in the consent form, but are 
possibly, probably or definitely related to the research.  A SAE is defined as an 
untoward medical occurrence that 
o resulted in a death; 
o was life-threatening; 
o required or prolonged hospitalization; 
o caused persistent or significant disability/incapacity; 
o resulted in congenital anomalies or birth defects; or 
o required intervention to prevent permanent impairment or death. 
• All other deaths that occur within 30 days of receiving R115777/placebo. 
• All grade 3 and 4 (CTC v3) events that are not in the consent and that are 
possibly, probably or definitely related to the research. 


4/21/2009 
T-99-0090, 01-C-0222 
 
 50
Reports must be received by the NCI-IRB within 7 days of notification of the event. 
 
Forms for submission of an AE to CTEP/NCI/DCTD and the POB/NCI can be 
obtained from the CTEP website at http://ctep.cancer.gov. 
The NCI POB will distribute Adverse Event Expedited Reports distributed by 
CTEP to responsible Investigators at participating sites. 
 
7.4 ASSURANCES 
Each participating institution is required to maintain a current Multiple Project 
Assurance in order to participate in government-sponsored Group research.  The files 
will be copied or made available for review by authorized persons as required for 
conduct of this trial.  
7.5 IRB APPROVALS 
As the coordinating center for this clinical trial, the POB will be responsible for 
verifying Institutional Review Board (IRB) approval of the protocol.  Each participating 
institution must provide a copy of their IRB approval to the POB before that center can 
enter and register a patient on study.  The participating institutions must also provide 
the POB with a copy of documentation that the protocol has undergone yearly IRB 
review and a copy of IRB approvals for any protocol amendments.  
7.6 PATIENT DATA REPORTING AND AUDITS 
Clinical data from patients treated on this trial will be submitted to the POB on the 
provided case report forms and will be entered into the CCR C3D database by POB data 
managers/research nurses.  The study will be monitored by Clinical Data Update 
Systems (CDUS) version 1.1.  Cumulative CDUS data will be submitted quarterly to 
CTEP by electronic means.  Reports are due to CTEP Jan 31, April 30, July 31, and 
October 31.  3-D MRI analysis for assessing the volume of plexiform neurofibromas will 
be performed centrally.  The NCI Clinical Trials Monitoring Service (CTMS) may 
independently audit selected charts on patients who are treated on this trial.  Selected 
patient charts to be audited must be sent to the POB from participating institutions.  In 
addition, the NCI CCR will audit this trial via contract for compliance and safety. 
8.0 PHARMACEUTICAL INFORMATION 
8.1 R115777 AND PLACEBO 
R115777 with matching placebo will be provided to study participants free-of-
charge by the Janssen Research Foundation and distributed by the Pharmaceutical 
Management Branch (PMB), Cancer Therapy Evaluation Program (CTEP), Division of 
Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI). 


4/21/2009 
T-99-0090, 01-C-0222 
 
 51
Note that this study involves a crossover from R115777 to placebo (Arm 1) or 
from placebo to R115777 (Arm 2). The medication for the first phase (initial 
randomization) will be labeled as “Phase A”, and the medication for the second 
phase (crossover randomization) will be labeled as “Phase B”, regardless of which 
arm the patient is randomized to. When dispensing the medication, please be certain 
that the physician has specified on the prescription (1) the patient ID number [e.g., 
‘01C0222-01’]; (2) the patient initials [e.g., ‘ABC’ = first three letters of the patient’s 
last name]; (3) the phase [i.e., “Phase A” or “Phase B”]; (4) the body surface area [in 
m2]; and (5) the dose [i.e., “___mg po q12h”].  Check to be certain that the patient ID 
number and phase specified on the patient’s box(es) of medication correspond to the 
patient ID number and phase specified on the patient’s prescription.  If the patient 
ID number or phase is missing from the patient’s prescription, you must contact the 
physician! 
R115777 (NSC 702818 / IND #58359) and matching placebo will be supplied in 
blister packages in a cardboard box.  Each box will contain 70 – 50mg tablets and will be 
sealed with a tamper-evident seal.  Each box will be labeled with: 
• the protocol number (i.e., ‘T99-0090’) 
• the patient ID number (e.g., ‘01C0222-01’ where ‘01C0222’ represents the NIH 
Clinical Center protocol number and ‘01’ represents a patient sequence number 
assigned at registration) 
• the patient initials (e.g., ‘ABC’ = first three letters of the patient’s last name) 
• a blank line for the patient’s name 
• the phase (i.e., ‘Phase A’ or  ‘Phase B’) 
• the agent identification (i.e., ‘R115777 50mg or Placebo’) 
• the number of tablets (i.e., ‘70 tablets’) 
• administration instructions (i.e., ‘Take ___ tablets every 12 hours after meals.’) 
• storage instructions (i.e., ‘Store at controlled room temperature [59° to 77° F].  
Protect from moisture.’) 
• emergency contact instructions 
• a Julian date 
At the time the box is dispensed to the patient, the pharmacist should enter the 
patient’s name and the number of tablets (based on the patient’s BSA / prescribed dose) 
in the spaces provided. 
BSA  
(m2) 
R115777 / Placebo 
(mg po q12h) 
R115777 / Placebo 
(# of 50 mg tablets po 
q12h) 
3-cycle supply 
(# of boxes of 70 tablets 
provided) 
0.00 - 0.37 
50 
1 
2 


4/21/2009 
T-99-0090, 01-C-0222 
 
 52
0.38 - 0.62 
100 
2 
4 
0.63 - 0.87 
150 
3 
6 
0.88 - 1.12 
200 
4 
8 
1.13 - 1.37 
250 
5 
9 
1.38 + 
300 
6 
11 
The Julian date indicates the day the box was labeled and shipped and is 
composed of the last two digits of the calendar year (e.g., 2001 = 01, 2002 = 02) and a 
day count (e.g., January 1 = 001, December 31 = 365).  For example, a box labeled and 
shipped on January 1, 2001 would have a Julian date of ‘01001’ and a box labeled and 
shipped on December 31, 2002 would have a Julian date of ‘02365’.  The Julian date will 
be used by PMB for recalls.  When a lot expires, PMB will determine the last date the 
expired lot was shipped and will recall all boxes (i.e., both R115777 and placebo) 
shipped on or before that date thus eliminating any chance of breaking the blind. 
8.1.1  CHEMICAL NAME: R115777 is a methyl-quinolone.  The full chemical name is 
(R)-6-[amino(4-chlorophenyl) (1-methyl –1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-
1-methyl-2(1H)-quinolinone. 
8.1.2  CHEMICAL STRUCTURE: 
Cl
N
O
NH 2
N
N
Cl
CH 3
H 3C
 
8.1.3  MOLECULAR FORMULA: C27H22Cl2N4O 
8.1.4  MOLECULAR WEIGHT:  489.4 
8.1.5  FORMULATION: Supplied as a film-coated compressed tablet containing 
either 50mg of R115777 (active) or 0 mg of R115777 (placebo) with lactose, 
unmodified maize starch, hypromellose, microcrystalline cellulose, crospovidone, 
colloidal silicon dioxide, and magnesium stearate.  The coating contains 
hypromellose, propylene glycol, titanium dioxide, and talc. 
8.1.6  STORAGE: Store at room temperature (59° to 77° F) and protect from 
moisture. 
8.1.7  STABILITY: Shelf life surveillance studies are ongoing. 
8.1.8  ROUTE OF ADMINISTRATION: Oral.  The bioavailability of the tablet 
increases under the influence of a meal.  Based on these findings, it is advised to 
administer the tablets of R115777 immediately after a meal.  The tablets may be 


4/21/2009 
T-99-0090, 01-C-0222 
 
 53
crushed if a patient is unable to swallow the intact tablet; however, the entire tablet 
must be administered. 
8.1.9 Dose:  For this protocol, the dose of R115777 is 200mg/m2 (rounded to the 
nearest 50mg) orally after meals every 12 hours for 21 days followed by a 7 day rest 
period for a cycle length of 28 days.  Cycles are repeated until the patient progresses. 
8.1.10 Drug Interactions: Pharmacokinetic data suggest that H2 antagonists and 
proton pump inhibitors do not alter the exposure to R115777 to a clinically 
significant extent. Patients may use proton pump inhibitors or H2 antagonists during 
the treatment portion of this study. However, patients should be instructed to use 
antacids (Mg- or Al-containing formulations), e.g., Maalox or Mylanta AT LEAST 2 
hours before or after intake of the oral study drug. 
8.1.11  KNOWN TOXICITIES:  
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a single, 
complete list of reported and/or potential adverse events (AE) associated with an agent 
using a uniform presentation of events by body system. In addition to the 
comprehensive list, a subset, the Agent Specific Adverse Event List (ASAEL), appears in 
a separate column and is identified with bold and italicized text. This subset of AEs 
(ASAEL) contains events that are considered ‘expected’ for expedited reporting 
purposes only. Refer to the “CTEP, NCI Guidelines: Adverse Event Reporting 
Requirements” http://ctep.cancer.gov/reporting/adeers.html for further clarification. 
Frequency is provided based on 2702 patients. Below is the CAEPR for R115777. 
Version 2.0, March 2, 2009 
 
Adverse Events with Possible 
Relationship to Tipifarnib (R115777) 
(CTCAE 3.0 Term) 
[n= 2702] 
 
Likely (>20%) 
Less Likely (<=20%) 
Rare but Serious (<3%)
 
Agent Specific Adverse Event 
List 
(ASAEL) 
 
BLOOD/BONE MARROW 
 
Hemoglobin 
 
 
Hemoglobin 
 
Leukocytes (total WBC) 
 
Leukocytes (total WBC) 
 
Lymphopenia 
 
 
Neutrophils/granulocytes 
(ANC/AGC) 
 
 
Neutrophils/granulocytes 
(ANC/AGC) 
Platelets 
 
 
Platelets 
CARDIAC GENERAL 
 
 
Hypotension 
 
 
CONSTITUTIONAL SYMPTOMS 
 
Fatigue (asthenia, lethargy, 
malaise) 
 
 
Fatigue (asthenia, lethargy, 
malaise) 
 
Fever (in the absence of neutropenia, where 
neutropenia is defined as ANC <1.0 x 
10e9/L) 
 
Fever (in the absence of 
neutropenia, where neutropenia 
is defined as ANC <1.0 x 10e9/L)
 
Insomnia 
 
 
DERMATOLOGY/SKIN 
 


4/21/2009 
T-99-0090, 01-C-0222 
 
 54
 
Photosensitivity 
 
Photosensitivity 
 
Rash/desquamation 
 
Rash/desquamation 
GASTROINTESTINAL 
 
Anorexia 
 
 
Anorexia 
 
Constipation 
 
Constipation 
 
Dehydration 
 
 
Diarrhea 
 
 
Diarrhea 
 
Heartburn/dyspepsia 
 
Heartburn/dyspepsia 
 
Mucositis/stomatitis 
(functional/symptomatic) - Select 
 
Mucositis/stomatitis 
(functional/symptomatic) - Select
Nausea 
 
 
Nausea 
Vomiting 
 
 
Vomiting 
HEMORRHAGE/BLEEDING 
 
 
 
  Hemorrhage, CNS 
 
 
Hemorrhage, pulmonary/upper respiratory - 
Nose 
 
 
 
Petechiae/purpura (hemorrhage/bleeding 
into skin or mucosa) 
 
 
INFECTION 
 
 
Febrile neutropenia (fever of unknown 
origin without clinically or 
microbiologically documented 
infection)(ANC <1.0 x 10e9/L, fever >=38.5 
degrees C) 
 
 
 
Infection (documented clinically or 
microbiologically) with Grade 3 or 4 
neutrophils (ANC <1.0 x 10e9/L) - Select 
 
Infection (documented clinically 
or microbiologically) with Grade 
3 or 4 neutrophils (ANC <1.0 x 
10e9/L) - Select 
 
Infection with normal ANC or Grade 1 or 2 
neutrophils - Select 
 
Infection with normal ANC or 
Grade 1 or 2 neutrophils - Select
 
Infection with unknown ANC - Select 
 
Infection with unknown ANC - 
Select 
LYMPHATICS 
 
 
Edema: limb 
 
 
METABOLIC/LABORATORY 
 
 
Bilirubin (hyperbilirubinemia) 
 
Bilirubin (hyperbilirubinemia) 
 
Creatinine 
 
Creatinine 
 
Lipase 
 
Lipase 
 
Potassium, serum-low (hypokalemia) 
 
Potassium, serum-low 
(hypokalemia) 
NEUROLOGY 
 
 
Confusion 
 
Confusion 
 
Dizziness 
 
Dizziness 
 
Neuropathy: sensory 
 
Neuropathy: sensory 
 
Somnolence/depressed level of 
consciousness 
 
 
PAIN 
 
 
Pain - Abdomen NOS 
 
Pain - Abdomen NOS 
 
Pain - Chest/thorax NOS 
 
 
 
Pain - Head/headache 
 
Pain - Head/headache 
 
Pain - Pain NOS 
 
 
PULMONARY/UPPER RESPIRATORY 
 
 
Cough 
 
 
 
Dyspnea (shortness of breath) 
 
Dyspnea (shortness of breath) 


4/21/2009 
T-99-0090, 01-C-0222 
 
 55
RENAL/GENITOURINARY 
 
 
Renal/Genitourinary - Other (Renal 
insufficiency) 
 
Renal/Genitourinary - Other 
(Renal insufficiency) 
 
1 


4/21/2009 
T-99-0090, 01-C-0222 
 
 56
 This table will be updated as the toxicity profile of the agent is revised.  Updates will be distributed to all Principal 
Investigators at the time of revision.  The current version can be obtained by contacting:  
PIO@CTEP.NCI.NIH.GOV. Your name, the name of the investigator, the protocol and the agent should be included 
in the e-mail. 


4/21/2009 
T-99-0090, 01-C-0222 
 
 57
 


4/21/2009 
T-99-0090, 01-C-0222 
 
 58
Also reported on tipifarnib (R115777) trials but with the relationship to tipifarnib (R115777) still 
undetermined: 
ALLERGY/IMMUNOLOGY – Allergic rhinitis (including sneezing, nasal stuffiness, postnasal 
drip) 
BLOOD/BONE MARROW – Blood/Bone Marrow – Other (leukocytosis) 
CARDIAC ARRHYTHMIA – Palpitations; Supraventricular and nodal arrhythmia ‐ Atrial 
fibrillation; Supraventricular and nodal arrhythmia ‐ Sinus tachycardia; Supraventricular and 
nodal arrhythmia ‐ Supraventricular tachycardia; Ventricular arrhythmia ‐ Ventricular 
tachycardia 
CARDIAC GENERAL – Cardiopulmonary arrest, cause unknown (non‐fatal); Left ventricular 
systolic dysfunction 
COAGULATION – PTT (Partial Thromboplastin Time) 
CONSTITUTIONAL SYMPTOMS – Rigors/chills; Sweating (diaphoresis); Weight loss 
DERMATOLOGY/SKIN – Dry skin; Hair loss/alopecia (scalp or body); Pruritus/itching 
ENDOCRINE – Hot flashes/flushes 
GASTROINTESTINAL – Dry mouth/salivary gland (xerostomia); Flatulence; Gastrointestinal – 
Other (polydipsia); Ileus, GI (functional obstruction of bowel, i.e., neuroconstipation); 
Obstruction, GI ‐ Small bowel NOS; Taste alteration (dysgeusia) 
HEMORRHAGE/BLEEDING – Hematoma; Hemorrhage, GI ‐ Oral cavity; Hemorrhage, GI – 
Upper GI NOS 
HEPATOBILIARY/PANCREAS – Liver dysfunction/failure (clinical) 
INFECTION – Opportunistic infection associated with >=Grade 2 Lymphopenia 
LYMPHATICS – Lymphatics ‐ Other (localized lymphadenopathy) 
METABOLIC/LABORATORY – Alkaline phosphatase; ALT, SGPT (serum glutamic pyruvic 
transaminase); AST,SGOT (serum glutamic oxaloacetic transaminase); Amylase; Calcium, 
serum‐high (hypercalcemia); Glucose, serum‐high (hyperglycemia); Magnesium, serum‐low 
(hypomagnesemia); Potassium, serum‐high (hyperkalemia); Sodium, serum‐low 
(hyponatremia); Triglyceride, serum‐high (hypertriglyceridemia) 
MUSCULOSKELETAL/SOFT TISSUE – Muscle weakness, generalized or specific area (not 
due to neuropathy) 
NEUROLOGY –  Ataxia (incoordination); Extrapyramidal/involuntary movement/restlessness; 
Memory impairment; Mood alteration – Agitation; Mood alteration ‐ Anxiety; Mood alteration ‐ 
Depression; Neuropathy: motor; Psychosis (hallucinations/delusions); Seizure; Syncope 
(fainting); Tremor 
OCULAR/VISUAL– Dry eye syndrome; Ocular/Visual ‐ Other (abnormal vision) 
PAIN – Pain ‐ Back; Pain ‐ Bladder; Pain ‐ Bone; Pain ‐ Joint; Pain ‐ Muscle 
PULMONARY/UPPER RESPIRATORY – Hiccoughs (hiccups, singulitus); Hypoxia; 
Pneumonitis/pulmonary infiltrates; Voice changes/dysarthria (e.g., hoarseness, loss or alteration 
in voice, laryngitis) 
RENAL/GENITOURINARY – Urine color change 
VASCULAR – Phlebitis (including superficial thrombosis); Thrombosis/thrombus/embolism  
 


4/21/2009 
T-99-0090, 01-C-0222 
 
 59
Note: Tipifarnib (R115777) in combination with other agents could cause an exacerbation of any 
adverse event currently known to be caused by the other agent, or the combination may result 
in events never previously associated with either agent. 
8.2 DRUG 
ORDERS, 
TRANSFERS, 
RETURNS, 
ACCOUNTABILITY 
/ 
EMERGENCY 
UNBLINDING 
Questions about drug orders, transfers, returns, or accountability should be 
addressed to the PMB by calling (301) 496-5725 Monday through Friday between 
8:30am and 4:30pm Eastern Time.  
8.2.1  DRUG ORDERS: No starter supplies will be available for this study.  Orkand 
will notify the PMB (see Section 3.1.2 and Appendix 8A/B) when a patient is registered 
by the Pediatric Oncology Branch research nurse.  Using the “On-Study Form” in 
Appendix 8B, Orkand will provide the protocol number (i.e., T99-0090), the patient ID / 
sequence number (e.g., ‘01C0222-01’), the patient initials (e.g., ‘ABC’ = first three letters 
of the patient’s last name), and the patient’s BSA (in m2).  Based on the patient’s BSA, 
the PMB will ship an initial three month patient-specific supply (see table in Section 8.1) 
for “Phase A” to the registering site. 
Two months after the initial request (i.e., one month before needed), clinical sites 
may reorder an additional three month supply by completing an NCI Clinical Drug 
Request form and faxing it to the PMB at 301-480-4612.  The NCI Clinical Drug Request 
form is available on the CTEP home page (http://ctep.cancer.gov) or by calling the PMB 
at 301-496-5725.  The patient ID number (e.g., ‘01C0222-01’) and patient initials (e.g., 
‘ABC’) should be entered in the “Patient or Special Code” field.  In addition, the 
patient’s BSA must be provided.  All drug orders should be shipped directly to the 
physician responsible for treating the patient. 
 
When the patient progresses on Phase A, the Pediatric Oncology Branch research 
nurse will notify the PMB (see Section 3.1.2 and Appendix 9A/B).  Based on the 
patient’s BSA, the PMB will again ship an initial three month patient-specific supply 
(see table in Section 8.1) for Phase B to the registering site.  Any remaining supplies for 
Phase A should be returned immediately on receipt of supplies for “Phase B” (see 
Section 8.2.3). 
8.2.2  DRUG TRANSFERS:  Boxes MAY NOT be transferred from one patient to 
another patient or from one protocol to another protocol.  All other transfers (e.g., a 
patient moves from one participating center to another participating center, the 
principal investigator at a participating center changes, etc) must be approved in 
advance by the PMB.  To obtain an approval for transfer, investigators should complete 
and submit to the PMB (fax number 301-480-4612) a Transfer Investigational Agent 
Form available on the CTEP home page http://ctep.cancer.gov, or by calling the PMB 
at 301-496-5725.  The patient ID number (e.g., ‘01C0222-01’) and patient initials (e.g., 
‘ABC’) should be entered in the “Received on NCI Protocol No.” and the “Transferred 
to NCI Protocol No.” fields in addition to the protocol number (i.e., T99-0090). 


4/21/2009 
T-99-0090, 01-C-0222 
 
 60
8.2.3  DRUG RETURNS: All unused drug supplies should be returned to the PMB.  
When it is necessary to return study drug (e.g., sealed boxes remaining when a patient 
completes the first blinded treatment phase, sealed boxes remaining when a patient 
completes the second blinded treatment phase, expired boxes recalled by the PMB), 
investigators should return the study drug to the PMB using the NCI Return Agent 
Form available on the CTEP home page http://ctep.cancer.gov, or by calling the PMB 
at 301-496-5725.  The patient ID number (e.g., ‘01C0222-01’) and patient initials (e.g., 
‘ABC’) should be entered in the “Lot No. and Sample No.” field. 
8.2.4  DRUG ACCOUNTABILITY:  The investigator, or a responsible party designated 
by the investigator, must maintain a careful record of the receipt, disposition, and 
return of all drugs received from the PMB using the NCI Investigational Agent 
Accountability Record available on the CTEP home page http://ctep.cancer.gov, or by 
calling the PMB at 301-496-5725.  A separate NCI Investigational Agent Accountability 
Record must be maintained for each patient on this protocol.  The patient ID number 
(e.g., ‘01C0222-01’) and the phase (i.e., “Phase A” or “Phase B”) should be entered in the 
“Patient’s ID No.” field. 
8.2.5  EMERGENCY UNBLINDING:  In the event of an emergency, call Dr. Brigitte 
Widemann (301-496-7387) or Dr. Frank Balis (301-496-0085).  These physicians can also 
be reached through 301-496-7704 or through the NIH Page Operator at 301-496-1211.  
Pediatric Oncology Branch staff will require the protocol number (i.e., T99-0090), the 
patient ID number (e.g., ‘01C0222-01), the patient initials (e.g., ‘ABC’), and the phase 
(i.e., ‘Phase A’ or ‘Phase B’) to unblind the patient. 
9.0 CLINICAL TRIALS AGREEMENT (CTA) 
The agent(s) (hereinafter referred to as “Agent”, R115777, used in this protocol 
is/are provided to the NCI under a Clinical Trials Agreement (CTA) between 
Company: Janssen Pharmaceuticals (hereinafter referred to as “Collaborator(s)”) and 
the NCI Division of Cancer Treatment, Diagnosis. Therefore the following 
obligations/guidelines apply to the Agent(s) in this study: 
1) The Agent(s) may not be used outside the scope of this protocol, nor can the 
Agent(s) be transferred or licensed to any party not participating in the clinical 
study. Collaborator(s) data for Agent(s) are confidential and proprietary to the 
Collaborator(s) and should be maintained as such by the investigators. 
2) For a clinical protocol where there is an investigational Agent used in combination 
with other investigational Agent(s), each the subject of different CTAs, the access to 
and use of data by each Collaborator shall be as follows (data pertaining to such 
combination use shall hereinafter be referred to as “Multi-Party Data”). 
a) NCI must provide all Collaborators with written notice regarding the existence 
and nature of any agreements governing their collaboration with NIH, the design 
of the proposed combination protocol, and the existence of any obligations which 
would tend to restrict NCI’s participation in the proposed combination protocol. 


4/21/2009 
T-99-0090, 01-C-0222 
 
 61
b) Each Collaborator shall agree to permit use of the Multi-Party Data from the 
clinical trial by any other Collaborator to the extent necessary to allow said other 
Collaborator to develop, obtain regulatory approval or commercialize its own 
investigational Agent. 
c) Any Collaborator having the right to use the Multi-Party Data from these trials 
must agree in writing prior to the commencement of the trials that it will use the 
Multi-Party 
Data 
solely 
for 
development, 
regulatory 
approval, 
and 
commercialization of its own investigational Agent. 
3) The NCI encourages investigators to make data from these clinical trials fully 
available to Collaborators for review at the appropriate time. Clinical trial data 
developed under the CTA will be made available exclusively to Collaborator(s), the 
NCI, and the FDA, as appropriate. 
4) When a Collaborator wishes to initiate a data request, the request should first be 
sent to the NCI, who will then notify the appropriate investigators (Group Chair for 
cooperative group studies, or PI for other studies) of Collaborator’s wish to contact 
them. 
5) Any data provided to Collaborator(s) must be in accordance with the guidelines and 
policies of the responsible Data Monitoring Committee (DMC), if there is a DMC for 
this clinical trial. 
6) Any manuscripts reporting the results of this clinical trial should be provided to 
CTEP for immediate delivery to Collaborator(s) for advisory review and comment 
prior to submission of publication. Collaborator(s) will have 30 days from the date of 
receipt for review. An additional 30 days may be requested in order to ensure that 
confidential and proprietary data, in addition to Collaborator(s) intellectual property 
rights, are protected. Copies of abstracts should be provided to Collaborator(s) for 
courtesy review following submission, but prior to presentation at the meeting or 
publication in the proceedings. Copies of any manuscript and/or abstract should be 
sent to: 
Regulatory Affairs Branch, CTEP, DCTD, NCI 
Executive Plaza North, Room 718 
Bethesda, MD 20892 
Fax: 301-402-1584 
The Regulatory Affairs Branch will then distribute them to Collaborator(s). 


4/21/2009 
T-99-0090, 01-C-0222 
 
 62
10.0 REFERENCES 
1. 
Bernards A (1995) Neurofibromatosis type 1 and Ras-mediated signaling: filling 
in the GAPs. Biochim Biophys Acta. 1242(1):43-59. Review. No abstract available. 
2. 
Bollag G, McCormick F (1992) GTPase activating proteins. Cancer Biology 3:199-
208. 
3. 
De Santis S, Pace A, Bove L, Cognetti F, Properzi F, Fiore M, Triaca V, Savarese 
A, Simone M, Jandolo B, Manzione L, Aloe L (2000) Patients treated with antitumor 
drugs displaying neurological deficits are characterized by a low circulating level of 
nerve growth factor. Clinical Cancer research 6:90-95. 
4. 
Gibbs JB, Oliff A (1997) The potential of farnesyltransferase inhibitors as cancer 
chemotherapeutics. Annu Rev Pharmacol Toxicol 37:143-166. 
5. 
Goldberg Y, Dibbern K, Klein J, Riccardi V, Graham J (1996) Neurofibromatosis 
Type I - an update and review for the primary physician. Clinical Pediatrics :545-561. 
6. 
Goyen J LA, Lavrijsen K, de Coster R (1996) Investigator's Brochure R115777.  
7. 
Graham S (1995) Inhibitors of protein farnesylation: a new approach to cancer 
chemotherapy. Exp Opin Ther Patents 5(12):1269-1285. 
8. 
Gutmann D, Collins F (1993) The neurofibromatosis type 1 gene product and its 
protein product, neurofibromin. Neuron 10:335-343. 
9. 
Gutmann DH, et al. (1997) The diagnostic evaluation and multidisciplinary 
management of neurofibromatosis 1 and neurofibromatosis 2. Jama. 278(1):51-57. 
Review. 
10. 
Hudson J, et al. (1997) Novel and recurrent mutations in the neurofibromatosis 
type 1 (NF1) gene. Hum Mutat. 9(4):366-367. No abstract available. 
11. 
James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P 
(1999) Measuring response in solid tumors: Unidimensional versus bidimensional 
measurement. Journal of the National Cancer Institute 91(6):523-528. 
12. 
Johnston SR, Ellis PA, Houston S, Hickish T, Howes A, Palmer P, Horak I (2000) 
A phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced 
breast cancer. New Orleans: ASCO: 83a. 
13. 
Kato K, Der C, Buss J (1992) Prenoids and palmitate: lipids that control the 
biological activity of Ras proteins. Cancer Biology 3:179-188. 
14. 
Kim HA, et al. (1997) Nf1-deficient mouse Schwann cells are angiogenic and 
invasive and can be induced to hyperproliferate: reversion of some phenotypes by an 
inhibitor of farnesyl protein transferase. Mol Cell Biol. 17(2):862-872. 


4/21/2009 
T-99-0090, 01-C-0222 
 
 63
15. 
Lancet J, Rosenblatt J, Liesveld D, End D, Hovak I, Ange D, Rosell K, Petronio S, 
Smith A, Karp J (2000) Use of farnesyl transferase inhibitor R115777 in relapsed and 
refractory leukemias: Preliminary results of a phase I trial. New Orleans: ASCO: 3a. 
16. 
Leonard DM (1997) Ras farnesyltransferase: a new therapeutic target. J Med 
Chem 40(19):2971-2990. 
17. 
Lowy D, Willumsin B (1993) Function and Regulation of Ras. Annu. Rev. 
Biochem 62:851-891. 
18. 
Needle MN, et al. (1997) Prognostic signs in the surgical management of 
plexiform neurofibroma: the Children's Hospital of Philadelphia experience, 1974-1994. 
J Pediatr. 131(5):678-682. 
19. 
Omer CA, Kohl NE (1997) CA1A2X-competitive inhibitors of farnesyltransferase 
as anti-cancer agents. Trends Pharmacol Sci 18(11):437-444. 
20. 
Patnik A, Eckhardt S, Itzbicka E, Hidalgo M, McCreery H, Mori M, Terada K, 
Tolcher A, Smith L, Britten C, Bowden C, Bol K, Ochon L, Davidson K, Hammond L, 
Schwartz G, Horak I, Gentner L, Rowinsky E (2000) A phase I and pharmacokinetic 
(PK) study of the farnesyltransferase inhibitor R115777 in combination with 
gemcitabine (Gem). New Orleans: ASCO: 2a. 
21. 
Rodenhuis S (1992) ras and human tumors. Cancer Biology 3:241-247. 
22. 
Satoh T, Kaziro Y (1992) Ras in signal transduction. Cancer Biology 3:169-177. 
23. 
Schellens JH, de Clerk G, Swart M, Palmer PA, Bol CJ, van't Veer LJ, Tan S, de 
Gast GC, Beijnen JH, ten Bokkel Huinink WW (2000) Phase I and pharmaologic study 
with the novel farnesyltransferase inhibitor (FTI) R115777. New Orleans: ASCO: 184a. 
24. 
Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N (1995) A 
peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-
dependent and -independent growth of human tumor cell lines. Cancer Res 55(22):5302-
5309. 
25. 
Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, Verweij 
J, Van Glabbeke M, Van Oosterom T, Chrisitan M, Gwyther S (2000) New guidelines to 
evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205-216. 
26. 
Warren K, Patronas N, Aikinb A, Balis F (2000) Unidimensional (1D), Bi-
dimensional (2D), and 3-Dimensional (3D) Measurements of Childhood Brain Tumors. 
New Orleans, LA: ASCO: 168a. 
27. 
Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V (1995) 
Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant 
phenotype. Cancer Res 55(16):3569-3575. 
28. Zujewski J, Horak I, Bol R, et al. (2000) Phase I and pharmacokinetic study of 
farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 
18(4):927-941. 


4/21/2009 
T-99-0090, 01-C-0222 
 
64 
11.0 
APPENDICES 
APPENDIX 1:  PROTOCOL FOR REQUIRED PRE STUDY AND ON STUDY MRI STUDIES 
Prior to starting treatment on this study all known measurable tumors should be 
imaged with MRI to obtain a baseline.  Tumor spread in patients with NF1 can be very 
extensive, and may not allow for all lesions to be followed using 3D-MRI.  
The goal will therefore be to use 3D-MRI only to follow the progressing plexiform 
neurofibroma(s) (a maximum of three lesions), which will be defined as index lesion(s).  
Pre-study radiographic evaluation: 
• Identify and select the progressive plexiform neurofibroma(s) (a maximum of three 
lesions) for 3-D MRI evaluation based on prior imaging studies. Should there be 
more than 3 progressing plexiform neurofibromas, the three most clinically relevant 
plexiform neurofibromas will be followed by 3-D MRI analysis. 
• Perform 3-D MRI sequences on the selected index lesions as outlined in the MRI 
acquisition protocols below.  
• In addition, if possible, perform MRI of all additional measurable plexiform 
neurofibroma(s). 
On study radiographic evaluation: 
Unless clinically indicated otherwise obtain MRI of the index lesions only as outlined in 
the MRI acquisition protocol below prior to cycles 4, 7, 10, and then after every 6 cycles 
on each treatment phase (“A”, “B”). 
At the time of disease progression on treatment phase “A”,if possible, a MRI scan of all 
known measurable plexiform neurofibromas in addition to the index lesions should be 
performed, in order to have a new baseline prior to treatment phase “B”.  
MRI protocols: 
Depending on the location of the index lesions the Spine, Head/Neck or 
Trunk/Extremities protocols outlined on the following pages will be used.  
The measurement of very irregular or infiltrative neurofibromas will present major 
challenges, and in some cases, it may be difficult to precisely define tumor margins.  If 
necessary, participating institutions may modify the MRI sequences to optimize 
differentiation of tumor and surrounding tissue. Modifications should be documented 
in the MRI protocols, and the same imaging protocol, and, if possible, the same MRI 
scanner, should be used for all subsequent MRI studies. 
Every attempt should be made to image the entire progressive plexiform 
neurofibroma(s).  
A written protocol for scanning each patient has to be established at the time of study 
entry to allow for reproducibility of follow-up studies.  
If possible, Ms. Andy Gillespie should be notified at least 24 hours prior to performing a 
MRI (Fax: 301-480-8871, phone: 301-402-1848, e-mail: gillesan@mail.nih.gov).  


4/21/2009 
T-99-0090, 01-C-0222 
 
65 
A copy of the MRI protocol used to acquire the baseline MRI study will be faxed to Ms. 
Andy Gillespie (301-480-8871) within 24 hours of obtaining the MRI study. 
MRI studies should be submitted electronically or on CD or optical disk to the NCI POB 
within 1 week of obtaining the study.  The institutional radiology report for each study 
should be faxed to Ms. Andy Gillespie within 1 week. 


4/21/2009 
T-99-0090, 01-C-0222 
 
66 
MRI PROTOCOL- SPINE 
 
Patient ID number: _________ 
Note: All series except for #4 and #5 should be performed as a normal clinical scan as specified by the 
radiologist.  The additional Series #4 and #5 may or may not be part of the normal clinical scan sequence, 
however these series are required for the NF1 study protocol and must be performed within protocol 
specifications as indicated below. 
1. SAGITTAL T1 
 LOCALIZER⎯SPINE COIL 
Per normal clinical scan 
2. SAGITTAL T1 
 
Per normal clinical scan 
3. SAGITTAL FSEIR 
 
Per normal clinical scan 
4. AXIAL FSEIR 
Axial FSEIR 
Protocol 
Specifications 
Actual 
Specifications 
Reason For Change 
Echo Train Length 
5 
 
 
TR 
6000 
 
 
TE 
34 
 
 
TI 
150 
 
 
Slice Thickness 
5 mm 
 
 
Skip 
0 
 
 
Matrix 
256x256 
 
 
FOV 
22 cm 
 
 
NEX 
1 
 
 
Frequency Direction 
R→L 
 
 
Options 
Tailored RF, FC, PC, 0.75 FOV 
5. 
CORONAL FSEIR  
Coronal FSEIR 
Protocol 
Specifications 
Actual 
Specifications 
Reason For Change 
Echo Train Length 
5 
 
 
TR 
6000 
 
 
TE 
34 
 
 
TI 
150 
 
 
Slice Thickness 
5 mm 
 
 
Skip 
0 
 
 
Matrix 
256x256 
 
 
FOV 
22 cm 
 
 
NEX 
1 
 
 
Frequency Direction 
S→I 
 
 
Options 
Tailored RF, FC, PC 
 
 
6. AXIAL T1 
 
Per normal clinical scan 
7. AXIAL T1- POST CONTRAST 
Per normal clinical scan 
 
Date:_________    Signature (responsible MRI technician):_____________________________ 
 


4/21/2009 
T-99-0090, 01-C-0222 
 
67 
Baseline study only, fax completed form to: Ms. Andy Gillespie at: 301-480-8871 (phone: 301-402-
1848) 


4/21/2009 
T-99-0090, 01-C-0222 
 
68 
MRI Protocol- Head/Neck  
PATIENT ID NUMBER: _________ 
Note: All series except for #2 and #3 should be performed as a normal clinical scan as specified by the 
radiologist.  The additional Series #2 and #3 may or may not be part of the normal clinical scan sequence, 
however these series are required for the NF1 study protocol and must be performed within protocol 
specifications as indicated below. 
1. SAGITTAL T1 
  
Per normal clinical scan 
2. AXIAL FSEIR 
Axial FSEIR 
Protocol 
Specifications 
Actual 
Specifications 
Reason For Change 
Echo Train Length 
5 
 
 
TR 
6000 
 
 
TE 
34 
 
 
TI 
150 
 
 
Slice Thickness 
4 mm 
 
 
Skip 
0 
 
 
Matrix 
256x256 
 
 
FOV 
22 cm 
 
 
NEX 
1 
 
 
Frequency Direction 
A→P 
 
 
Options 
Tailored RF, FC, 0.75 FOV 
3. 
CORONAL FSEIR  
Coronal FSEIR 
Protocol 
Specifications 
Actual 
Specifications 
Reason For Change 
Echo Train Length 
5 
 
 
TR 
6000 
 
 
TE 
34 
 
 
TI 
150 
 
 
Slice Thickness 
5 mm 
 
 
Skip 
0 mm 
 
 
Matrix 
256x192 
 
 
FOV 
22 cm 
 
 
NEX 
1 
 
 
Frequency Direction 
S→I 
 
 
Options 
Tailored RF, PC 
4. 
AXIAL T1 
 
Per normal clinical scan 
5. 
AXIAL T1- POST CONTRAST 
Per normal clinical scan 
 
Date:_________         Signature (responsible MRI technician):_____________________________ 
 
Baseline study only, fax completed form to: Ms. Andy Gillespie at: 301-480-8871 (phone: 301-402-1848) 


4/21/2009 
T-99-0090, 01-C-0222 
 
69 
MRI Protocol-Trunk/Extremities  
PATIENT ID NUMBER: _________ 
Note: All series except for #1 and # 2 should be performed as a normal clinical scan as specified by the 
radiologist.  The additional Series #1 and # 2 may or may not be part of the normal clinical scan sequence, 
however these series are required for the NF1 study protocol and must be performed within protocol 
specifications as indicated below. 
1. AXIAL PLANE-STIR 
Axial Plane STIR 
Protocol 
Specifications 
Actual 
Specifications 
Reason For Change 
Coil: Body 
 
 
 
Sequence:  Fast Spin Echo (Turbo) FSEIR 
 
 
Echo Train Length 
5 
 
 
TR 
6000 
 
 
TE 
15 
 
 
TI 
150 
 
 
Slice Thickness 
10 mm 
 
 
Skip 
0 
 
 
Matrix 
512x160 
 
 
FOV 
40x30 
 
 
No. of Excitations/ 
Sequence 
0.5 
 
 
No. of Acquisitions 
1 
 
 
Saturation 
None 
 
 
2. 
CORONAL PLANE STIR  
Coronal Plane STIR 
Protocol 
Specifications 
Actual 
Specifications 
Reason For Change 
Coil:  Body 
 
 
 
Sequence:  Fast Spin Echo (Turbo) FSEIR 
 
 
Echo Train Length 
5 
 
 
TR 
3400 
 
 
TE 
15 
 
 
TI 
150 
 
 
Slice Thickness 
5 mm 
 
 
Skip 
0 
 
 
Matrix 
512x160 
 
 
FOV 
48x48 
 
 
No. of Excitations/ 
Sequence 
1 
 
 
No. of Acquisitions 
1 
 
 
Saturation 
None 
 
 
Date:_________            Signature (responsible MRI technician):_____________________________ 
 


4/21/2009 
T-99-0090, 01-C-0222 
 
70 
Baseline study only, fax completed form to: Ms. Andy Gillespie at: 301-480-8871 (phone: 301-
402-1848) 


4/21/2009 
T-99-0090, 01-C-0222 
 
71 
Data Analysis:  
• All MRI data will be analyzed at the Pediatric Oncology Branch of the NCI under 
guidance of Dr. N. Patronas (head neuroradiologist).  The MRI data from each 
scan will be processed to assess the volume of the index plexiform 
neurofibroma(s). The tumor will be traced on subsequent contiguous MR slices, 
the numbers summed and then multiplied by the slice thickness to obtain a 
numerical volume measurement.  The tumor will be identified by high signal on 
the T2 images not corresponding to known normal anatomic structures and 
corresponding with the course of known nerves. Each patient’s volumetric 
measurement obtained from the initial MRI will serve as the baseline against 
which to assess incremental changes in volume that occur during the subsequent 
intervals.  Volumetric measurements and 1D-, and 2D-data analysis will be done 
by 2 physicians trained in 1D-, 2D-, and 3D-MRI data analysis at the Pediatric 
Oncology Branch, NCI at an Image Review Workstation using MEDx software 
(Sensor Systems Inc.).  Dr. Nicholas Patronas, NCI, will review and confirm 1D-, 
2D-, and volumetric measurements for all images obtained on the study.  
Volumetric measurements will be used to determine disease progression as 
outlined in Section 5.2.  After review by Dr. Patronas, the Principal Investigator 
will inform the Participating Investigators about the results of the MRI study by 
written report. 
• The results of volumetric MRI measurements will be compared with 1D- and 2D-
MRI measurements, with results of the photographic evaluation, the physical 
examination and the study subject’s subjective impression following clinical 
variables.  
Image And Data Acquisition: 
In order to perform quantitative analysis the Pediatric Oncology Branch must 
receive the imaging data from the investigator sites.   
Distribution of images from all participating institutions to the NCI POB will be 
performed by a contractor. 
The contractor will: 
• Contact participating institutions to determine the best mode of electronic data 
transfer 
• Prepare each site for electronic data transfer via network access device, File Transfer 
Protocol (ftp), optical disk or modem depending on the investigator site. 
• Provide training and technical support for each site 
• Ensure complete, secure and timely data transfer to the POB, NCI within 24-72 
hours of obtaining the MRI study. 
The Pediatric Oncology Branch will check all materials received for completeness 
and will notify the site if data, images, or information are missing or incomplete.   


4/21/2009 
T-99-0090, 01-C-0222 
 
72 
APPENDIX 2: PATHOLOGY ANALYSIS OF PLEXIFORM NEUROFIBROMAS 
PATHOLOGICAL ANALYSIS OF PLEXIFORM NEUROFIBROMAS: 
The ability to design rational therapies for plexiform neurofibromas in NF1 is 
heavily dependent upon an improved understanding of the composition, biological 
properties, and growth characteristics of these tumors.  The cellular constituency of 
plexiform neurofibromas is often complex and mixed, including Schwann cells, 
fibroblasts, perineurial and dendritic/monocytic cells.  The patterns are further 
complicated due to the intrinsic intra-neural growth pattern as well as entrapment of 
native neural elements.  This complex intermingling of cellular elements has impeded 
our most basic understanding of these tumors.  It has also rendered molecular studies, 
which require relatively pure cellular populations difficult to interpret.  Therefore, 
combined morphologic, immunohistochemical, and molecular studies are needed to 
elucidate the histogenesis, growth patterns, and malignant evolution of these tumors.   
The Plexiform Neurofibroma Analysis component consists of two parts: (1) the 
central diagnostic neuropathology review with accompanying light- and electron-
microscopic effort to identify the actual cell populations comprising the tumor and (2) 
immunohistochemical and FISH analysis of tumor specimens.  All tissues received from 
surgical biopsies and/or resections will be reviewed by Dr. Arie Perry. 
With this combined approach, the range of cellular constituents and their 
neoplastic properties will be carefully documented in plexiform neurofibromas.  Along 
with related assays being developed (see below), we will provide a better 
understanding of histogenesis, growth potential, and malignant transformation of these 
tumors, thus facilitating a rational approach for guiding patient management. 
The detailed pathological analysis outlined below will only be performed on 
biopsies of plexiform neurofibromas, from patients enrolled in the Phase II FTI study.  
We expect 5-10 such samples per year.   
Standard Pathological Analysis: The paraffin blocks will be sectioned and the 
resulting slides will be stained with hematoxylin-and-eosin (overview).  Selected blocks 
with the greatest degree of tumor purity and/or foci of malignant degeneration will be 
additionally stained with Masson’s trichrome (collagen and myelin), alcian blue (acid 
proteoglycan), reticulin (basement membrane) and peroxidase-linked antibodies against 
neurofilament protein (axons), S-100 protein (Schwann cells), vimentin (mesenchymal 
elements including fibroblasts), chromogranin (entrapped or neoplastic ganglion cells), 
GFAP (some Schwann cells), Leu-7 (some Schwann cells), epithelial membrane antigen 
(perineurial cells), cytokeratin (epithelial differentiation), HMB-45 (melanin-containing 
cells), desmin (skeletal muscle differentiation), MIB-1 (Ki-67) antigen (growth fraction = 
proliferation index), collagen type IV (basement membrane), CD34 (endothelial cells 
and endoneurial dendritic/monocytic cells), muscle specific actin (some perineurial 
cells), and CD68 (macrophages).   
Gluteraldehyde-fixed tissue will be processed into epoxy resin for high-resolution 
light microscopy, and electron microscopy; ultrastructural criteria exist for the 
differential identification of Schwann cells, perineurial-like cells, and endoneurial 


4/21/2009 
T-99-0090, 01-C-0222 
 
73 
fibroblasts and macrophages.  All the attendant microscopy will be done, and the 
findings entered in the project’s database, by Dr Perry. 
Investigational Neuropathology Studies:  Although initial studies will focus on 
routine morphologic, immunohistochemical, and ultrastructural characterization of 
submitted tumors, a number of additional novel studies are currently being developed.  
In this section, we propose to critically evaluate the following questions:   
(1) What are the cell types present in plexiform neurofibromas?  
(2) Are cell types different for plexiform neurofibromas obtained from different sites 
(e.g., cranial nerve, spinal nerve, peripheral nerve)? 
(3) Does proliferation index correlate with growth or molecular/cellular characteristics? 
(4) What is the range of neoplastic properties commonly seen in plexiform 
neurofibromas and how do these differ in benign and malignant lesions? 
(5) Are there any immunohistochemical or DNA FISH markers (e.g. p53 protein 
expression or gene copy number) which may predict a high risk of subsequent 
tumor progression or malignant transformation in plexiform neurofibromas? 
(6) Is there any correlation between tumor vascularity, which may correlate with tumor 
progression in plexiform neurofibromas? 
(7) Is there a correlation between MAPK activity in the tumor and FTI treatment? 
Immunohistochemical analysis of tumors will include p53 protein (overexpression 
due to mutation or protein stabilization common in MPNST components), Factor VIII 
and vascular endothelial growth factor (highly vascular tumors) and neurofibromin 
protein (antibody provided by Dr. David Gutmann, Director of the Neurofibromatosis 
Clinic, Washington Univ. School of Medicine). Recently, Drs. Perry and Gutmann have 
successfully applied a neurofibromin antibody to archival paraffin-embedded 
astrocytomas resected from patients with NF1.  A similar approach will be utilized in 
our study of plexiform neurofibromas, enabling morphologic correlation and the 
determination of what proportion of cells have lost expression.  This will be followed by 
the development of several dual-color immunohistochemical assays such as 
Neurofibromin/MIB-1, Neurofibromin/p53, S-100/MIB-1, S-100/Neurofibromin, etc.  
Results will determine for the first time, which cell types are actively proliferating, lack 
expression of neurofibromin, and/or overexpressing p53 protein.  Tumor vascularity 
will be determined based on the VEGF and Factor VIII expression.   
Dr. Perry has extensive experience with fluorescence in situ hybridization (FISH) 
studies in paraffin embedded tumor. FISH and combined FISH/Immunohistochemistry 
assays will be utilized to identify specifically which cell types have deleted the NF1 
gene. 
Snap-frozen specimens when available will be homogenized for Western 
immunoblot analysis of ras pathway effector protein activities using activation-specific 
antibodies.  In these experiments, equal amounts of total protein will be analyzed by 
Western blotting with phospho-MAPK and phospho-akt/PKB antibodies and 
normalized to the total MAPK and akt/PKB protein levels in each tumor.  Densitometry 


4/21/2009 
T-99-0090, 01-C-0222 
 
74 
will be performed to quantitate the levels of MAPK and akt/PKB activation in these 
tumors.  
The Neuropathological Review Facility is intended to provide a resource for 
consistent pathological analysis of plexiform neurofibromas.  This will, in the long run, 
facilitate better pathological classification of plexiform neurofibromas and permit 
correlations of pathological characteristics with clinical and cellular/molecular features. 
CONTRIBUTION OF TUMOR SPECIMENS TO A CENTRAL TUMOR REPOSITORY: 
All tumor samples obtained on this study (obtained from biopsies of discrete 
neurofibromas and plexiform neurofibromas), with the exception of the tumor sample 
obtained for establishment of tumor cell lines, will be sent to the tissue procurement 
facility. 
Tissue Acquisition (Appendix 3):  To assist in the collection of tissue specimens, 
the project’s Tissue Procurement Facility will provide submitting centers with a 
complete specimen shipping kit after notification by the Pediatric Oncology Branch.  
This kit will be sent to the submitting institution several days before the planned tissue 
resection.  The kit will contain all materials and instructions for the proper collection 
and shipping of specimens to the Tissue Procurement Facility.  A second specimen 
shipment kit for shipment of a tumor sample dedicated to the establishment of tumor 
cell lines will be sent to the participating institution by the Pediatric Oncology Branch, 
and also contain all materials and instructions for the proper collection and shipping of 
specimens .  
Tissue shipment (Appendix 4):  All patient specimens (with exception of the 
specimen obtained for tissue culture), and a copy of the patient consent will be sent by 
overnight express courier to Dr. Mark Watson at the Tissue Procurement Facility.  After 
performing the local institutional evaluation and issuing a pathology report, a copy of 
the pathology report, and all paraffin blocks should be sent to the tissue procurement 
facility.  If submission of all paraffin blocks is not possible or prohibited by participating 
pathology departments, 5 unstained slides from each block will be sent instead.  These 
slides will then be stained and reviewed by Dr. Perry, who will then select 1 or 2 
appropriate blocks to be sent for further study.  Blocks will be returned to the 
submitting institutions upon completion of studies or within 24 hours of written request 
by the submitting institution. 
Upon entry to the Tissue Procurement Facility, all specimens will be coded and 
recorded in the facility database.  The Tissue Procurement Facility will forward 
appropriate coded specimens to Dr. Perry for centralized pathology review and other 
studies described above, and to Dr. Wanda Salzer (analysis of ras expression, and NF1 
mutation) and Janssen Pharmaceuticals (FPTase activity) for investigations related to 
the protocol.  The remainder of the specimens (including paraffin blocks) will be stored 
by the Tissue Procurement Facility until needed for future research studies or recall by 
the submitting institution.  Figure 1 diagrams the proposed flow of information and 
specimens, the coding scheme, and the residence of each data set.  This is a coded, 
double-broker model designed to maintain patient confidentiality while making 
meaningful research studies possible.  All tumor samples remain linked to the patient 


4/21/2009 
T-99-0090, 01-C-0222 
 
75 
data by the study number.  Only the coordinating Center (POB) will have access to the 
clinical data.  Communication between the central tissue repository and the POB will 
use the patient study number.  Communication between research laboratories and the 
tissue bank will use the specimen code number.  The tumor sample obtained for 
establishment of tumor cell lines will be sent directly form the participating institution 
to Dr. Wallace and will be identified by the patient study number. 
  


4/21/2009 
T-99-0090, 01-C-0222 
 
76 
Figure 1: Proposed Scheme for Specimen and data exchange, and specimen and data encoding 
 
 
Trial coordinating 
Center: POB, NCI 
Patient Identifiers 
Clinical Data 
Study Number 
Tissue Procurement and Specimen
Bank 
 
Delete identifiers 
Maintain study number 
 
Code specimens 
Anonymize institutional path data 
Participating Institution 
Diagnostic block 
Pathology report 
Patient consent 
Tumor specimens 
Ship tumor specimen to 
Dr. P. Wallace (tumor cell 
culture). 
Neuropath Review and 
Database (Dr. Perry, Dr. 
Gutmann) 
Coded specimens 
Anonymized institutional 
path data 
RESEARCH 
LABORATORY 
Coded specimens for 
IRB approved research 
question 
Communication and data likage by study number 
Communication and data 
likage by specimen code 
number 
Communication 
and data linkage 
by specimen 
code number 
Ship tumor samples to: 
Dr W. Salzer (ras analysis) 
Dr. D. End (FPTase activity)
Communication and data likage 
by specimen code number 
Communication 
and data 
linkage by 
study number 
Communication 
and data 
linkage by 
study number 


4/21/2009 
T-99-0090, 01-C-0222 
 
77 
APPENDIX 3: INSTRUCTIONS FOR TISSUE ACQUISITION OF DISCRETE AND PLEXIFORM 
NEUROFIBROMAS 
Five to seven days prior to the planned tumor biopsy please notify Ms Andy Gillespie 
at the POB, NCI, about the planned biopsy: Phone: 301-402-1848, Fax: 301-480-8871, e-
mail: gillesan@mail.nih.gov.  To assist in the collection of tissue specimens, two 
specimen shipment kits will be sent to participating institutions: 
• The project’s Tissue Procurement Facility will provide submitting centers with a 
specimen shipping kit for shipment of tumor samples.  The kit will contain all 
materials and instructions for the proper collection and shipping of specimens to the 
Tissue Procurement Facility.   
• The NCI, Pediatric Oncology Branch will provide submitting institutions with a 
second specimen shipment kit (to ship the tumor sample for the culture of tumor 
cells), which will contain all materials and instructions for proper collection.  
STEPS FOR TISSUE COLLECTION ARE AS FOLLOWS: 
1. To enable future molecular and biochemical analyses with the specimen, the 
participating institutional pathologist must receive the tumor tissue fresh, rather 
than “fixed in formalin”.  After resection, the tissue should be transported from the 
O.R. to the pathologist within 30 minutes.  The specimen must not be placed in 
formalin, but may be placed in normal saline, Ringer’s solution, or any other 
physiologic buffer solution. 
2. A representative and sufficiently large piece of the specimen should be fixed in 
formalin for paraffin processing as per the institution’s standard policies and 
procedure. Pathologists will be instructed to thoroughly sample the surgical 
specimen (at least one block per centimeter in greatest dimension).  This material 
will be used to make the clinical diagnosis and, later, sent for central pathology 
review. 
3. If tissue remains, an additional piece of tissue 0.5-1 cm3 in size will be snap frozen in 
liquid nitrogen or a –50oC histological bath.  This material will be shipped to the 
Tissue Procurement Facility on dry ice for future molecular and genetic research 
studies. 
4. If tissue remains, aseptically remove any capsular material and slice at least 0.5 cm3 
of the tumor tissue to increase the exposed surface area.  Half fill a 50 ml screw top, 
conical centrifuge tube with Transport Medium (Leibovitz’s L-15 Medium with 1.0% 
penicillin/streptomycin, 100U/ml) and shake vigorously to oxygenate. Label the tube 
with patient’s study number.  Place the slices into the medium, secure the top and 
wrap with parafilm.  Insulate the tube by encasing with several wraps of fine bubble 
wrap. Place the package on top of a small reusable cold ice pack in a size-matching 
styrofoam shipping box with cardboard outer.  Tape the box lid shut.  Ship by 


4/21/2009 
T-99-0090, 01-C-0222 
 
78 
overnight express courier, priority delivery to Dr. Peggy Wallace, University of 
Florida for culture of tumor cells. 
5. If tissue still remains, 2-4 2 mm  fragments, preferably from various sites 
representing a spectrum of gross appearances, will be placed in the provided 
gluteraldehyde container.  These specimens will be used for electron microscopy 
studies. 
6. If tissue still remains, another representative specimen will be placed in the 
provided formaldehyde container.  This specimen will be embedded at the Tissue 
Procurement Facility and used in the event that the submitting institution’s 
specimen block is not available. 
7. If tissue still remains, the remainder of the specimen will be divided into 1 cm3 
segments and snap frozen as described in (3). 


4/21/2009 
T-99-0090, 01-C-0222 
 
79 
APPENDIX 4: INSTRUCTIONS FOR SHIPMENT OF TUMOR BIOPSIES 
Shipments should not be sent on Fridays or on the day preceeding a holiday. 
Five to seven days prior to tumor resection, please call Ms Andy Gillespie at the 
Pediatric Oncology Branch, NCI (phone: 301-402-1848, fax: 301-480-8871, e-mail: 
gillesan@mail.nih.gov).  Provide the name, phone number and shipping address of the 
physician responsible for tissue acquisition. 
Two shipping modules will be mailed via overnight express to the physician indicated: 
At the time of resection, tissue should be IMMEDIATELY transported from the 
operating room to the attending surgical pathologist.  Material should be handled as 
outlined in Appendix 3. 
After collection the tumor sample, which will be used for establishment of a tumor cell 
line, should be placed in L-15 (a tissue culture medium), identified with the patient’s 
study number, and be sent on top of a small reusable cold ice pack in the specimen kit 
provide by the POB, NCI immediately via FedEx to: 
Margaret Wallace, Ph.D. 
Professor, Molecular Genetics & Micro., and Pediatric Genetics 
University of Florida 
Box 100266, 1600 SW Archer Road, ARB Room R2-220 
Gainesville, FL 32610-0266 
Phone: (352)-392-3055 
Fax: (352) 392-2042 
E-mail: peggyw@ufl.edu 
Please notify Dr. Wallace prior to shipment, and contact her with any questions you 
may have regarding this sample. 
All other tumor specimens (snap frozen tissue, tissue in glutaraldehyde, and 
formaldehyde container) should be placed in the specimen kit provided by the Tissue 
Procurement Facility, and shipped on dry ice to:  
M. Watson, M.D., Ph.D. 
Division of Laboratory Medicine / Box 8118 
Alvin J. Siteman Cancer Center / Box 8100 
Washington University School of Medicine 
660 S. Euclid Avenue, St. Louis, MO 63110 
Phone: (314)-454-7919, Fax: (314)-454-5525 
Snap frozen tissue has to be maintained in the cryobath or a –70 degree freezer until it is 
ready for shipment.  It is very important that: (1) Tissue be frozen as soon as possible 
after resection; (2) Tissue be frozen rapidly; and (3) Tissue be maintained at or below –
50 degrees until shipment. 


4/21/2009 
T-99-0090, 01-C-0222 
 
80 
Please notify Dr. Watson prior to shipment, and contact him with any questions you 
may have regarding these samples. 


4/21/2009 
T-99-0090, 01-C-0222 
 
81 
APPENDIX 5: PROCEDURE PBMC SEPARATION FOR FARNESYLTRANSFERASE ACTIVITY 
 
PBMC Collection Steps: 
• Collect peripheral blood (20 ml in children >10 kg weight, 10 ml in children ≤10 kg 
weight) in preservative free heparin (10-20 units heparin/1ml of blood). 
• Place peripheral blood in polypropylene screw top tube(s). 
• Label tube with: Patient initials, Patient ID number, date, treatment phase (“A”, 
“B”), and day of treatment (pre, day 15-21). 
Shipment Of Peripheral Blood: 
• Place tube(s) in container. 
• Place the container with the polypropylene tube(s) in Styrofoam box. Add a 
package of wet ice in Styrofoam box, if it is expected that the ambient temperature 
cannot be maintained between below 90 º Fahrenheit.   
• Package sample as appropriate for biologic material. 
 
Required PBMC samples
Date of sample collection 
Pretreatment (prior to phase “A”)
 
Steady state on treatment phase “A” (day 15-21, cycle#1)
 
Steady state on treatment phase “B” (day 15-21, cycle#1)
 
 
• Ship the sample and the information requested above on the same day it was 
obtained with Federal express overnight priority delivery to: 
Dr. Brigitte Widemann 
Pediatric Oncology Branch, NCI 
10 Center Drive 
1—CRC, Rm 1-5750, 
Bethesda, MD 20892-1101 
• Notify Dr. Widemann prior to shipment of the sample (Phone:301-496-7387, e-mail: 
bw42y@nih.gov). 
• Do not ship samples for delivery on a weekend or Holiday. 
• Samples must be received by Dr. Widemann within 24 hours of obtaining the 
sample. 
PROCESSING OF SAMPLES 
• After arrival at the Pediatric Oncology Branch, NCI: 
• Mononuclear cells will be separated using the ficoll technique. 
• The number of mononuclear cells in the specimen will be determined. 


4/21/2009 
T-99-0090, 01-C-0222 
 
82 
• The samples will be processed for FPTase activity 


4/21/2009 
T-99-0090, 01-C-0222 
 
83 
 
APPENDIX 6:  DETERMINATION OF NERVE GROWTH FACTOR  
All materials necessary will be provided by the POB, NCI. 
Obtain exactly 3 cc of whole blood in a red top tube (pretreated with a protease 
inhibitor, provided by the POB, NCI). After obtaining the sample:  
• Storage for 1 hour at room temperature (15-25 °C),  
• Overnight storage in the refrigerator at 2-8 °C.  
• Centrifugation for 20 minutes at 2-8 °C at 2000 x g.  
• Remove supernatant, and place supernatant in tube (provided by POB).  
• Label tube (labels provided by POB) with patient initials, ID#, date, cycle and 
treatment phase. 
• Storage of samples until shipment: -20 °C. 
Ship frozen samples and completed collection sheet on dry ice to: 
Ms. Nalini Jayaprakash 
Pediatric Oncology Branch, NCI 
10 Center Drive, 10-CRC, Rm 1-3872 
Bethesda, Maryland 20892-1101 
Please notify Ms. Jayaprakash prior to shipping at (301) 402-6642, e-mail: 
jayapran@mail.nih.gov. No shipments to arrive on Holidays or on Saturdays. 
Samples can be batched for each treatment phase. 
Patient initials:  
Patient ID number:
 
 
Treatment 
Phase 
Sample 
Date obtained 
A 
Pior to phase A 
 
A 
Pre cycle # 4 
 
A 
Pre cycle # 7 
 
A 
Pre cycle # 10 
 
A 
Pre cycle # 16* 
 
B 
Pre cycle #4 
 
B 
Pre cycle # 7 
 
B 
Pre cycle # 10 
 
B 
Pre cycle # 16* 
 


4/21/2009 
T-99-0090, 01-C-0222 
 
84 
* And then after completion of every 6 treatment cycles. 
 
 


4/21/2009 
T-99-0090, 01-C-0222 
 
85 
APPENDIX 7: REQUIRED STUDY EVALUATIONS  
Prior To Starting Treatment, During, And Post Treatment for Each Study Phase  (“A” and “B”):  
Observation 
Pretreatment
(Phase A&B)
During Cycle 
(Phase A&B) 
Prior to Each Cycle 
(Phase A&B) 
Post Study 
History & physical exam 
X 
q 2 weeks, Cycles 1-3 
X 
X 
Performance status 
X 
 
X   (document if changed) 
X 
Body surface area 
X 
 
X 
 
Photography of lesions, if 
possible 
X 
 
Cycles 4, 7, 10, then q 6 cycles
X 
CBC, platelets, differential 
X 
q 2 weeks, Cycles 1-3 
X 
X 
PT, PTT, Fibrinogen 
X 
 
X 
X 
Electrolytes and creatinine 
X 
q 2 weeks, Cycles 1-3 
X 
X 
Ca+2, Mg+2, PO4 
X 
q 2 weeks, Cycles 1-3 
X 
X 
SGPT, bilirubin 
X 
q 2 weeks, Cycles 1-3 
X 
X 
Urinalysis 
X 
 
Cycles 4, 7, 10, then q 6 cycles
X 
Urine pregnancy test 
Females 
 
 
 
3D-MRI of index lesions Phase A only
 
Cycles 4, 7, 10, then q 6 cycles
X 
Ophthalmologic examination 
X 
 
 
X 
QOL assessment Phase A only
 
Cycles 4, 7, 10, then q 6 cycles
 
Tumor Biopsy Phase A only Between days 15-21, Cycle 1 
Phase A and B 
 
 
PBMC for FPTase Phase A only Between days 15-21, Cycle 1 
 
 


4/21/2009 
T-99-0090, 01-C-0222 
 
86 
Nerve growth factor Phase A only
 
Cycles 4, 7, 10, then q 6 cycles
 


4/21/2009 
T-99-0090, 01-C-0222 
 
87 
APPENDIX 8 A:  ELIGIBILITY CHECKLIST FOR PROTOCOL  
Patient initials:
First three letters of last name:
 
Date of birth:
 
Race:
 
Gender:
 
Weight (kg):
 
Height (cm):
 
BSA 
(m2):
 
Patient measurements: 
(please average 3 heights and weights)
 
 
 
Institution:
 
Physician:  
NF1 diagnostic criteria:
Plexiform neurofibroma:
 
≥6 Café-au-lait spots:
 
Freckling:
 
Optic glioma: 
 
≥ 2 Lisch 
nodules:
 
Bony dysplasia: 
 
1st degree relative with NF1:
 
≥20% increase in tumor volume: 
%: 
≥ 13% increase in product of two 
longest perpendicular diameters: 
 
%: 
 
Progressive plexiform 
Neurofibroma
over prior two scans:
≥6% increase in longest diameter:
%: 
 
Date of scans:
1. 
 
2.
 
Tumor measurements:
cm: 
 
cm:
 
Inoperable:
Yes: 
 
No:
 
Measurable:
Yes: 
 
No:
 
Potential for morbidity:
Yes: 
 
No:
 
Location:
 
 
 
Recovered from tox. of prior Rx:
Yes:
 
No:
 
 
Date of last dose of (NA if none):
Radiation Rx:
 
ChemoRx:  
ECOG performance score:
 
Life expectancy ≥12 mo: 
Yes:  
No:
 
Date CBC/Diff and coags drawn:
 
Hematologic parameters:
ANC:
Hgb:
Plt: 
Fibrinogen:
Normal range: 
Date chemistries drawn:
 
 
 
Liver function tests:
SGPT:
 
ULN:
 
Bili: 
 
ULN:
 
Renal function:
Creat:
Normal range:
 
or Creat clear:
Signed informed consent:
Yes:
 
Date:
 
No:  
Pregnant or breast feeding:
Yes:
 
No:
 
Date of pregnancy test:
 
Other significant illnesses:
Yes:
No:
DPA offered:
Yes: 
 No: 
 
NA:
>1 myelosuppressive chemoRX: 
Yes:
 
No:
 
Prior R115777: 
Yes
: 
No:
Investigational agent last 30 days: 
Yes: 
 
No: 
 
 
Active MPNST or other cancer
Yes:
 
No:
 
 
Ongoing XRT, chemoRX, GCSF, 
hormonal or immunoRx
Yes:
 
No:
 
 
Able to return for follow-up
Yes
 
No:
 
 


4/21/2009 
T-99-0090, 01-C-0222 
 
88 
Name of person completing form:
 
Signature/Date:
 


4/21/2009 
T-99-0090, 01-C-0222 
 
89 
APPENDIX 8 B: BLINDED PATIENT ON-STUDY FORM 
 
PROTOCOL T99-0090 / 01-C-0222 
A Phase II Randomized, Crossover, Double-Blind, Placebo-Controlled Trial of the 
Farnesyltransferase Inhibitor R115777 in Pediatric Patients with Neurofibromatosis Type I 
and Progressive Plexiform Neurofibromas 
Patient ID: 01C0222-___ ___ 
 
 
Patient Initials: ___ ___ ___ 
(provided by Orkand) 
(CC protocol number - patient sequence number) 
(first three letters of last name) 
 
 
On-Study Form: 
Date of Registration / On-Study Date (MM/DD/YYYY):   ____ / ____ / ________ 
 
Drug Order: 
NSC Number:   702818 
Drug Name, Strength, Unit, Form:   Phase A R115777 50mg / Placebo tablets 
Quantity Ordered: 
 
Check 
One 
BSA (m2) 
R115777 / Placebo  
(mg  po q12h) 
# of Boxes  
(70 tablets per box) 
θ 
0.00 - 0.37 
50 
2 
θ 
0.38 - 0.62 
100 
4 
θ 
0.63 - 0.87 
150 
6 
θ 
0.88 - 1.12 
200 
8 
θ 
1.13 - 1.37 
250 
9 
θ 
1.38 + 
300 
11 
 
Registering Physician: 
Name (print):   Dr. ______________________________ 
Institution:   ________________________________________ 
Address (city / state):   _________________________, ______ 
NCI Investigator Number:   ___ ___ ___ ___ ___ 
Phone Number:   ___ ___ ___ - ___ ___ ___ - ___ ___ ___ ___ 
 
Date Faxed to PMB by Orkand (MM/DD/YYYY):   ____ / ____ / ________ 
Name of person faxing to PMB (print):   ___________________________________ 
Signature of person faxing to PMB:   ________________________________________ 
Phone number of person faxing to PMB:   ___ ___ ___ - ___ ___ ___ - ___ ___ ___ ___ 
 
Fax to: Donna Shriner / Melizza Ford 


4/21/2009 
T-99-0090, 01-C-0222 
 
90 
Pharmaceutical Management Branch, Cancer Therapy Evaluation 
Program, DCTD, NCI: 301-402-4870 
 
Questions: 
Contact Donna Shriner or Melizza Ford of the Pharmaceutical Management 
Branch at 301-496-5725. 


4/21/2009 
T-99-0090, 01-C-0222 
 
91 
APPENDIX 9A: PROGRESSION CHECKLIST FOR PROTOCOL  
To be completed when patient progresses on Phase A and Phase B 
Patient initials: 
First three letters of last name:
 
Patient ID number:  
  
Patient measurements: 
Weight (kg):
Height (cm):
 
BSA (m2):
Institution:  
  
Registering physician: 
Name:
 
Contact RN: 
Name:
 
Phone:  
Treatment phase completed: 
A:
 
B:
 
Date:  
Cycle number completed:  
 
 
Last R115777/Placebo dose: 
Date:
 
 
Location of progressive 
plexiform neurofibroma(s): 
 
Evidence for progression: 
≥20% increase in tumor 
volume:
 
 
Clinical progression:
 
 
 
Name of person completing form:  
Signature/Date:  
 
 
POB RN:  
Date PMB notified:  
Date Orkand notified:  
 
Fax completed form to Ms Andy Gillespie at 301-480-8871, call with questions:  301-402-1848 


4/21/2009 
T-99-0090, 01-C-0222 
 
92 
APPENDIX 9 B: BLINDED PATIENT CROSSOVER / OFF-STUDY FORM  
 
PROTOCOL T99-0090 / 01-C-0222 
A Phase II Randomized, Crossover, Double-Blind, Placebo-Controlled Trial of the 
Farnesyltransferase Inhibitor R115777 in Pediatric Patients with Neurofibromatosis Type I 
and Progressive Plexiform Neurofibromas 
Patient ID:   01C0222-___ ___ 
 
 
Patient Initials:   ___ ___ ___ 
(CC protocol number - patient sequence number) 
(first three letters of last name) 
 
Crossover Form: 
Date of Progression on Phase A / Crossover Date (MM/DD/YYYY):  ___ / ____/ ____ 
 
Drug Order: 
NSC Number: 702818 
Drug Name, Strength, Unit, Form:   Phase B R115777 50 mg / Placebo tablets 
Quantity Ordered: 
 
Check 
One 
BSA 
(m2) 
R115777 / Placebo  
(mg po q12h) 
# of Boxes  
(70 tablets per box) 
θ 
0.00 - 0.37 
50 
2 
θ 
0.38 - 0.62 
100 
4 
θ 
0.63 - 0.87 
150 
6 
θ 
0.88 - 1.12 
200 
8 
θ 
1.13 - 1.37 
250 
9 
θ 
1.38 + 
300 
11 
 
Off-Study Form: 
Date of Progression on Phase B / Off-Study Date (MM/DD/YYYY):   __ / ___ / ____ 
 
Registering Physician: 
Name (print): Dr. ______________________________ 
Institution: ________________________________________ 
Address (city / state):   _________________________, ______ 
NCI Investigator Number:   ___ ___ ___ ___ ___ 
Phone Number:   ___ ___ ___ - ___ ___ ___ - ___ ___ ___ ___ 
 
Date faxed to PMB by Pediatric Oncology Branch (MM/DD/YYYY):   ___ / __ / ___ 
Name of person faxing to PMB (print):   ___________________________________ 
Signature of person faxing to PMB:   ________________________________________ 
Phone number of person faxing to PMB:   ___ ___ ___ - ___ ___ ___ - ___ ___ ___ ___ 
 
Fax to: 
Donna Shriner / Melizza Ford 


4/21/2009 
T-99-0090, 01-C-0222 
 
93 
Pharmaceutical Management Branch Cancer Therapy Evaluation 
Program, DCTD, NCI: 301-402-4870 
 
Questions: 
Contact Donna Shriner or Melizza Ford of the Pharmaceutical Management 
Branch at 301-496-5725. 


4/21/2009 
T-99-0090, 01-C-0222 
 
94 
APPENDIX 10: ROADMAP FOR PATIENT REGISTRATION AND CROSSOVER 
PATIENT REGISTRATION 
1) 
Contact Dr. Brigitte Widemann (301) 496-7387 or Dr. Frank Balis (301) 496-0085, to 
discuss the patient prior to entry on study. Call Ms. Andy Gillespie, RN to register 
patient at (301-402-1848). FAX the completed Eligibility Checklist (Appendix 8A) 
and Blinded Patient On Study Form (Appendix 8B) to the Pediatric Oncology 
Branch c/o Andy Gillespie, RN at (301) 480-8871.  
2) 
POB RN registers patient with Orkand (phone: 301-402-1732, fax: 301-480-0757) 
using the completed Eligibility Checklist (Appendix 8A) and Blinded Patient On 
Study Form (Appendix 8B). 
3) 
Orkand notifies the POB RN and the Pharmaceutical Management Branch (PMB), 
NCI, (phone; 301-496-5725, fax: 301-402-4870) of the patient’s ID number using the 
Blinded Patient On Study Form (Appendix 8B).  
4) 
The POB RN notifies the registering site of the patient’s ID number using the 
Blinded Patient On Study Form (Appendix 8B).  
5) 
The PMB ships drug for that ID number for “phase A” to registering site.  
6) 
POB ships module with necessary materials to administer quality of life 
assessment and tests outlined in appendix 5, 6, and7 to participating institution. 
DISEASE PROGRESSION ON “PHASE A” 
1) 
FAX the completed Progression Checklist (Appendix 9A) and Blinded Patient 
Crossover/Off Study Form (Appendix 9B) to the Pediatric Oncology Branch c/o 
Andy Gillespie, RN at (301) 480-8871. 
2) 
Return unused drug to the PMB (Section 8.2.3)  
3) 
POB RN notifies the PMB (phone: 301-496-5725, fax: 301-402-4870) using the 
completed Blinded Patient Crossover/Off Study Form (Appendix 9B). 
4) 
PMB ships drug for that ID number for “phase B” to registering site.  
DISEASE PROGRESSION ON “PHASE B” 
1) 
FAX the completed Progression Checklist (Appendix 9A) and the Blinded Patient 
Crossover/Off Study Form (Appendix 9B) to the Pediatric Oncology Branch: Andy 
Gillespie, RN at (301) 480-8871. 
2) 
Return unused drug to the Pharmaceutical Management Branch (Section 8.2.3) 
3) 
POB RN notifies Orkand (phone: 301-402-1732, fax: 301-480-0757) and the PMB 
(phone: 301-496-5725, fax: 301-402-4870) using the completed Progression Checklist 
(Appendix 9A) and Blinded Patient Crossover/Off Study Form (Appendix 9B). 
4) 
POB RN will take Patient off protocol. 
EMERGENCY UNBLINDING 


4/21/2009 
T-99-0090, 01-C-0222 
 
95 
In the event of an emergency, call the Dr. Brigitte Widemann (301) 496-7387 or Dr. 
Frank Balis (301) 496-0085.  These physicians can also be reached through the NIH page 
operator (301) 496-7704 or (301) 496-1211. Pediatric Oncology Branch staff will require 
the protocol number (i.e., ‘T99-0090’), the patient’s ID number (e.g., ‘00-C0222-01’), the 
phase (i.e., ‘A’ or ‘B’), and the patient’s initials (first three letters of last name, eg., 
‘ABC’) to unblind the patient.


4/21/2009 
T-99-0090, 01-C-0222 
 
96 
APPENDIX 11A: PATIENT DIARY FOR R115777/PLACEBO  
Patient initials/ID number:  
 
Dose: 
Treatment Phase: 
Cycle Number:  
Cycle Start Date: 
 
Date → 
 
 
 
 
 
 
 
 
AM 
PM 
AM 
PM 
AM 
PM 
AM 
PM 
AM 
PM 
AM 
PM 
AM 
PM 
Time R115777 /Placebo dose taken* → 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indicate reason for missed doses → 
 
 
 
 
 
 
 
SIDE EFFECTS 
 
 
 
 
 
 
 
Nausea (see scale below)† → 
 
 
 
 
 
 
 
Vomiting (# of times in 24 hr) → 
 
 
 
 
 
 
 
Diarrhea (# of times in 24 hr)  → 
 
 
 
 
 
 
 
Pain, or numbness in hands/feet  → 
 
 
 
 
 
 
 
OTHER SIDE EFFECTS (list below) 
 
 
 
 
 
 
 
→ 
 
 
 
 
 
 
 
→ 
 
 
 
 
 
 
 
→ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OTHER MEDICATIONS (Name) 
Dose 
Frequency 
Start Date 
Stop Date 
Reason for Use of Medication 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* If you miss a dose write “M” in the box. 
† Rate nausea mild if you are able to eat and drink a reasonable amount, moderate if you can eat and drink but the amount is substantially decreased, or 
severe if you are unable to eat and drink. 
 
 
 
 
 
 
 
 
 
 
Physicians should fax completed form to Ms Andy Gillespie at 301-480-8871, call with questions: 301-402-1848 Parent/patient initials  
 
 


4/21/2009 
T-99-0090, 01-C-0222 
 
97 
 


4/21/2009 
T-99-0090, 01-C-0222 
 
98 
 
 
 
 
APPENDIX 11 B: PILL COUNT CASE REPORT FORM 
 
PROTOCOL T99-0090 / 01-C-0222 
 
A Phase II Randomized, Crossover, Double-Blind, Placebo-Controlled Trial of the 
Farnesyltransferase Inhibitor R115777 in Pediatric Patients with Neurofibromatosis Type I 
and Progressive Plexiform Neurofibromas 
Patient’s Institution ID#:   _______________ 
Patient’s Name:_____________ 
Patient ID: 01C0222-___ ___ 
 
 
Patient Initials:   ___ ___ ___ 
(CC protocol number - patient sequence number) 
(first three letters of last name) 
Phase:   ____ Phase A      ____ Phase B 
 
Cycle:   ______ 
Strength: ____ 50mg 
 
(28 day cycle – 21 days on / 7 days off) 
Start Date (MM/DD/YYYY):   ____ / ____ / ________ 
Number of boxes dispensed (place additional labels on page 2 – make copies if 
necessary) 
______ 
Total number of tablets dispensed to patient (number of boxes * 70 tablets per 
box) ______ 
 
End Date (MM/DD/YYYY):   ____ / ____ / ________ 
Total number of tablets returned by patient:  
 
 
 
 
 
______ 
Number of tablets taken by patient (total dispensed minus total returned) 
______ 
 
Date Pill Count Form Completed (MM/DD/YYYY):   ____ / ____ / ________ 
Name of person Completing Pill Count Form (Print): _____________________ 
Name of Principal Investigator (print):   Dr. ______________________________ 
Institution:   ________________________________________ 
 
Please fax completed forms to Ms. Andy Gillespie (301 480-8871) after completion of 
every 3 treatment cycles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
PLACE BOX ONE LABEL HERE 
 
 
 
PLACE BOX TWO LABEL HERE 
 
 
 
PLACE BOX THREE LABEL HERE 
(if applicable) 
 
 
 
PLACE BOX FOUR LABEL HERE 
(if applicable) 


4/21/2009 
T-99-0090, 01-C-0222 
 
99 
 
 
 
 
 
 


4/21/2009 
T-99-0090, 01-C-0222 
 
100 
 
 
 
 
 
 
 
 
 
 
PLACE ADDITIONAL BOX LABEL 
HERE 
(if applicable) 
 
 
 
PLACE ADDITIONAL BOX LABEL 
HERE 
(IF APPLICABLE) 
 
 
 
PLACE ADDITIONAL BOX LABEL 
HERE 
(if applicable) 
 
 
 
PLACE ADDITIONAL BOX LABEL 
HERE 
(if applicable) 
 
 
 
PLACE ADDITIONAL BOX LABEL 
HERE 
(if applicable) 
 
 
 
PLACE ADDITIONAL BOX LABEL 
HERE 
(if applicable) 
 
 
 
PLACE ADDITIONAL BOX LABEL 
HERE 
(if applicable) 
 
 
 
PLACE ADDITIONAL BOX LABEL 
HERE 
(if applicable) 
 
 
 
PLACE ADDITIONAL BOX LABEL 
HERE 
(if applicable) 
 
 
 
PLACE ADDITIONAL BOX LABEL 
HERE 
(if applicable) 


 
 
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
   MEDICAL RECORD 
               •  Adult Patient or     •  Parent, for Minor Patient 
 
 
INSTITUTE: 
National Cancer Institute 
 
 
STUDY NUMBER: 
01-C-0222 
PRINCIPAL INVESTIGATOR:  Brigitte Widemann, M.D. 
 
 
STUDY TITLE: 
A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled Trial of the 
Farnesyltransferase Inhibitor R115777 in Pediatric Patients with Neurofibromatosis Type 1 and 
Progressive Plexiform Neurofibromas 
 
 
Continuing Review Approved by IRB on 1/12/09  
Amendment Approved by IRB on 6/5/09 (J) 
 
 
 
 
Date Posted to Web:  6/27/09 
Standard 
PATIENT IDENTIFICATION 
CONSENT TO PARTICIPATE IN A CLINICAL 
 
RESEARCH STUDY 
 
•   Adult Patient or    •   Parent, for Minor Patient 
 
NIH-2514-1 (4-97) 
 
P.A.: 09-25-0099 
 
File in Section 4:  Protocol Consent (1) 
 
 
INTRODUCTION 
 
We invite you/your child to take part in a research study at the National Institutes of Health (NIH). 
 
First, we want you/your child to know that: 
 
Taking part in NIH research is entirely voluntary. 
 
 
You/your child may choose not to take part, or you/your child may withdraw from the study at any time.  In 
either case, you/your child will not lose any benefits to which you are otherwise entitled.  However, to receive 
care at the NIH, you/your child must be taking part in a study or be under evaluation for study participation. 
 
 
You/your child may receive no benefit from taking part.  The research may give us knowledge that may help 
people in the future. 
 
Second, some people have personal, religious or ethical beliefs that may limit the kinds of medical or research 
treatments they would want to receive (such as blood transfusions).  If you/your child have such beliefs, please discuss 
them with your NIH doctors or research team before you/your child agree to the study. 
 
Now we will describe this research study.  Before you/your child decide to take part, please take as much time as you 
need to ask any questions and discuss this study with anyone at NIH, or with family, friends or your/your child’s 
personal physician or other health professional. 
 
You/your child have neurofibromatosis type I (also called NF1), and one or more tumors called plexiform neurofibroma(s) 
that appear to be increasing in size over the past year and have the potential to cause serious medical problems.  
Plexiform neurofibromas, which are tumors that arise from nerves, occur commonly in patients with NF1.  The only 
known effective treatment for plexiform neurofibromas is surgery, but many times complete surgical removal of all of the 
plexiform neurofibromas is not possible, because of the number or location of the tumors. 
The underlying cause of NF1 is a defective gene. Genes carry the information for the body composition and 
characteristics. For example, genes determine the color of the eyes. The function of the gene, which is defective in NF1, 
is to produce a protein called neurofibromin.  In patients with NF1, neurofibromin is decreased, and the decrease in 
neurofibromin is felt to contribute directly to tumor formation.  Neurofibromin helps control the activity of another protein 
called ras. Ras can be thought of as an "on/off" switch for cell growth.  When ras is "on", cells grow.  When ras is "off", 


 
 
  
CONTINUATION SHEET for either: 
  MEDICAL RECORD 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
 
STUDY NUMBER: 
01-C-0222 
CONTINUATION:  page  2  of  7  pages 
 
 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
 
NIH-2514-1 (10-84) 
 
NIH-2514-2 (10-84) 
 
P.A.: 09-25-0099 
 
 
 
the cells do not grow.  Neurofibromin helps to keep ras "off".  Decreased levels of neurofibromin therefore may allow for 
uncontrolled cell growth and tumor formation.   
Drugs that inactivate ras are being studied as a new way to treat cancer.  These drugs may also provide a logical means 
of controlling the tumors in patients with NF1.  R115777 is a new experimental drug that interferes with the function of 
the ras protein and other proteins in cells by blocking a step in the formation of these proteins.  R115777 can block the 
growth of cancer cells in test tubes and in animals, but we do not know yet whether it will be effective for the treatment 
of plexiform neurofibromas in patients with NF1. This experimental drug has only been administered to a small number of 
adult and pediatric patients with a variety of different types of cancer and NF1. We do not know if this drug will be 
effective in your/your child’s plexiform neurofibromas. R115777 is not approved by the Food and Drug Administration 
(FDA) for commercial use, but the FDA has permitted its use in this research study. 
 
DESCRIPTION OF RESEARCH STUDY 
 
The main purposes of this research study are (1) to determine if R115777 can slow down the growth rate of plexiform 
neurofibromas in patients with NF1, (2) to determine if R115777 can result in shrinkage of progressive plexiform 
neurofibromas, (3) to determine the types of side effects that can be produced by R115777 in children and young adults 
with NF1 and (4) to study the biology of the tumors from patients with NF1. 
The growth of plexiform neurofibromas can be unpredictable, including periods of rapid growth and other periods of no 
measurable tumor growth. This unpredictable behavior can make it difficult to measure the effectiveness of R115777 as a 
treatment for plexiform neurofibromas.  In order to find out if R115777 will be helpful for patients with plexiform 
neurofibromas, we will compare the effects of the drug to a placebo (a similar tablet that does not contain R115777) in 
each patient who is treated on the study. Before starting any treatment we will randomly determine (determined by coin 
flip) whether you/your child will initially receive either R115777 or placebo.  Neither you/your child nor anyone involved in 
the care of you/your child, such as the nurses and physicians at the NCI and your/your child’s doctor at home, will know 
if you/your child are is receiving R115777 or the placebo. 
We will follow you/your child closely throughout the study for signs of increase of the plexiform neurofibroma by regular 
clinical examinations, if possible photography of visible tumors (with your permission, please see below), and MRI scans. 
You/your child will be identified on photographs only by the study ID number, and photographs will be located in a 
separate locked folder at the Pediatric Oncology Branch, NCI. If we find that the plexiform neurofibromas are increasing 
in size, you/your child will be switched to the other treatment.  For example, if you/your child were getting the placebo 
first, then you/your child will be switched to R115777.  As long as we find tumor growth during the initial part of the 
study, at some point you/your child will receive R115777.  Should the tumor be stable or decrease in size, you/your child 
will continue to receive the same treatment for as long as it is well tolerated and appears to be of benefit.  The treatment 
will only be switched or stopped if it is not controlling the growth of the plexiform neurofibromas. You/your child will be 
removed from the study when growth of the plexiform neurofibroma is noted on the second treatment phase. At that 
time we will perform a thorough clinical evaluation, in addition to a MRI study, and arrange for necessary follow-up care 
by your/your child’s physician. Other reasons for removal from the protocol could be if you/your child did not tolerate 
R115777/placebo because of side effects of the drug, if you/your child developed another serious medical condition, 
which would not allow the administration of R115777/placebo, or if you/your child were unable to comply with the 
protocol. Although the design of this study is complicated, we think that it offers the best chance of determining if 
R115777 is of benefit for progressive plexiform neurofibromas. A total of approximately 60 patients will be entered on this 
study. 
R115777 or placebo will be given by mouth in the form of tablets taken every 12 hours for 21 days followed by a 7 day 
rest period (1 cycle = 28 days, 21 days drug, 7 days rest period). R115777 will be given at the highest dose, which was 


 
 
  
CONTINUATION SHEET for either: 
  MEDICAL RECORD 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
 
STUDY NUMBER: 
01-C-0222 
CONTINUATION:  page  3  of  7  pages 
 
 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
 
NIH-2514-1 (10-84) 
 
NIH-2514-2 (10-84) 
 
P.A.: 09-25-0099 
 
 
 
found to be well tolerated by most patients in a prior clinical trial.  Each dose will be 200 mg/m2 body surface area, which 
is calculated from your/your child’s height and weight. Tablets can be crushed for easier consumption, if necessary.  
R115777 or placebo should be taken after a meal.  This treatment will be continued, unless unacceptable side effects or 
increase in the size of the plexiform neurofibromas are observed. You/your child will be examined by a doctor initially 
every other week during this treatment, and will have routine blood tests performed initially every other week.  The 
frequency of these studies will be spread out after three cycles of treatment.  MRI scans to measure the size of your/your 
child’s plexiform neurofibromas will be performed periodically throughout the course of treatment.  In addition to 
measuring the plexiform neurofibroma in the longest dimensions, we will also determine the volume of the plexiform 
neurofibroma to test if changes in the tumor volume may better reflect changes in the tumor size than standard 
measurements.  
We will provide you with a form on which you will record the time each dose is administered, any side effects that 
you/your child experience, and any other medicines that you/your child are taking.  This diary is an important part of our 
monitoring of this experimental drug. 
Blood samples of 2 to 4 teaspoons each will also be taken prior to the first dose of treatment, and at one time point after 
at least 14 days of treatment on each study phase (R115777 or placebo) to measure the effect of R115777 on proteins in 
blood cells.  A blood sample of less than one teaspoon will be obtained prior to starting treatment and prior to cycles 4, 7, 
10, and then after every 6 cycles on each study phase to measure the level of a substance called nerve growth factor.  
The analysis of nerve growth factor will be used to determine if it can predict which patients may be at risk to develop 
side effects from R115777. 
Should you/your child have superficial (just under the skin) tumor nodules, we would also like to ask you/your child to 
provide a piece of tumor from one of these nodules prior to the first dose of any treatment, and if feasible at one time 
point after at least 14 days of treatment on each study phase (R115777 or placebo) to learn more about changes in 
tumors of patients with NF1.  In addition, should you/your child have to undergo surgery for a complication of your/your 
child’s tumor, we would like to obtain a sample of the tumor. In this case we would only obtain the tumor sample after 
the pathologist and surgeon have determined that any material necessary for clinical care has been obtained. We will 
perform a detailed analysis of the tumor samples to better understand the cell components of plexiform neurofibromas, 
and will attempt to grow tumor cells in culture.  In addition we will analyze the tumor samples for changes in the NF1 
gene and in the ras gene and ras protein.  These studies may help us to better understand which patients may benefit 
from the treatment with R115777.  Any results from these studies will be preliminary and will require further analysis for 
verification. Therefore, neither you/your child nor anyone else will be informed about results of the studies performed on 
your/your child’s neurofibroma tissue.   
Should any tumor sample be left over after performing the above studies, we would like to retain these samples in a 
central tumor repository (storage site) at Washington University in St. Louis, Missouri.  The tissue will be identified with a 
code number, and will only be possible to connect with your/your child’s name through the trial coordinating center 
“Pediatric Oncology Branch of the NCI” in Bethesda, MD.  The tissue may be distributed to investigators to help with their 
research on neurofibromatosis. There is a chance that the tumor sample you/your child are providing for this study, may 
have some commercial applicability. There are no plans to provide financial compensation to you/your child, should this 
occur. Any future research done with these samples will be conducted under a protocol approved by the Institutional 
Review Board with oversight of the tissue bank. You/your child will not receive further notice of future uses of your/your 
child’s sample, unless a future use could involve more than minimal risk to you/your child. Any results from these studies 
will be preliminary and will require further analysis for verification. Therefore, neither you/your child nor anyone else will 
be informed about results of the studies performed on your/your child’s neurofibroma tissue. All research results will be 
kept confidential.  You can decide not to allow storage of your/your child’s tumor sample at the tissue repository (please 


 
 
  
CONTINUATION SHEET for either: 
  MEDICAL RECORD 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
 
STUDY NUMBER: 
01-C-0222 
CONTINUATION:  page  4  of  7  pages 
 
 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
 
NIH-2514-1 (10-84) 
 
NIH-2514-2 (10-84) 
 
P.A.: 09-25-0099 
 
 
 
see below), or withdraw your/your child’s specimen from the tissue repository at any time. Please contact Dr. Brigitte 
Widemann, Principal Investigator of this study, if you wish to do so.  
If you decide not to have a tumor sample taken, you/your child can still participate in the treatment part of this study 
(please see below). We will give you/your child a separate consent form, for the tumor biopsy that explains the 
procedure and its risks more fully. If you decide not to give permission for storage of the tumor sample in the central 
tumor repository, you/your child can still participate in the treatment part of the study (please see below).  
In addition we would like to assess your/your child’s quality of life by giving you/your child a questionnaire, which 
you/your child would complete periodically throughout the treatment course. 
Should significant new findings regarding the treatment of NF1 become available during the course of this study, which 
may influence your decision to continue on this study, we will provide you/your child with that information. 
R115777 and placebo will be provided without charge, as will all examinations and studies performed at the NIH. The 
NIH will usually not pay for physical examinations or laboratory tests  required for the study, which are performed outside 
of the NIH. 
 
Please indicate below if you/your child agree or disagree to the following study procedures: 
 
1) Regular photographs of visible tumors: 
 
 
Agree: θ 
Disagree: θ 
Initials: 
2) Obtain tumor sample(s) of superficial tumor nodules:  
Agree: θ 
Disagree: θ 
Initials: 
3) Storage of the tumor sample(s) in a central tumor repository: Agree: θ 
Disagree: θ 
Initials: 
 
ALTERNATIVE APPROACHES OR TREATMENTS 
 
You/your child will only be eligible for this trial if complete surgical removal of the progressive plexiform neurofibroma(s) 
is not feasible. Alternatives to this treatment may include partial surgical removal of the plexiform neurofibroma, other 
experimental therapies, or you/your child may decide not to receive any treatment at this point in time. 
 
RISKS OR DISCOMFORTS OF PARTICIPATION 
 
The side effects of R115777 have been studied in animals, in adult patients with cancer, and in children with cancer and 
NF1.  R115777 may affect several organs or tissues of your/your child’s body.  The side effects most commonly observed 
in adults were decrease in the bone marrow function leading to a drop in the white blood cell count (neutropenia, 
granulocytopenia), platelet count, or red blood cell count, and nausea and vomiting. A decrease in white blood cells leads 
to an increased risk for infections and fever including sepsis. A decrease in the platelet count can result in bleeding or 
bruising and may require platelet transfusions to correct it. A decreased red blood cell count leads to anemia causing 
tiredness, and may require red blood cell transfusions to correct it. Other likely side effects include loss of appetite, 
diarrhea, nausea or vomiting.  When R115777 was given continuously to adult patients with breast cancer (every day 
without a rest period) for a time period exceeding 12 weeks, more than half of the patients developed signs of nerve 
damage with pain, tingling and numbness or weakness in the hands or feet.  Less frequently, R115777 caused 
headaches, dehydration, skin rash, sensitivity to sunlight (photosensitivity) and peeling skin, a decrease in kidney 
function (increase in serum creatinine), a decrease in the potassium level (an important chemical), reversible liver 
damage, heartburn, decrease in blood pressure, irritation or sores in the lining of your mouth or esophagus or intestines, 
constipation, nosebleed, fever or infection, tiny broken blood vessels under the skin and changes in a  chemical called 
lipase, which is required to digest food.  One adult developed headaches and a defect in vision, which were reversible.  
The same patient later developed a stroke, which was felt not to be related to the R115777.  In adult patients with 


 
 
  
CONTINUATION SHEET for either: 
  MEDICAL RECORD 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
 
STUDY NUMBER: 
01-C-0222 
CONTINUATION:  page  5  of  7  pages 
 
 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
 
NIH-2514-1 (10-84) 
 
NIH-2514-2 (10-84) 
 
P.A.: 09-25-0099 
 
 
 
leukemia who received high doses of R115777 (900 to 1200 mg twice daily) increased thirst, confusion, changes in vision, 
and difficulties to coordinate body movements were observed. These side effects subsided completely within a few days 
after stopping R115777. Other less-frequently observed side effects include swelling of the arms and legs, dizziness, 
sleepiness, pain in the belly, chest or in general, or cough or shortness of breath.  One rare but serious side effect 
observed was bleeding into the brain or spinal cord. 
The side effects observed to date in the children and adolescents treated with R115777 are similar to those observed in 
adults and include: 1) A decrease in the bone marrow function, with a drop in the white blood cell, platelet count and red 
blood cell count, 2) the development of a rash which may be more pronounced in skin areas exposed to sun, and 3) the 
development of nausea, vomiting, diarrhea and abdominal pain. One patient had a seizure while receiving R115777, and 
one patient experienced a reversible decrease in fibrinogen (a substance important for blood clotting). Few children with 
leukemia developed an increase in blood tests, which measure liver function (bilirubin, AST), with an unclear relationship 
to R115777.  In addition, 1 patient with leukemia developed mouth sores (mucositis).  Signs of nerve damage have not 
been reported in any of the children treated to date.  However, this does not guarantee that children will not develop 
neurologic toxicity, particularly after administration of R115777 for a long time period. All of these side effects have been 
reversible. 
The dose of R115777 that you/your child get was determined in a prior clinical study in pediatric patients with cancer and 
NF1.  This dose of R115777 was well tolerated by most patients.  However, since this is a new experimental treatment, 
other presently unknown side effects may occur.  These side effects could potentially be serious and even fatal. You/your 
child will be watched closely and the drug will be discontinued if serious side effects develop.  
The risks from the blood drawing to assess the affect of R115777 in the body include the discomfort from having needle 
sticks if required and a small risk of infection. 
Participation in the present study may render you/your child ineligible to participate in other research studies that limit 
the number or type of treatments that patients may have received, and in some cases, the types of side effects that 
patients may have experienced. 
Tumor Studies: You/your child will receive a separate consent form for the tumor biopsy that explains the procedure and 
risks more fully.  Tumor material will be obtained for research purposes on this study.  With your permission, left over 
tumor will be sent to a central tissue repository.  Although there is no immediate plan to perform studies from any tumor 
samples obtained, tumor material will be stored for possible future testing.  It is expected that the tissue samples will be 
stored indefinitely in the repository.  The sample will be identified by a code number that can be traced to you/your child 
only by contact with the trial coordinating center “Pediatric Oncology Branch, NCI” in Bethesda, MD. Neither you nor 
anybody else will be informed about results of testing performed on your/your child’s blood sample or tumor tissue. Every 
effort will be made to keep test results confidential. However, as the tumor and sample can be linked to your/your child’s 
name, a small risk persists that unauthorized persons could gain access to the information. Some testing may eventually 
reveal information that, in some cases, may result in discrimination with health or life insurance or employment.  We 
believe that these risks are minimal since it is already known that you/your child have neurofibromatosis. 
MRI:  Magnetic resonance imaging (MRI) is a standard procedure used for imaging plexiform neurofibromas. When 
having a MRI, you/your child will lie motionless on a table that slides into a tunnel slightly wider than your/your child’s 
body for about one hour.  There is very little room in the MRI, however you/your child will easily be able to hear and 
speak to research staff.  As images are taken, the MRI makes loud banging noises as though it was being pounded on 
the outside with a hammer.  Earplugs will be offered to help reduce the noise.  MRIs use powerful magnets. There are no 
known or foreseeable risks associated with exposures to MRI provided no metal implanted prostheses (e.g., vascular 
clamps or pacemakers; braces are not a problem) are present. Should you/your child have a metal prosthesis you/your 
child may be excluded from participating in the study for your/your child’s own safety.  All potential subjects will be 


 
 
  
CONTINUATION SHEET for either: 
  MEDICAL RECORD 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
 
STUDY NUMBER: 
01-C-0222 
CONTINUATION:  page  6  of  7  pages 
 
 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
 
NIH-2514-1 (10-84) 
 
NIH-2514-2 (10-84) 
 
P.A.: 09-25-0099 
 
 
 
screened for the presence of such prior to the examination.  Some participants in the study may require sedation or 
anesthesia to perform MRI.  Consent for this will be obtained prior to the MRI.  There are risks associated with sedation 
and anesthesia, including the risk of death in rare instances.   
If you/your child are a female and old enough to get pregnant, you/your child will be given a pregnancy test before 
you/your child begin the treatment, in order to make sure that you/your child are not pregnant. If there is a chance that 
you/your child could become pregnant during this study, you/your child should not participate in the study.  If you/your 
child are sexually active, you/your child must use an appropriate and effective method of birth control while you/your 
child are taking part in this study. If you/your child become or are found to be pregnant while taking part in this study, 
you/your child must notify one of the doctors listed on this form right away so the treatment can be discussed. 
If you/your child are a male, you/your child should also use a means of birth control while taking part in this study (if 
sexually active), because we do not know what effect the experimental drug may have on your/your child’s sex cells and 
what effect this would have upon the development of an unborn child. 
 
POTENTIAL BENEFITS OF PARTICIPATION 
 
The potential benefit of this treatment with R115777 is that it may cause your/your child’s neurofibroma to stop growing 
or shrink for a period of time or it may lessen the symptoms, such as pain, that are caused by the tumor. It is our intent 
to benefit each subject in the trial. However, because there is not much information about the drug’s effect on plexiform 
neurofibromas in humans, we do not know if you/your child will benefit from taking part in this study, although the 
knowledge gained from this study may benefit others. The MRI data in this study will be analyzed by a special approach 
called “volumetric MRI,” in addition to being read in a standard manner by a radiologist. The volumetric MRI approach 
will provide more precise measurement of the size of plexiform neurofibromas, and therefore will give more complete and 
objective information on which to base any possible future treatment decisions.  Volumetric MRI is currently not available 
on a routine clinical basis. 
 
RESEARCH SUBJECT'S RIGHTS 
 
Joining this research study is voluntary. You/your child may ask the doctors and nurses any questions about this 
treatment.  If you/your child decide at any time that you/your child do not want to receive this treatment any more, then 
tell us (Dr. Brigitte Widemann, phone 301-496-7387, Dr. Frank Balis phone 301-496-0085, or Ms. Andy Gillespie, RN, 
phone 301-402-1848) and we will discontinue it. You/your child may be eligible to receive experimental therapy other 
than the drug described here, or can receive therapy consisting of symptomatic treatment only. 
Your/your child’s medical record may be reviewed by qualified representatives from the National Cancer Institute, or by 
representatives from the Food and Drug Administration (FDA). 
 
 


 
  
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
   MEDICAL RECORD 
•  Adult Patient or    •  Parent, for Minor Patient 
 
STUDY NUMBER: 
01-C-0222 
CONTINUATION:  page  7  of  7  pages 
 
PATIENT IDENTIFICATION 
CONSENT TO PARTICIPATE IN A CLINICAL 
 
RESEARCH STUDY (Continuation Sheet) 
 
•  Adult Patient or   •  Parent, for Minor Patient 
 
NIH-2514-1 (12-08) 
 
P.A.: 09-25-0099 
 
FAX TO:  (301) 480-3126 
 
File in Section 4:  Protocol Consent 
 
 
OTHER PERTINENT INFORMATION 
 
1. Confidentiality.  When results of an NIH research study are reported in medical journals or at scientific meetings, 
the people who take part are not named and identified.  In most cases, the NIH will not release any information about 
your/your child’s research involvement without your written permission.  However, if you sign a release of information 
form, for example, for an insurance company, the NIH will give the insurance company information from your/your 
child’s medical record.  This information might affect (either favorably or unfavorably) the willingness of the insurance 
company to sell you insurance. 
 
The Federal Privacy Act protects the confidentiality of your/your child’s NIH medical records.  However, you/your child 
should know that the Act allows release of some information from your/your child’s medical record without your 
permission, for example, if it is required by the Food and Drug Administration (FDA), members of Congress, law 
enforcement officials, or other authorized people. 
 
2. Policy Regarding Research-Related Injuries.  The Clinical Center will provide short-term medical care for any 
injury resulting from your/your child’s participation in research here.  In general, no long-term medical care or financial 
compensation for research-related injuries will be provided by the National Institutes of Health, the Clinical Center, or 
the Federal Government.  However, you/your child have the right to pursue legal remedy if you believe that your/your 
child’s injury justifies such action. 
 
3. Payments.  The amount of payment to research volunteers is guided by the National Institutes of Health policies.  
In general, patients are not paid for taking part in research studies at the National Institutes of Health. Reimbursement of 
travel and subsistence will be offered consistent with NIH guidelines. 
 
4. Problems or Questions.  If you/your child have any problems or questions about this study, or about your/your 
child’s rights as a research participant, or about any research-related injury, contact the Principal Investigator, Dr. 
Brigitte Widemann;  Building 10, Room 13C103, Telephone:301-496-7387.  Other researchers you/your child may call 
are: Dr. Frank Balis, Telephone 301-496-0085; and Andy Gillespie, R.N., Telephone 301-402-1848.  
 
You/your child may also call the Clinical Center Patient Representative at 301-496-2626. 
 
5. Consent Document.  Please keep a copy of this document in case you/your child want to read it again. 
COMPLETE APPROPRIATE ITEM(S) BELOW: 
 
A. Adult Patient’s Consent 
B. Parent’s Permission for Minor Patient. 
I have read the explanation about this study and have been given the 
opportunity to discuss it and to ask questions.  I hereby consent to take 
part in this study. 
I have read the explanation about this study and have been given the 
opportunity to discuss it and to ask questions.  I hereby give permission 
for my child to take part in this study.   
(Attach NIH 2514-2, Minor’s Assent, if applicable.) 
 
  
 
 
  
 
Signature of Adult Patient/Legal Representative 
Date 
Signature of Parent(s)/Guardian 
Date 
 
 
C. Child’s Verbal Assent (If Applicable) 
The information in the above consent was described to my child and my child agrees to participate in the study. 
 
 
  
 
 
Signature of Parent(s)/Guardian 
Date 
 
 
 
THIS CONSENT DOCUMENT HAS BEEN APPROVED FOR USE  
FROM JANUARY 12, 2009 THROUGH JANUARY 11, 2010. 
 
 
 
  
 
 
  
 
Signature of Investigator 
Date 
Signature of Witness 
Date 
 
 


 
 
MINOR PATIENT'S ASSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
   MEDICAL RECORD 
  •  Attach to NIH-2514-2, Consent to Participate in a Clinical Research Study 
 
 
INSTITUTE: 
National Cancer Institute 
 
 
STUDY NUMBER: 
01-C-0222 
PRINCIPAL INVESTIGATOR:  Brigitte Widemann, M.D. 
 
 
STUDY TITLE: 
A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled Trial of the 
Farnesyltransferase Inhibitor R115777 in Pediatric Patients with Neurofibromatosis Type 1 and 
Progressive Plexiform Neurofibromas 
 
 
Continuing Review Approved by IRB on 1/12/09  
Amendment Approved by IRB on 6/5/09 (J) 
 
 
 
 
Date Posted to Web: 6/27/09 
Minor 7 thorugh 12 years of age 
 
PATIENT IDENTIFICATION 
MINOR PATIENT'S ASSENT TO PARTICIPATE IN A CLINICAL 
 
RESEARCH STUDY 
 
NIH-2514-2 (4-97) 
 
P.A.: 09-25-0099 
 
File in Section 4:  Protocol Consent (3) 
 
 
You have an illness called neurofibromatosis type 1.  We will call it NF1 for short.  NF1 can cause lumps that are called 
tumors to grow inside of your body and these tumors can cause pain or other problems.  Sometimes the tumors can be 
taken out with an operation, but if they can’t then doctors don’t have other ways to make them stop growing or make 
them go away. 
We are trying to find new medicines that can slow down or stop NF1 tumors from growing, and we are asking you to help 
us test one of these new medicines that is called R115777.  We don’t know yet whether this new medicine will work. 
We can measure the size of your tumor and check to see if your tumor is growing by doing scans that can take a picture 
of the inside your body without hurting you. This is called an MRI scan. You will lie down on a bed, and the bed is pushed 
into a machine.  This can be scary because you are in a small space and the machine makes a lot of noise.  The scan 
usually takes about 1 hour, and you have to lie still during the scan.  Some kids need medicines to make them sleep 
during the scan because it is too scary or they can’t lie still that long. 
NF1 tumors don’t grow all of the time.  They can grow for a while and then stop growing for a while without any 
treatment.  This makes it hard for us to tell if a new medicine is really working. 
To find out if a new medicine works we will measure the change in the size of your tumor while you are taking pills that 
have the new medicine in them, and we will also measure the change in tumor size while you are taking pills with no 
medicine in them.  You, your parents, and your doctors will not know whether the pills that you are taking have the 
medicine or not.  You may start with the pills that have the medicine first or you may start with the empty pills first.  If 
your tumor grows, then we will switch you to the other type of pills.  If your tumor stays the same size then you will keep 
taking the same pills. 
You will take pills twice a day for 21 days and then you will have a break for 7 days before you start taking the pills 
again.  We will do the MRI scans to check the size of your tumor after every 3 months for the first year and then after 
every 6 months. 
The new medicine that we are testing can cause side effects, which can make you feel bad.  Side effects can happen 
when the new medicine effects other parts of your body than the tumor.  These side effects do not happen to everyone 
who takes the new medicine.  In some people the medicine can make them feel sick to their stomach or throw up.  It can 
also cause diarrhea (watery poop), skin rash, which is red itchy bumps, make your nose bleed, or have tingling, 
numbness or pain in your hands and feet.  Let us know if you feel dizzy, confused, have a sore mouth, have trouble 
catching your breath, have trouble going to the bathroom (poop), or have trouble going to sleep.  The new medicine can 


 
  
MINOR PATIENT'S ASSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
  MEDICAL RECORD 
 
STUDY NUMBER: 
01-C-0222 
CONTINUATION:  page  2  of  2  pages 
 
PATIENT IDENTIFICATION 
MINOR PATIENT'S ASSENT TO PARTICIPATE IN A 
also lower your blood cells that carry oxygen to your body, fight infections, and make your blood clot when you get a cut.  
It can also change how your kidneys or liver work, so we will check for all of these by doing blood tests every 2 weeks 
after you start the new medicine and then every 4 weeks after you have been on the medicine for a while.  We get this 
blood by putting a small needle into a vein in your arm.  This feels like a prick or bee sting.  If the side effects happen to 
you, they will go away after you stop taking the medicine.  Tell your parents or your doctors if you think that you have 
any of these side effects. 
If this new medicine works, it may slow down or stop the growth of your tumor. 
Ask your parents or your doctors or nurses if you have questions about this new medicine or the way that we are testing 
it.  We are asking for your permission and your parents permission before we test this new medicine on you.  You can 
decide not to take part in this study if you don’t want to and you can stop taking the medicine at any time, if you change 
your mind. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I have had this study explained to me in a way that I understand, and I have had the chance to ask questions.  
I agree to take part in this study. 
 
 
 
Signature of Minor Patient: 
 
Date: 
 
 
 
 
Signature of Investigator: 
 
Date: 
 
 
 
 
 
CLINICAL RESEARCH STUDY 
 
NIH-2514-2 (4-97) 
 
P.A.: 09-25-0099  
FAX TO:  (301) 480-3126 
 
File in Section 4:  Protocol Consent 
 
 


 
 
MINOR PATIENT'S ASSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
   MEDICAL RECORD 
  •  Attach to NIH-2514-2, Consent to Participate in a Clinical Research Study 
 
 
INSTITUTE: 
National Cancer Institute 
 
 
STUDY NUMBER: 
01-C-0222 
PRINCIPAL INVESTIGATOR:  Brigitte Widemann, M.D. 
 
 
STUDY TITLE: 
A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled Trial of the 
Farnesyltransferase Inhibitor R115777 in Pediatric Patients with Neurofibromatosis Type 1 and 
Progressive Plexiform Neurofibromas 
 
 
Continuing Review Approved by IRB on 1/12/09  
Amendment Approved by IRB on 6/5/09 (J) 
 
 
 
 
Date Posted to Web: 6/27/09 
Minor 13 through 17 years of age 
 
PATIENT IDENTIFICATION 
MINOR PATIENT'S ASSENT TO PARTICIPATE IN A CLINICAL 
 
RESEARCH STUDY 
 
NIH-2514-2 (4-97) 
 
P.A.: 09-25-0099 
 
File in Section 4:  Protocol Consent (4) 
 
 
Introduction: We would like to invite you to take part in a research study at the National Institutes of Health (NIH). 
Before you decide about taking part in the study, we want you to know why we are doing the study and if it will help you. 
We also want you to know about any risks (what might go wrong) and what you will have to do. You can only be in the 
study if you and your parent(s) agree. 
 
This form gives you information about the study. Your doctor will talk to you about the study and answer questions you 
have. If you would like to take part in this study, we will ask you to sign this form to show that you understand this 
study. We will give you a copy of this form to keep. It is important that you know: 
You do not have to join the study 
You may change your mind and drop out of the study at any time 
If we make important changes to the study we will tell you about it and make sure you still want to be in the study. 
 
Purpose of the study 
You have an illness called neurofibromatosis type 1 or NF1, which has caused a tumor (called plexiform neurofibroma) to 
grow inside your body. This tumor may cause you pain, discomfort, or other problems as it gets larger. There are no 
effective treatments other than surgery, to make these tumors go away. Because your tumor cannot be taken out 
completely, we want to see if a new drug with the name R115777 will help to stop your tumor from growing, or shrink 
your tumor. This drug has been given in the past to adults with other diseases than NF1, and to some children with 
cancer or NF1.  
 
Because we do not know whether this new drug will work, we are doing a study where we are giving R115777 to just a 
few children and adults with NF1 and a tumor called a plexiform neurofibroma, which has shown recent growth and 
cannot be completely removed by surgery. 
 
We want to answer four questions about this new drug R115777 and NF1 tumors:  
Will this new drug, R115777, slow down how fast your NF1 tumor(s) grow(s)?  
Will R115777 make your NF1 tumor(s) smaller?  
Does R115777 make you feel different or cause anything new to happen to you (for example, does the drug make you 
feel tired or does it make your stomach upset)? 
What more can we learn about NF1 tumors? 


 
 
  
CONTINUATION SHEET for either: 
  MEDICAL RECORD 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
 
STUDY NUMBER: 
01-C-0222 
CONTINUATION:  page  2  of  3  pages 
 
 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
 
NIH-2514-1 (10-84) 
 
NIH-2514-2 (10-84) 
 
P.A.: 09-25-0099 
 
 
 
Study plan 
These are difficult questions to answer but we have written a plan or study, which we think, will help us find the answers.  
We want to watch you and look at your tumors when you are taking the R115777 pills for a period of time and when you 
are taking pills that don’t have the drug.  The pill that does not contain R115777 looks just like the R115777 pill. This way 
you, your parents, and your doctors will not know which type of pill you are taking and we will be able to find out if the 
R115777 is really working.  Before you take any drug, a coin will be flipped to decide if you will take the R115777 pills or 
the empty pills first.  You will continue to take that pill until your tumor(s) grow(s) and then you will be switched over to 
the other pill and take it until your tumor(s) grow(s) once again.  We will not know when you are taking the R115777 or 
the empty pills. 
 
The plan or protocol we have written explains the rules about this study.  It tells us how you take the drug, when you 
take the drug and how we will keep a very close eye on you while you are on our study.  You will take the R115777 or 
empty pills two times a day for 21 straight days and then you will stop taking the pills for 7 days in a row.  You will 
continue taking the R1115777 or empty pills this way until your tumors grow or you do not feel well enough to swallow 
the pills.  We will know when your tumors grow because after every 3 months during the first year, and then after every 
6 months, you will have a MRI scan, which takes a picture of the inside of your body. To take the picture you lay down 
on a bed, which slides into a large machine.  It may be scary if you don’t like small places.  You will need to lie still for 
approximately 1 hour.  The scanner is also very noisy while it is working. You may have to receive a medicine to make 
you sleep while you get the scans.  The medicine will be put into a vein in your arm through a small needle.  It will feel 
like a prick or bee sting when the needle is placed in your arm.  In addition to the pictures we take, we will also look at 
your blood, in the beginning every 2 weeks, and then every 4 weeks.  We draw the blood from your arm by placing a 
small needle into the vein in your arm, which will feel like a prick or a bee sting.  Once the blood is drawn the needle is 
taken out and you will be given a band-aid.  
 
Risks or side effects: 
Drugs can make you feel different or cause something new to happen to you. These are called side effects of a drug. At 
the dose of R115777 you will receive, the drug has been well tolerated by a small number of children with NF1. However, 
the following side effects may happen to you.  Your stomach may be upset, causing some nausea or vomiting.  The drug 
may cause you to have diarrhea or watery bowel movements.  A bumpy redness called a skin rash may appear on your 
skin that can itch or your skin may become more sensitive to sunlight.  R115777 may also affect your blood, which is 
made up of many different parts or cells.  One of them is your white blood cells, which helps your body fight germs or 
infections.  R115777 may lower the number of white blood cells in your body, which may cause you to have a fever or 
get sick. Few adult patients who took the drug continuously without a break for more than 3 months developed pain and 
tingling in the tips of the fingers and toes. All reported side effects from R115777 went away after the drug was stopped. 
Less likely side effects may include difficulty having a bowel movement, heartburn, nosebleed, mouth sores, swelling of 
the arms or legs, confusion or dizziness, sleepiness, pain in the chest or belly, headache, cough or having difficulty 
breathing.  This drug may change how your kidneys or liver work so we will check for this by doing blood tests.  Should 
you develop a side effect we may decide to stop the drug until the side effects go away, and then restart the drug at a 
lower dose.  One rare but serious side effect observed was bleeding into the brain or spinal cord. 
 
Taking R115777 might be harmful to an unborn child. Birth control measures must be used by all females of child-
bearing age or who can become pregnant and are sexually active or by their sexual partners while in this study, such 
as: Contraceptive pill or use of condom and spermicide cream. As effects of R115777 on a newborn child are unknown, 
breast-feeding mothers must stop breast- feeding their child. Males who are sexually active, must also use means of 
birth control while participating in the study. 
 


 
  
MINOR PATIENT'S ASSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
  MEDICAL RECORD 
 
STUDY NUMBER: 
01-C-0222 
CONTINUATION:  page  3  of  3  pages 
 
PATIENT IDENTIFICATION 
MINOR PATIENT'S ASSENT TO PARTICIPATE IN A 
Potential Benefits: 
R115777 might slow down or stop the growth of your tumor or even might decrease its size. Taking part in this study will 
help us to find out if R115777 works. 
  
Alternatives to Participation 
The only known effective treatment for plexiform neurofibromas is surgery. In many cases the tumor cannot be removed 
completely, and in some cases surgery cannot be safely done. Participation in this study will only be offered to you if your 
tumor cannot be safely removed, or if you or your parents don’t want you to have surgery. 
 
Confidentiality 
We will keep the records of this study confidential. Only people working on the study will know your name. 
 
Please ask your doctor or research nurse any questions you might have about this study.  Keep asking until you 
understand.  You can decide not to take part in this study if you don’t want to.  Your doctors and nurses will understand 
if you don’t want to participate.  If you agree to go on this study, know that you can stop whenever you choose.   
 
We are asking for your permission and your parent’s permission before we give this new medicine to you.  A copy of this 
form will be given to you and your parents. 
 
By signing this form, you agree that you have talked to your doctor about the study and understand it, and want to be in 
the study. You also agree that we have talked to you about the risks and benefits of the study, and about other choices. 
You may drop out of the study at any time and no one will mind. Please call the Principal Investigator Dr. Brigitte 
Widemann, M.D., at 301-496-7387 if you have any questions. 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I have had this study explained to me in a way that I understand, and I have had the chance to ask questions.  
I agree to take part in this study. 
 
 
 
Signature of Minor Patient: 
 
Date: 
 
 
 
 
Signature of Investigator: 
 
Date: 
 
 
 
 
 
CLINICAL RESEARCH STUDY 
 
NIH-2514-2 (4-97) 
 
P.A.: 09-25-0099  
FAX TO:  (301) 480-3126 
 
File in Section 4:  Protocol Consent